0001079973-16-000953.txt : 20160511 0001079973-16-000953.hdr.sgml : 20160511 20160511084145 ACCESSION NUMBER: 0001079973-16-000953 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 52 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160511 DATE AS OF CHANGE: 20160511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Venaxis, Inc. CENTRAL INDEX KEY: 0001167419 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 841553387 STATE OF INCORPORATION: CO FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33675 FILM NUMBER: 161637930 BUSINESS ADDRESS: STREET 1: 1585 S. PERRY STREET CITY: CASTLE ROCK STATE: CO ZIP: 80104 BUSINESS PHONE: (303) 794-2000 MAIL ADDRESS: STREET 1: 1585 S. PERRY STREET CITY: CASTLE ROCK STATE: CO ZIP: 80104 FORMER COMPANY: FORMER CONFORMED NAME: AspenBio Pharma, Inc. DATE OF NAME CHANGE: 20051110 FORMER COMPANY: FORMER CONFORMED NAME: ASPENBIO INC DATE OF NAME CHANGE: 20020213 10-Q 1 appy_10q-033116.htm FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2016

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________ to __________

Commission file number: 001-33675

VENAXIS, INC.

(Exact name of registrant as specified in its charter)

Colorado	84-1553387
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

1585 South Perry Street, Castle Rock, Colorado 80104

(Address of principal executive offices) (Zip Code)

(303) 794-2000

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one)

Large accelerated filer☐ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of no par value common stock outstanding as of May 11, 2016 was 3,876,960.

VENAXIS, INC.

		Page
PART I - Financial Information

Item 1.	Condensed Financial Statements

	Balance Sheets as of March 31, 2016 (unaudited) and December 31, 2015	3

	Statements of Operations for the Three Months Ended March 31, 2016 and 2015 (unaudited)	4

	Statements of Cash Flows for the Three Months Ended March 31, 2016 and 2015 (unaudited)	5

	Notes to Condensed Financial Statements (unaudited)	6

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	16

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	20

Item 4.	Controls and Procedures	21

PART II - Other Information

Item 1.	Legal Proceedings	22

Item 1A.	Risk Factors	22

Item 6.	Exhibits	23

	Signatures	24

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION AND STATEMENTS

Certain statements in this Quarterly Report on Form 10-Q, including in Management’s Discussion and Analysis of Financial Condition and Results of Operations, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or other comparable terminology. Please see the “Risk Factors” in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 for a discussion of certain important factors that relate to forward-looking statements contained in this report. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

PART I — FINANCIAL INFORMATION

Item I. Condensed Financial Statements

Venaxis, Inc.

Balance Sheets

	March 31, 2016 (Unaudited)				December 31, 2015

ASSETS
Current assets:
Cash and cash equivalents		$	3,841,065			$	2,012,283
Short-term investments (Note 1)			12,759,109				14,147,991
Prepaid expenses and other current assets (Note 1)			241,817				251,778

Total current assets			16,841,991				16,412,052

Property and equipment, net (Note 2)			896				1,954,496

Long-term investments (Note 1)			250,000				972,000

Other long term assets, net (Notes 1 and 3)			1,381,566				1,523,649

Total assets		$	18,474,453			$	20,862,197

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable		$	321,054			$	701,064
Accrued compensation			12,549				449,873
Accrued expenses			171,129				241,882
Notes and other obligations, current portion (Note 4)			57,152				301,250
Deferred revenue, current portion (Note 7)			96,698				96,698

Total current liabilities			658,582				1,790,767

Notes and other obligations, less current portion (Note 4)			-				1,838,779
Deferred revenue, less current portion (Note 7)			1,137,840				1,162,015

Total liabilities			1,796,422				4,791,561

Commitments and contingencies (Notes 7 and 9)

Stockholders' equity (Notes 5 and 6):
Common stock, no par value, 60,000,000 shares authorized;
3,876,960 shares issued and outstanding			121,700,959				121,653,075
Accumulated deficit			(105,022,928	)			(105,582,439	)

Total stockholders' equity			16,678,031				16,070,636

Total liabilities and stockholders' equity		$	18,474,453			$	20,862,197

See Accompanying Notes to Unaudited Condensed Financial Statements

Venaxis, Inc.

Statements of Operations

Three Months Ended March 31

(Unaudited)


	2016			2015

Sales (Note 1)	$	-		$	11,288
Cost of sales		-			4,007

Gross profit		-			7,281

Other revenue – fee (Note 7)		24,175			24,175

Operating expenses:
Selling, general and administrative		1,030,126			1,535,851
Research and development		372,586			707,742

Total operating expenses		1,402,712			2,243,593

Operating loss		(1,378,537	)		(2,212,137	)

Other (expense) income:
Gain on sale of property and equipment (Note 2)		1,919,361			-
Interest expense		(25,598	)		(25,064	)
Investment income		44,285			50,828

Total other income		1,938,048			25,764

Net income (loss)	$	559,511		$	(2,186,373	)

Basic and diluted net loss per share (Note 1)	$	0.14		$	(0.56	)

Basic and diluted weighted average number
of shares outstanding (Note 1)		3,876,960			3,876,960

See Accompanying Notes to Unaudited Condensed Financial Statements

Venaxis, Inc.

Statements of Cash Flows

Three Months Ended March 31

(Unaudited)

	2016			2015
Cash flows from operating activities:
Net income (loss)	$	559,511		$	(2,186,373	)
Adjustments to reconcile net loss to
net cash used in operating activities:
Stock-based compensation for services		47,884			433,402
Depreciation and amortization		19,401			64,021
Amortization of license fees		(24,175	)		(24,175	)
Other non-cash charges		133,899			-
Gain on sale of property and equipment		(1,919,361	)		-
Change in:
Accounts receivable		-			7,077
Prepaid expenses and other current assets		69,155			89,690
Accounts payable		(380,010	)		(34,707	)
Accrued compensation		(437,324	)		(565,862	)
Accrued expenses		28,058			(69,744	)

Net cash (used in) operating activities		(1,902,962	)		(2,286,671	)

Cash flows from investing activities:
Purchases of short-term investments		(7,537,862	)		(11,305,556	)
Sales of short-term investments		9,648,744			14,402,745
Proceeds from sale of property and equipment		1,748,571			-
Purchases of patent and trademark application costs		(10,778	)		(14,679	)

Net cash provided by investing activities		3,848,675			3,082,510

Cash flows from financing activities:
Repayment of notes payable and other obligations		(116,931	)		(133,715	)

Net cash (used in) financing activities		(116,931	)		(133,715	)

Net change in cash and cash equivalents		1,828,782			662,124

Cash and cash equivalents at beginning of period		2,012,283			3,539,911

Cash and cash equivalents at end of period	$	3,841,065		$	4,202,035

Supplemental disclosure of cash flow information:
Cash paid during the period for interest	$	31,140		$	25,286

Supplemental disclosure of investing information:
Liability payoffs upon property sale	$	2,064,758		$	-

See Accompanying Notes to Unaudited Condensed Financial Statements

Venaxis, Inc.

Notes to Condensed Financial Statements

(Unaudited)

INTERIM FINANCIAL STATEMENTS

The accompanying financial statements of Venaxis, Inc. (the “Company,” “we,” or “Venaxis”) have been prepared in accordance with the instructions to quarterly reports on Form 10-Q. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and changes in financial position at March 31, 2016 and for all periods presented have been made. Certain information and footnote data necessary for fair presentation of financial position and results of operations in conformity with accounting principles generally accepted in the United States of America have been condensed or omitted. It is therefore suggested that these financial statements be read in conjunction with the summary of significant accounting policies and notes to financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015. The results of operations for the period ended March 31, 2016 are not necessarily an indication of operating results for the full year.

Management’s plans and basis of presentation:

The Company has experienced recurring losses and negative cash flows from operations. At March 31, 2016, the Company had approximate balances of cash and liquid investments of $16,600,000, working capital of $16,183,000, total stockholders’ equity of $16,678,000 and an accumulated deficit of $105,023,000. To date, the Company has in large part relied on equity financing to fund its operations. The Company expects to continue to incur losses from operations for the near-term and these losses could be significant as professional and other associated expenses in connection with possible strategic considerations, evaluations and transactions, appendicitis portfolio related expenses, public company and administrative related expenses are incurred. The Company believes that its current working capital position will be sufficient to meet its estimated cash needs into early 2017. The Company is closely monitoring its cash balances, cash needs and expense levels.

As of January 26, 2016, Venaxis publically disclosed that it had entered into a series of agreements, including a Master Agreement, for a combination transaction (the “Strand transaction”) with Strand Life Sciences Private Limited and its shareholders (“Strand”). Strand is privately-held, and operates clinical reference labs in the US and in India, providing testing and lab services in India and other world-wide markets. Strand has commercialized a next generation sequencing (NGS) based, targeted, multi-gene, pan-cancer diagnostic panel in select international markets and has engaged in initial commercialization activities in the United States.

On March 11, 2016, Venaxis and Strand entered into a Mutual Termination Agreement to terminate the series of agreements. Pursuant to the Mutual Termination Agreement, each of the parties was relieved of any obligations or responsibilities under the Master Agreement and other transaction agreements. Each party remains responsible for its respective transaction-related costs.

Following the recent termination of the Strand transaction, the Company has begun evaluating potential strategic alternatives. The Company expects, in the near term, to establish the primary criteria it will consider as it evaluates its next steps and strategic path forward with the goal of maximizing value for its shareholders. As a result of the current market trends and uncertainties, and the impact on many companies, management believes that there may currently be attractive opportunities available to the Company.

Management’s strategic assessment includes the following potential options:

exploring other possible strategic options available to the Company following termination of the Strand transaction;

evaluating options to monetize, partner or license the Company's appendicitis product portfolio;

continuing to explore prospective partnering or licensing opportunities with complementary opportunities and technologies; and

continuing to implement cost control initiatives to conserve cash.

As part of the Company’s process to identify possible strategic partners, several targets were identified that the Company assessed as possibly having a business model that could be interested in discussions with Venaxis for possibly acquiring or licensing the appendicitis assets. Venaxis has made initial contact with several of these parties to gauge their interest level, which initially is more focused on the APPY2 development assets. Management believes that the estimated potential market for an appendicitis test continues to be significant. If Venaxis is unable to locate a new strategic target, a partner or other third-party interested in advancing development and commercial activities of the Venaxis appendicitis portfolio, the capitalized costs on the Company’s balance sheet, totaling approximately $374,000, as of March 31, 2016 for the acute appendicitis patents may be deemed impaired.

Note 1. Significant accounting policies:

Cash, cash equivalents and investments:

The Company considers all highly liquid investments with an original maturity of three months or less at the date of acquisition to be cash equivalents. From time to time, the Company’s cash account balances exceed the balances as covered by the Federal Deposit Insurance System. The Company has never suffered a loss due to such excess balances.

The Company invests excess cash from time to time in highly-liquid debt and equity investments of highly-rated entities, which are classified as trading securities. Historically, the purpose of the investments has been to fund research and development, product development, FDA clearance-related activities and general corporate purposes. Such amounts are recorded at market values using Level 1 inputs in determining fair value and are generally classified as current, as the Company does not intend to hold the investments beyond twelve months. Investment securities classified as trading are those securities that are bought and held principally for the purpose of selling them in the near term, with the objective of preserving principal and generating profits. These securities are reported at fair value with unrealized gains and losses reported as an element of other (expense) income in current period earnings. The Company’s Board of Directors has approved an investment policy covering the investment parameters to be followed with the primary goals being the safety of principal amounts and maintaining liquidity. The policy provides for minimum investment rating requirements as well as limitations on investment duration and concentrations. Based upon market conditions, the investment guidelines have been tightened to increase the minimum acceptable investment ratings required for investments and shorten the maximum investment term. As of March 31, 2016, approximately 11% of the investment portfolio was in cash and cash equivalents, which is presented as such on the accompanying balance sheet, and the remaining funds were invested in marketable securities with none individually representing a material amount of the portfolio. Investments with a scheduled maturity beyond one year are classified as long-term investments on the balance sheet. To date, the Company’s cumulative realized market loss from the investments has not been significant. For the three months ended March 31, 2016 and 2015, there was approximately $5,900 and $8,400, respectively, in management fee expenses.

Fair value of financial instruments:

The Company accounts for financial instruments under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification Topic (“ASC”) 820, Fair Value Measurements. This statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements, ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels as follows:

Level 1— quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 — observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and

Level 3 — assets and liabilities whose significant value drivers are unobservable.

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment. There were no financial assets or liabilities measured at fair value, with the exception of cash, cash equivalents and short-term investments as of March 31, 2016 and December 31, 2015.

The carrying amounts of the Company’s financial instruments (other than cash, cash equivalents and short-term investments as discussed above) approximate fair value because of their variable interest rates and / or short maturities combined with the recent historical interest rate levels.

Revenue recognition and accounts receivable:

We recognize sales of goods under the provisions of ASC 605 and the U.S. Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin (“SAB”) 104, Revenue Recognition. Future revenue is expected to be generated primarily from the sale of products. Product revenue primarily consists of sales of instrumentation and consumables.

Revenue is recognized when the following four basic criteria have been met: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred and risk of loss has passed; (iii) the seller’s price to the buyer is fixed or determinable; and (iv) collectability is reasonably assured. In international markets, the Company sells its products to distributors or re-sellers, who subsequently resell the products to hospitals. The Company has an agreement with the distributor which provides that title and risk of loss pass to the distributor upon shipment of the products, FOB to the distributor. Revenue is recognized upon shipment of products to the distributor as the products are shipped based on FOB shipping point terms.

Revenues are recorded less a reserve for estimated product returns and allowances which to date has not been significant. Determination of the reserve for estimated product returns and allowances is based on management’s analyses and judgments regarding certain conditions. Should future changes in conditions prove management’s conclusions and judgments on previous analyses to be incorrect, revenue recognized for any reporting period could be adversely affected.

The Company extends credit to customers generally without requiring collateral. As of March 31, 2016, there were no accounts receivable and no sales. At December 31, 2015, the Company did not have any accounts receivable. During the three months ended March 31, 2015, three European-based customers accounted for the total net sales, each representing 12%, 44% and 44%, respectively.

The Company monitors its exposure for credit losses and maintains allowances for anticipated losses. The Company records an allowance for doubtful accounts when it is probable that the accounts receivable balance will not be collected. When estimating the allowance, the Company takes into consideration such factors as its day-to-day knowledge of the financial position of specific clients, the industry and size of its clients. A financial decline of any one of the Company’s large clients could have an adverse and material effect on the collectability of receivables and thus the adequacy of the allowance for doubtful accounts receivable. Increases in the allowance are recorded as charges to bad debt expense and are reflected in other operating expenses in the Company’s statements of operations. Write-offs of uncollectible accounts are charged against the allowance.

Recently issued and adopted accounting pronouncements:

The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company's financial reporting, the Company undertakes a study to determine the consequences of the change to its financial statements and assures that there are proper controls in place to ascertain that the Company's financial statements properly reflect the change.

In May 2014, the FASB issued Accounting Standards Update ("ASU") No. 2014-09 "Revenue from Contracts from Customers," which supersedes the revenue recognition requirements in "Revenue Recognition (Topic 605)," and requires entities to recognize revenue in a way that depicts the transfer of potential goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to the exchange for those goods or services. In July 2015, the FASB extended the effective date of ASU 2014-09 by one year, to now be effective for fiscal years, and interim periods beginning after December 15, 2017, and is to be applied retrospectively, with early adoption now permitted for fiscal years, and interim periods beginning after December 31, 2015. The Company does not believe the new standard will have a material impact on its operations and financial statements.

Income (loss) per share:

ASC 260, Earnings Per Share, requires dual presentation of basic and diluted earnings per share (“EPS”) with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity.

Basic net earnings (loss) per share includes no dilution and is computed by dividing net earnings (loss) available to shareholders by the weighted average number of common shares outstanding for the period. Diluted net earnings (loss) per share reflect the potential dilution of securities that could share in the Company’s earnings (loss). The outstanding options and warrants did not have a dilutive effect on earnings per share for the three months ended March 31, 2016 pursuant to the treasury stock method. The effect of the inclusion of the dilutive shares would have resulted in a decrease in loss per share for the three months ended March 31, 2015. Accordingly, the weighted average shares outstanding have not been adjusted for dilutive shares for either period presented. Outstanding stock options and warrants are not considered in the calculation, as the impact of the potential common shares (totaling approximately 757,000 shares and 779,000 shares for the three month periods ended March 31, 2016 and 2015, respectively) would be anti-dilutive.

Upon the completion of a special shareholders meeting on March 24, 2016, where such action was approved by shareholders, the Board of Directors authorized a reverse stock split of the Company’s common stock at a ratio of one-for-eight, whereby each eight shares of common stock were combined into one share of common stock (the “Reverse Stock Split”). The Reverse Stock Split was implemented and effective on March 31, 2016. All historical references to shares and share amounts in this report have been retroactively revised to reflect the Reverse Stock Split. A reconciliation of basic and diluted weighted average number of shares outstanding adjusted for the Reverse Stock Split for the period ended March 31, 2016 was 30,990,029 shares on a pre-split basis and 3,876,960 shares on a post-split basis.

Note 2. Property and equipment:

Property and equipment consisted of the following:

	March 31, 2016 (Unaudited)		December 31, 2015

Land and improvements	$	-	$	1,107,508
Building		-		2,589,231
Building improvements		-		253,526
Laboratory equipment		-		848,014
Office and computer equipment		66,104		318,254

		66,104		5,116,533
Less accumulated depreciation		65,208		3,162,037

	$	896	$	1,954,496

Depreciation expense totaled approximately $400 and $40,000 for the three month periods ended March 31, 2016 and 2015, respectively.

On February 25, 2016, the Company completed the sale of its corporate headquarters, land, building and certain fixtures and equipment to a third party at a purchase price of approximately $4,000,000 . The sale resulted in a gain of approximately $1,900,000 and generated approximately $1,700,000 in net cash after expenses and mortgage payoffs. The Company is leasing back space in the building under short term lease agreements that provide office and storage space required for its current level of operations.

Note 3. Other long-term assets:

Other long-term assets consisted of the following:

	March 31, 2016 (Unaudited)		December 31, 2015

Patents, trademarks and applications, net of accumulated amortization of $534,692 and $548,327, respectively	$	994,327	$	1,136,410
Goodwill		387,239		387,239

	$	1,381,566	$	1,523,649

The Company capitalizes legal costs and filing fees associated with obtaining patents on its new discoveries. Once the patents have been issued, the Company amortizes these costs over the shorter of the legal life of the patent or its estimated economic life using the straight-line method. Based upon the current status of the above intangible assets, the aggregate amortization expense is estimated to be approximately $76,000 for each of the next five fiscal years. The Company tests intangible assets with finite lives for impairment upon significant changes in the Company’s business environment. The testing resulted in net patent impairment charges of $134,000 and zero during the three months ended March 31, 2016 and 2015 respectively. The impairment charges are related to the Company’s ongoing analysis of which specific country patents in its portfolio are determined as potentially worth pursuing.

Note 4. Notes and Other Obligations:

Notes payable and other obligations consisted of the following:

	March 31, 2016 (Unaudited)		December 31, 2015

Mortgage notes	$	-	$	1,997,701
Other short-term installment obligations		57,152		142,328

		57,152		2,140,029
Less current portion		57,152		301,250

	$	-	$	1,838,779

Mortgage notes:

Prior to the February 2016 sale of the corporate headquarters, the Company had a permanent mortgage on its land and building that was refinanced in May 2013. The mortgage was held by a commercial bank and included a portion guaranteed by the U. S. Small Business Administration (“SBA”). The loan was collateralized by the real property and the SBA portion was also personally guaranteed by a former officer of the Company. The commercial bank loan terms included a payment schedule based on a fifteen year amortization, with a balloon maturity at five years. The commercial bank portion had an interest rate fixed at 3.95%, and the SBA portion bore interest at the rate of 5.86%. The commercial bank portion of the loan required total monthly payments of approximately $11,700, which included approximately $4,500 per month in interest. The SBA portion of the loan required total monthly payments of approximately $9,000 through July 2023, which included approximately $3,500 per month in interest and fees in 2016.

On February 25, 2016, the Company completed the sale of its corporate headquarters, land and building, and also paid off its mortgage obligations. See Note 2.

Future maturities:

The Company’s total debt obligations require minimum annual principal payments of approximately $57,000 for the remainder of 2016, with nothing due beyond that date.

Note 5. Stockholders’ equity:

Upon the completion of a special shareholders meeting on March 24, 2016, where such action was approved by shareholders, the Board of Directors authorized the Reverse Stock Split at a ratio of one-for-eight, whereby each eight shares of common stock were combined into one share of common stock . The Reverse Stock Split was implemented and effective on March 31, 2016. All historical references to shares and share amounts in this report have been retroactively revised to reflect the Reverse Stock Split. Following the Reverse Stock Split, the Company regained its compliance with the Nasdaq minimum bid price, allowing its common stock to continue to be listed on the Nasdaq Capital Market.

For the three months periods ended March 31, 2016 and 2015, the Company did not issue any common shares and no options or warrants were exercised during those same periods.

Note 6. Stock options and warrants:

Stock options:

The Company currently provides stock-based compensation to employees, directors and consultants, both under the Company's 2002 Stock Incentive Plan, as amended (the "Plan"), and non-qualified options and warrants issued outside of the Plan. During September 2015, the Company's shareholders approved amendments to the Plan to increase the number of shares reserved under the Plan from 459,141 to 709,141. The Company estimates the fair value of the share-based awards on the date of grant using the Black-Scholes option-pricing model (the "Black-Scholes model"). Using the Black-Scholes model, the value of the award that is ultimately expected to vest is recognized over the requisite service period in the statement of operations. Option forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company attributes compensation to expense using the straight-line single option method for all options granted.

The Company’s determination of the estimated fair value of share-based payment awards on the date of grant is affected by the following variables and assumptions:

·	The grant date exercise price – the closing market price of the Company’s common stock on the date of the grant;
·	Estimated option term – based on historical experience with existing option holders;
·	Estimated dividend rates – based on historical and anticipated dividends over the life of the option;
·	Term of the option – based on historical experience, grants have lives of approximately 3-5 years;
·	Risk-free interest rates – with maturities that approximate the expected life of the options granted;
·	Calculated stock price volatility – calculated over the expected life of the options granted, which is calculated based on the daily closing price of the Company’s common stock over a period equal to the expected term of the option; and
·	Option exercise behaviors – based on actual and projected employee stock option exercises and forfeitures.

The Company recognized total expenses for stock-based compensation during the three-month periods ended March 31, 2016 and 2015 of $47,884 and $433,402, respectively. These expenses are included in the accompanying statements of operations for the three-month periods ended March 31, in the following categories:

	2016		2015

Selling, general and administrative expenses	$	45,324	$	392,362
Research and development expenses		2,560		41,040

Total stock-based compensation	$	47,884	$	433,402

During the three months ended March 31, 2016 and 2015, respectively, no options were exercised.

Stock incentive plan options:

The Company currently provides stock-based compensation to employees, directors and consultants under the Plan. The Company did not grant any stock-based compensation to employees, directors or consultants for the three months ended March 31, 2016. Stock-based compensation to employees, directors and consultants for the three months ended March 31, 2015 utilized assumptions in the estimation of fair value of stock-based compensation as follows: a dividend yield of 0%, an expected price volatility of 93%, a risk free interest rate of 1.39%, and an expected term of 5 years.

A summary of activity under the Plan for the three months ended March 31, 2016 is presented below:

	Shares Underlying Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value

Outstanding at January 1, 2016		332,560		$	35.36
Granted		-			-
Exercised		-			-
Forfeited		(7,382	)		20.98

Outstanding at March 31, 2016		325,178		$	35.75		7.5		$	-

Exercisable at March 31, 2016		305,265		$	37.10		7.5		$	-

The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company’s closing stock price on March 31, 2016 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders, had all option holders been able to, and in fact had, exercised their options on March 31, 2016.

During the three months ended March 31, 2015, 43,000 options were issued to non-employee directors under the Plan, exercisable at an average of $15.12 per share. The options expire ten years from the date of grant and vested over one year, based upon 25% on the date of grant, and 25% on each of April 1, 2015, July 1, 2015, and October 1, 2015.

During the three months ended March 31, 2015, 98,813 options were issued to officers and employees under the Plan, exercisable at an average of $15.12 per share. The options expire ten years from the date of grant and vest over two years with 50% vesting upon six month anniversary of grant date and the remaining balance vesting over the following six quarters in arrears.

During the three months ended March 31, 2016, a total of 7,382 options that were granted under the Plan were forfeited, of which 3,762 were vested and 3,620 were unvested. The vested options were exercisable at an average of $26.61 per share and the unvested options were exercisable at an average of $15.13 per share. During the three months ended March 31, 2015, a total of 21,668 options that were granted under the Plan were forfeited, of which 1,876 were vested and 19,792 were unvested. The vested options were exercisable at an average of $193.36 per share and the unvested options were exercisable at an average of $16.48 per share.

The total fair value of stock options granted to employees, directors and consultants that vested and became exercisable during the three months ended March 31, 2016 and 2015, was approximately $127,000 and $234,000, respectively. Based upon the Company’s experience, approximately 80% of the outstanding nonvested stock options, or approximately 16,000 options, are expected to vest in the future, under their terms.

A summary of the activity of nonvested options under the Plan to acquire common shares granted to employees, officers, directors and consultants during the three months ended March 31, 2016 is presented below:

Nonvested Shares	Nonvested Shares Underlying Options			Weighted Average Exercise Price		Weighted Average Grant Date Fair Value

Nonvested at January 1, 2016		33,336		$	15.54	$	11.41
Granted		-			-		-
Vested		(9,803	)		16.67		12.92
Forfeited		(3,620	)		15.13		10.75

Nonvested at March 31, 2016		19,913		$	15.06	$	10.79

At March 31, 2016, based upon employee, officer, director and consultant options granted under the Plan to that point, there was approximately $128,000 of additional unrecognized compensation cost related to stock options that will be recorded over a weighted average future period of less than one year.

Other common stock purchase options and warrants:

As of March 31, 2016, in addition to the stock incentive plan options discussed above, the Company had outstanding 432,003 non-qualified options and warrants in connection with offering warrants and an officer’s employment that were not issued under the Plan.

During the three month periods ended March 31, 2016 and 2015, respectively, no stock options were granted outside of the Plan. Operating expenses for the three months ended March 31, 2016 and 2015, did not include any value related to stock-based compensation of non-qualified options and warrants.

Following is a summary of outstanding options and warrants that were issued outside of the Plan for the three months ended March 31, 2016:

	Shares Underlying Options / Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value

Outstanding at January 1, 2016		432,003	$	15.47
Granted		-		-
Exercised		-		-
Forfeited		-		-

Outstanding and exercisable at March 31, 2016		432,003	$	15.47	2.0	$	-

During the three months ended March 31, 2016 and 2015, no warrants were exercised.

The total fair value of stock options previously granted to a former officer that vested and became exercisable during the three months ended March 31, 2016 and 2015, was zero. At March 31, 2016, there was no unrecognized cost for non-qualified options that will be recorded in the future.

Note 7. Animal Health License Agreements:

Effective May 1, 2004 Washington University in St. Louis (“WU”) and Venaxis entered into an Exclusive License Agreement (“WU License Agreement”), which grants Venaxis exclusive license and right to sublicense WU’s technology (as defined under the WU License Agreement) for veterinary products worldwide, except where such products are prohibited under U.S. laws for export. The term of the WU License Agreement continues until the expiration of the last of WU’s patents (as defined in the WU License Agreement) expire. Venaxis has agreed to pay minimum annual royalties of $20,000 annually during the term of the WU License Agreement and such amounts are creditable against future royalties. Royalties payable to WU under the WU License Agreement for covered product sales by Venaxis carry a mid-single digit royalty rate and for sublicense fees received by Venaxis carry a low double-digit royalty rate. The WU License Agreement contains customary terms for confidentiality, prosecution and infringement provisions for licensed patents, publication rights, indemnification and insurance coverage. The WU License Agreement is cancelable by Venaxis with ninety days advance notice at any time and by WU with sixty days advance notice if Venaxis materially breaches the WU License Agreement and fails to cure such breach.

In July 2012, the Company entered into an Exclusive License Agreement (the “License Agreement”) with Ceva Santé Animale S.A. (“Licensee”), under which the Company granted the Licensee an exclusive royalty-bearing license, until December 31, 2028, to the Company’s intellectual property and other assets, including patent rights and know-how, relating to recombinant single chain reproductive hormone technology for use in non-human mammals (the “Company’s Animal Health Assets”). The License Agreement is subject to termination by the Licensee (a) for convenience on 180 days prior written notice, (b) in the Licensee’s discretion in the event of a sale or other disposal of the Company’s animal health assets, (c) in the Licensee’s discretion upon a change in control of the Company, (d) for a material breach of the License Agreement by the Company; or (e) in the Licensee’s discretion, if the Company becomes insolvent. The License Agreement is also terminable by the Company if there is a material breach of the License Agreement by the Licensee, or if the Licensee challenges the Company’s ownership of designated intellectual property. The License Agreement includes a sublicense of the technology licensed to the Company by WU. Under the terms of the WU License Agreement, a portion of license fees and royalties Venaxis receives from sublicensing agreements will be paid to WU. The obligation for such license fees due to WU is included in accrued expenses at March 31, 2016.

Under the License Agreement, the Licensee obtained a worldwide exclusive license to develop, seek regulatory approval for and offer to sell, market, distribute, import and export luteinizing hormone (“LH”) and/or follicle-stimulating hormone (“FSH”) products for bovine (cattle), equine and swine in the field of the assistance and facilitation of reproduction in bovine, equine and swine animals.

Under the License Agreement as of March 31, 2016, the following future milestone payments are provided, assuming future milestones are successfully achieved:

•	Milestone payments, totaling up to a potential of $1.1 million in the aggregate, based on the satisfactory conclusion of milestones as defined in the License Agreement;

•	Potential for milestone payments of up to an additional $2 million for development and receipt of regulatory approval for additional licensed products; and

•	Royalties, at low double digit rates, based on sales of licensed products.

Revenue recognition related to the License Agreement and WU License Agreement is based primarily on the Company’s consideration of ASC 808-10-45, “Accounting for Collaborative Arrangements”. For financial reporting purposes, the license fees and milestone payments received from the License Agreement, net of the amounts due to third parties, including WU, have been recorded as deferred revenue and are amortized over the term of the License Agreement. License fees and milestone revenue totaling a net of approximately $1,500,000 commenced being amortized into income upon the July 2012 date of milestone achievement. As of March 31, 2016, deferred revenue of $96,698 has been classified as a current liability and $1,137,840 has been classified as a long-term liability. The current liability represents the next twelve months’ portion of the amortizable milestone revenue. During the three months ended March 31, 2016 and 2015, $24,175 in each period was recorded as the amortized license fee revenue arising from the License Agreement.

A tabular summary of the revenue categories and cumulative amounts of revenue recognition associated with the License Agreement follows:

Category		Totals
License fees and milestone amounts paid / achieved		$	1,920,000
Third party obligations recorded, including WU			(363,700	)
Deferred revenue balance			1,556,300
Revenue amortization to March 31, 2016			(321,762	)

Net deferred revenue balance at March 31, 2016		$	1,234,538
Commencement of license fees revenue recognition	Upon signing or receipt
Commencement of milestone revenue recognition	Upon milestone achievement over then remaining life
Original amortization period	197 months

Note 8. Commitments and contingencies:

Commitments:

As of March 31, 2016, the Company had employment agreements with two officers providing aggregate annual minimum commitments totaling $655,000. The agreements automatically renew at the end of each year unless terminated by either party and contain customary confidentiality and benefit provisions.

Venaxis determined in the first quarter of 2016 to begin winding down and ceasing its APPY1 commercial activities, due to continuing limited sales and losses from the European operations. This decision also resulted in a reduction of the Company’s workforce, which was implemented as of January 31, 2016. In February 2016, Venaxis sent notices to its four European distributors informing them of the wind down and therefore the termination of their distribution agreements. Two of the distributors, linked by common management / ownership subsequently communicated to Venaxis that they dispute that Venaxis had the right to terminate the agreements. Under the terms of the distribution agreements, such a dispute shall first be attempted to be resolved between management of the parties and then subject to binding arbitration. Venaxis believes that the distributors’ claims are without merit and any potential settlement or resolution will not be material to the Company’s financial position.

Contingencies:

In the ordinary course of business and in the general industry in which the Company is engaged, it is not atypical to periodically receive a third party communication which may be in the form of a notice, threat, or “cease and desist” letter concerning certain activities. For example, this can occur in the context of the Company’s pursuit of intellectual property rights. This can also occur in the context of operations such as the using, making, having made, selling, and offering to sell products and services, and in other contexts. The Company makes rational assessments of each situation on a case-by-case basis as such may arise. The Company periodically evaluates its options for trademark positions and considers a full spectrum of alternatives for trademark protection and product branding.

We are currently not a party to any legal proceedings, the adverse outcome of which would, in our management’s opinion, have a material adverse effect on our business, financial condition and results of operations.

Note 9. Subsequent event:

Subsequent to March 31, 2016, 77,000 options were issued to non-employee directors under the Plan, exercisable at an average of $2.89 per share. The options expire ten years from the date of grant and vest over one year, based upon 50% on the date of grant, and 25% on each of July 1, 2016, and October 1, 2016.

Subsequent to March 31, 2016, 150,000 options were issued to officers and employees under the Plan, exercisable at an average of $2.89 per share. The options expire ten years from the date of grant and vest 50% upon each of the six month and the one year anniversary of the grant date.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Management’s plans and basis of presentation:

Management’s strategic assessment includes the following potential options:

exploring other possible strategic options available to the Company following termination of the Strand transaction;

evaluating options to monetize, partner or license the Company's appendicitis product portfolio;

continuing to explore prospective partnering or licensing opportunities with complementary opportunities and technologies; and

continuing to implement cost control initiatives to conserve cash.

Results of Operations

Comparative Results for the Three Months Ended March 31, 2016 and 2015

No sales were recorded for the three months ended March 31, 2016, as compared to sales of $11,000 in the 2015 period. The 2015 sales resulted from APPY1 product sales in the EU. Sales of the APPY1 products have been to customers for initial stocking and market study orders in the EU under commercial development agreements. The decrease is attributable to the wind down of the APPY1 activities.

Cost of sales was zero and 35% of revenue for the three months ended March 31, 2016 and 2015, respectively. The decrease in the 2016 period is attributable to the wind down of the APPY1 activities.

During the three month periods ended March 31, 2016 and 2015, $24,000 in each period, of license payments under the License Agreement was recognized as revenue.

Selling, general and administrative expenses in the three months ended March 31, 2016 totaled $1,030,000, which is approximately $506,000, or 33%, decrease as compared to the 2015 period. Commercialization, marketing and compensation related expenses decreased by approximately $329,000 in the 2016 period as the Company began winding down APPY1 commercialization activities. Stock based compensation also decreased by approximately $347,000 for the three months ended March 31, 2016 as compared to the 2015 period due to no options being granted to directors, management and employees. A decrease of $78,000 in legal expenses for the 2016 period was due to the settlement/dismissal of litigation in late 2015. These decreases were offset by an increase in strategic evaluation costs of approximately $302,000 as the Company continued to evaluate possible alternatives including the Strand transaction.

Research and development expenses in the three months ended March 31, 2016 totaled $373,000, which is approximately a $335,000, or 47%, decrease as compared to the 2015 period. A decrease of $294,000 was due primarily to winding down development and commercialization of APPY2 and APPY1 operations. A decrease of $137,000 was due to staff reductions related to winding down such operations. These decreases were partially offset by an increase in patent impairment costs of approximately $134,000.

Interest expense for the three months ended March 31, 2016, increased to $26,000 compared to $25,000 in the 2015 period. For the three months ended March 31, 2016, the Company recorded investment income of approximately $44,000 compared to investment income of $51,000 in the 2015 period.

On February 25, 2016, the Company completed the sale of its corporate headquarters, land, building and certain fixtures and equipment to a third party at a purchase price of $4,053,000. The sale resulted in a gain of approximately $1,900,000 and generated approximately $1,700,000 in net cash after expenses and mortgage payoffs. The Company is leasing back space in the building under short term lease agreements that provide office and storage space required for its current level of operations.

No income tax benefit was recorded on the net loss for the three months ended March 31, 2016 and 2015, as management was unable to determine that it was more likely than not that such benefit would be realized.

Liquidity and Capital Resources

At March 31, 2016, we had working capital of $16,183,000, which included cash, cash equivalents and short term investments of $16,600,000. We reported a net income of $560,000 during the three months ended March 31, 2016, which included $1,742,000 in non-cash items consisting of stock-based compensation totaling $48,000, depreciation and amortization totaling $19,000, and impairment of patent costs of $134,000, a net of gain on sale of property and equipment totaling $1,919,000, and amortization of license fees totaling $24,000.

We expect to continue to incur losses from operations for the near-term and these losses could be significant as we incur professional and other associated expenses in connection with the various strategic opportunities that are being evaluated, appendicitis portfolio related expenses, public company and administrative related expenses. We believe that our current working capital position will be sufficient to meet our estimated cash needs into early 2017. We may pursue potential additional financing opportunities; however, there can be no assurance that we will be able to obtain sufficient additional financing on terms acceptable to us, if at all. We are closely monitoring our cash balances, cash needs and expense levels. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that might result in our possible inability to continue as a going concern.

As a result of the termination of the Strand transaction, the Company is evaluating new strategic alternatives. If the Company is unable to locate a new strategic target, or a partner or other third-party interested in advancing development and or commercial activities of the Venaxis appendicitis portfolio, the costs the Company has incurred for the acute appendicitis patents and other development assets may be deemed impaired.

In July 2012, the Company entered into an Exclusive License Agreement (the “License Agreement”) with Ceva Santé Animale S.A. (“Licensee”), under which the Company granted the Licensee an exclusive royalty-bearing license, until December 31, 2028, to the Company’s intellectual property and other assets, including patent rights and know-how, relating to recombinant single chain reproductive hormone technology for use in non-human mammals (the “Company’s Animal Health Assets”). The License Agreement is subject to termination by the Licensee (a) for convenience on 180 days prior written notice, (b) in the Licensee’s discretion in the event of a sale or other disposal of the Company’s animal health assets, (c) in the Licensee’s discretion upon a change in control of the Company, (d) for a material breach of the License Agreement by the Company, or (e) in the Licensee’s discretion, if the Company becomes insolvent. The License Agreement is also terminable by the Company if there is a material breach of the License Agreement by the Licensee, or if the Licensee challenges the Company’s ownership of designated intellectual property. The License Agreement includes a sublicense of the technology licensed to the Company by Washington University in St. Louis (“WU”). Under the terms of the WU License Agreement, a portion of license fees and royalties Venaxis receives from sublicensing agreements will be paid to WU. The obligation for such license fees due to WU is included in accrued expenses at March 31, 2016.

Under the License Agreement as of March 31, 2016, the following future milestone payments are provided, assuming future milestones are successfully achieved:

•	Milestone payments, totaling up to a potential of $1.1 million in the aggregate, based on the satisfactory conclusion of milestones as defined in the License Agreement;

•	Potential for milestone payments of up to an additional $2 million for development and receipt of regulatory approval for additional licensed products; and

•	Royalties, at low double digit rates, based on sales of licensed products.

The Company periodically enters into generally short-term consulting agreements, which at this time are primarily for assistance with our strategic evaluations. Such commitments at any point in time may be significant but the agreements typically contain cancellation provisions.

Prior to the February 2016 sale of its corporate headquarters, the Company had a permanent mortgage on its land and building that was refinanced in May 2013. The mortgage was held by a commercial bank and included a portion guaranteed by the U. S. Small Business Administration (“SBA”). The loan was collateralized by the real property and the SBA portion was also personally guaranteed by a former officer of the Company. The commercial bank loan terms included a payment schedule based on a fifteen year amortization, with a balloon maturity at five years. The commercial bank portion had an interest rate fixed at 3.95%, and the SBA portion bore interest at the rate of 5.86%. The commercial bank portion of the loan required total monthly payments of approximately $11,700, which included approximately $4,500 per month in interest. The SBA portion of the loan required total monthly payments of approximately $9,000 through July 2023, which included approximately $3,500 per month in interest and fees in 2016.

Due to recent market events that have adversely affected all industries and the economy as a whole, management has placed increased emphasis on monitoring the risks associated with the current environment, particularly the investment parameters of the short term investments, the recoverability of current assets, the fair value of assets, and the Company’s liquidity. At this point in time, there has not been a material impact on the Company’s assets and liquidity. Management will continue to monitor the risks associated with the current environment and their impact on the Company’s results.

Operating Activities

Net cash consumed by operating activities was $1,903,000 during the three months ended March 31, 2016. Cash was generated by a net income of $560,000, less non-cash expenses of $201,000 for stock-based compensation, depreciation and amortization, and impairment of patent costs, offset by the gain on sale of property and equipment of $1,919,000 and amortization of license fees totaling $24,000. Decreases in prepaid and other current assets of $69,000 provided cash, primarily related to routine changes in operating activities. There was a $789,000 decrease in accounts payable and accrued expenses in the three months ended March 31, 2016, primarily due to the payment of 2015 accrued incentives in early 2016, and a reduction in overall expenses due to the wind down of the APPY1 activities.

Net cash consumed by operating activities was $2,287,000 during the three months ended March 31, 2015. Cash was consumed by the loss of $2,186,000, less non-cash expenses of $497,000 for stock-based compensation and depreciation and amortization, offset by the amortization of license fees totaling $24,000. Decreases in prepaid and other current assets of $97,000 provided cash, primarily related to routine changes in operating activities. There was a $670,000 decrease in accounts payable and accrued expenses in the three months ended March 31, 2015, primarily due to a decrease in the accrued compensation.

Investing Activities

Net cash inflows from investing activities provided $3,849,000 during the three months ended March 31, 2016. Sales of marketable securities investments totaling approximately $9,649,000 provided cash net of marketable securities purchased totaling approximately $7,538,000. An $11,000 use of cash was attributable to additional costs incurred from patent filings. The sale of the land, building and assets generated approximately $1,749,000 in cash.

Net cash inflows from investing activities provided $3,083,000 during the three months ended March 31, 2015. Sales of marketable securities investments totaled approximately $14,403,000 and marketable securities purchased totaled approximately $11,306,000. A $15,000 use of cash was attributable to additional costs incurred from patent filings.

Financing Activities

Net cash outflows from financing activities consumed $117,000 during the three months ended March 31, 2016 in scheduled payments under debt agreements.

Net cash outflows from financing activities consumed $134,000 during the three months ended March 31, 2015 in scheduled payments under debt agreements.

Critical Accounting Policies

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions about future events that affect the amounts reported in the financial statements and accompanying notes. Future events and their effects cannot be determined with absolute certainty. Therefore, the determination of estimates requires the exercise of judgment. Actual results inevitably will differ from those estimates, and such differences may be material to the financial statements. The most significant accounting estimates inherent in the preparation of our financial statements include estimates associated with revenue recognition, impairment analysis of intangibles and stock-based compensation.

The Company’s financial position, results of operations and cash flows are impacted by the accounting policies the Company has adopted. In order to get a full understanding of the Company’s financial statements, one must have a clear understanding of the accounting policies employed. A summary of the Company’s critical accounting policies follows:

Investments: The Company invests excess cash from time to time in highly liquid debt and equity securities of highly rated entities which are classified as trading securities. Such amounts are recorded at market and are generally classified as current, as the Company does not intend to hold the investments beyond twelve months. Such excess funds are invested under the Company’s investment policy but an unexpected decline or loss could have an adverse and material effect on the carrying value, recoverability or investment returns of such investments. Our Board has approved an investment policy covering the investment parameters to be followed with the primary goals being the safety of principal amounts and maintaining liquidity of the fund. The policy provides for minimum investment rating requirements as well as limitations on investment duration and concentrations.

Intangible Assets: Intangible assets primarily represent legal costs and filings associated with obtaining patents on the Company’s new discoveries. The Company amortizes these costs over the shorter of the legal life of the patent or its estimated economic life using the straight-line method. The Company tests intangible assets with finite lives upon significant changes in the Company’s business environment. The testing resulted in $134,000 net patent impairment charges written off during the three month periods ended March 31, 2016 and zero for the three months ended March 31, 2015.

Long-Lived Assets: The Company records property and equipment at cost. Depreciation of the assets is recorded on the straight-line basis over the estimated useful lives of the assets. Dispositions of property and equipment are recorded in the period of disposition and any resulting gains or losses are charged to income or expense when the disposal occurs. The Company reviews for impairment whenever there is an indication of impairment.

Revenue Recognition: The Company’s revenues are recognized when products are shipped or delivered to unaffiliated customers. The Securities and Exchange Commission’s Staff Accounting Bulletin (SAB) No. 104, provides guidance on the application of generally accepted accounting principles to select revenue recognition issues. The Company has concluded that its revenue recognition policy is appropriate and in accordance with SAB No. 104. Revenue is recognized under sales, license and distribution agreements only after the following criteria are met: (i) there exists adequate evidence of the transactions; (ii) delivery of goods has occurred or services have been rendered; and (iii) the price is not contingent on future activity and (iv) collectability is reasonably assured.

Stock-based Compensation: ASC 718, Share-Based Payment, defines the fair-value-based method of accounting for stock-based employee compensation plans and transactions used by the Company to account for its issuances of equity instruments to record compensation cost for stock-based employee compensation plans at fair value as well as to acquire goods or services from non-employees. Transactions in which the Company issues stock-based compensation to employees, directors and consultants and for goods or services received from non-employees are accounted for based on the fair value of the equity instruments issued. The Company utilizes pricing models in determining the fair values of options and warrants issued as stock-based compensation. These pricing models utilize the market price of the Company’s common stock and the exercise price of the option or warrant, as well as time value and volatility factors underlying the positions.

Recently issued and adopted accounting pronouncements: The Company has evaluated all recently issued accounting pronouncements and believes such pronouncements do not have a material effect on the Company’s financial statements.

In May 2014, FASB issued Accounting Standards Update ("ASU") No. 2014-09 "Revenue from Contracts from Customers," which supersedes the revenue recognition requirements in "Revenue Recognition (Topic 605)," and requires entities to recognize revenue in a way that depicts the transfer of potential goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to the exchange for those goods or services. In July 2015, the FASB extended the effective date of ASU 2014-09 by one year, to now be effective for fiscal years, and interim periods beginning after December 15, 2017, and is to be applied retrospectively, with early adoption now permitted for fiscal years, and interim periods beginning after December 31, 2015. The Company does not believe that the new standard will have a material impact on its future operations and financial statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

General

We have limited exposure to market risks from instruments that may impact the Balance Sheets, Statements of Operations, and Statements of Cash Flows. Such exposure is due primarily to changing interest rates.

Interest Rates

The primary objective for our investment activities is to preserve principal while maximizing yields without significantly increasing risk. This is accomplished by investing excess cash in highly liquid debt and equity investments of highly rated entities which are classified as trading securities. As of March 31, 2016, approximately 11% of the investment portfolio was in cash and cash equivalents with very short term maturities and therefore not subject to any significant interest rate fluctuations. We have no investments denominated in foreign currencies and therefore our investments are not subject to foreign currency exchange risk.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Management of the Company, including the Chief Executive Officer and the Chief Financial Officer, has conducted an evaluation of the effectiveness of the Company’s disclosure controls and procedures (as defined in the Securities Exchange Act of 1934 Rule 13a-15(e)) as of the last day of the period of the accompanying financial statements. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective as of March 31, 2016.

Changes in Internal Control Over Financial Reporting

There was no change in the Company’s internal control over financial reporting that occurred during the fiscal quarter to which this report relates that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

We are not a party to any other legal proceedings, the adverse outcome of which would, in our management’s opinion, have a material adverse effect on our business, financial condition and results of operations.

Item 1A. Risk Factors

There have been no material changes from the risk factors disclosed in our Annual Report on Form 10-K, for the year ended December 31, 2015.

Item 6. Exhibits

(a)

Exhibits

EXHIBIT		DESCRIPTION

3.1		Articles of Amendment to amend and restate the Articles of Incorporation, as amended, of Venaxis, Inc. (Incorporated by reference to the Registrant’s Report on Form 8-K, dated March 24, 2016 and filed on March 29, 2016).
10.14		Master Agreement, dated January 26, 2016, by and among Strand Life Sciences Private Limited, Strand Genomics, Inc. and Venaxis, Inc. (Incorporated by reference to the Registrant’s Report on Form 8-K, dated January 26, 2016 and filed on January 27, 2016).
10.15		Asset Purchase Agreement, dated January 26, 2016, by and between Strand Genomics, Inc., as seller, and Venaxis sub, Inc., as buyer. (Incorporated by reference to the Registrant’s Report on Form 8-K, dated January 26, 2016 and filed on January 27, 2016).
10.16		Form of Share Sale Agreement between Venaxis, Inc. and a Strand Life Sciences Private Limited Shareholder. (Incorporated by reference to the Registrant’s Report on Form 8-K, dated January 26, 2016 and filed on January 27, 2016).
10.17		Form of Investment Agreement between Venaxis, Inc. and a Strand Life Sciences Private Limited Shareholder. (Incorporated by reference to the Registrant’s Report on Form 8-K, dated January 26, 2016 and filed on January 27, 2016).
10.18		Form of Investment Agreement between Venaxis, Inc. and Biomark Capital Fund IV, L.P. (Incorporated by reference to the Registrant’s Report on Form 8-K, dated January 26, 2016 and filed on January 27, 2016).
10.19		Mutual Termination Agreement, dated March 11, 2016, by and among Venaxis, Inc., Strand Life Sciences Private Limited and Strand Genomics, Inc. (Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, dated and filed March 14, 2016).
31.1		Rule 13a-14(a)/15d-14(a) - Certification of Chief Executive Officer. Filed herewith.
31.2		Rule 13a-14(a)/15d-14(a) - Certification of Chief Financial Officer. Filed herewith.
32		Section 1350 Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Furnished herewith.
99.1		Notice to Corporate Stock Transfer Inc., as Warrant Agent, dated April 1, 2016 (incorporated by reference to Exhibit 99.1 to the Registrant’s Current Report on Form 8-K, dated March 31, 2016, and filed April 4, 2016).
101		Interactive data files pursuant to Rule 405 of Regulation S-T: (i) the Balance Sheets, (ii) the Statements of Operations, (iii) the Statement of Cash Flows and (iv) the Notes to Condensed Financial Statements. (1)

(1)	Pursuant to Rule 406T of Regulation S-T, the XBRL related information in Exhibit 101 to this Quarterly Report on Form 10-Q shall not be deemed to be filed by the Company for purposes of Section 18 or any other provision of the Exchange Act of 1934, as amended.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Venaxis, Inc. (Registrant)
	By:	/s/ Jeffrey G. McGonegal
Dated: May 11, 2016		Jeffrey G. McGonegal, Chief Financial Officer and duly authorized officer

EX-31.1 2 ex31x1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATION

I, Stephen T. Lundy, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Venaxis, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


May 11, 2016
	/s/ Stephen T. Lundy
	Stephen T. Lundy, Chief Executive Officer and President

EX-31.2 3 ex31x2.htm EXHIBIT 31.2

EXHIBIT 31.2

CERTIFICATION

I, Jeffrey G. McGonegal, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Venaxis, Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


May 11, 2016
	/s/ Jeffrey G. McGonegal
	Jeffrey G. McGonegal, Chief Financial Officer

EX-32.1 4 ex32x1.htm EXHIBIT 32.1

EXHIBIT 32

CERTIFICATION PURSUANT

TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q (the “Report”) of Venaxis, Inc. (the “Company”) for the quarter ended March 31, 2016, each of the undersigned Stephen T. Lundy and Jeffrey G. McGonegal, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of the undersigned’s knowledge and belief:

	(1)	the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
	(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

May 11, 2016
			/s/ Stephen T. Lundy
			Stephen T. Lundy, Chief Executive Officer and President
May 11, 2016
			/s/ Jeffrey G. McGonegal
			Jeffrey G. McGonegal, Chief Financial Officer

* * * * *

EX-101.INS 5 appy-20160331.xml XBRL INSTANCE DOCUMENT 0001167419 2016-05-11 0001167419 2015-12-31 0001167419 2016-03-31 0001167419 2015-01-01 2015-03-31 0001167419 us-gaap:LandAndLandImprovementsMember 2016-03-31 0001167419 us-gaap:LandAndLandImprovementsMember 2015-12-31 0001167419 us-gaap:BuildingMember 2016-03-31 0001167419 us-gaap:BuildingMember 2015-12-31 0001167419 us-gaap:BuildingAndBuildingImprovementsMember 2016-03-31 0001167419 us-gaap:BuildingAndBuildingImprovementsMember 2015-12-31 0001167419 us-gaap:OtherMachineryAndEquipmentMember 2016-03-31 0001167419 us-gaap:OtherMachineryAndEquipmentMember 2015-12-31 0001167419 us-gaap:OfficeEquipmentMember 2016-03-31 0001167419 us-gaap:OfficeEquipmentMember 2015-12-31 0001167419 us-gaap:MortgagesMember appy:UnitedStatesSmallBusinessAdministrationMember 2016-01-01 2016-03-31 0001167419 us-gaap:MortgagesMember 2016-01-01 2016-03-31 0001167419 us-gaap:MortgagesMember us-gaap:NotesPayableToBanksMember 2016-03-31 0001167419 us-gaap:MortgagesMember appy:UnitedStatesSmallBusinessAdministrationMember 2016-03-31 0001167419 us-gaap:MortgagesMember us-gaap:NotesPayableToBanksMember 2016-01-01 2016-03-31 0001167419 appy:StockIncentivePlanMember 2016-01-01 2016-03-31 0001167419 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2015-01-01 2015-03-31 0001167419 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember appy:CustomerOneMember 2015-01-01 2015-03-31 0001167419 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember appy:CustomerTwoMember 2015-01-01 2015-03-31 0001167419 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember appy:CustomerThreeMember 2015-01-01 2015-03-31 0001167419 2015-08-31 0001167419 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-01-01 2015-03-31 0001167419 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-03-31 0001167419 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-03-31 0001167419 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-03-31 0001167419 appy:StockIncentivePlanMember 2015-01-01 2015-03-31 0001167419 appy:StockIncentivePlanMember 2016-03-31 0001167419 appy:StockIncentivePlanMember appy:IndependentDirectorsMember 2015-01-01 2015-03-31 0001167419 appy:StockIncentivePlanMember appy:DirectorsEmployeesAndConsultantsMember 2015-01-01 2015-03-31 0001167419 appy:NonqualifiedMember 2016-03-31 0001167419 appy:NonqualifiedMember 2015-12-31 0001167419 appy:NonqualifiedMember 2016-01-01 2016-03-31 0001167419 us-gaap:EmploymentContractsMember 2016-03-31 0001167419 2016-01-01 2016-03-31 0001167419 2014-12-31 0001167419 2015-03-31 0001167419 2016-02-29 0001167419 2015-09-01 0001167419 appy:StockIncentivePlanMember appy:OfficersAndEmployeesMember 2015-01-01 2015-03-31 0001167419 appy:StockIncentivePlanMember us-gaap:MaximumMember 2016-01-01 2016-03-31 0001167419 appy:StockIncentivePlanMember 2015-12-31 0001167419 appy:StockIncentivePlanMember us-gaap:MinimumMember 2016-01-01 2016-03-31 0001167419 us-gaap:SubsequentEventMember appy:StockIncentivePlanMember appy:IndependentDirectorsMember 2016-04-01 2016-05-11 0001167419 us-gaap:SubsequentEventMember appy:StockIncentivePlanMember appy:OfficersAndEmployeesMember 2016-04-01 2016-05-11 iso4217:USD iso4217:USD xbrli:shares xbrli:shares xbrli:pure appy:item appy:Officers 3876960

14147991

12759109

251778

241817

16412052

16841991

1954496

896

1523649

1381566

20862197

18474453

701064

321054

449873

12549

241882

171129

301250

57152

96698

1790767

658582

1838779

1162015

1137840

4791561

1796422

60000000

3876960

121653075

121700959

-105582439

-105022928

16070636

16678031

2012283

3841065

3539911

4202035

20862197

18474453

11288

4007

7281

24175

1535851

1030126

707742

372586

2243593

1402712

-2212137

-1378537

25064

25598

50828

44285

25764

1938048

-2186373

559511

-0.56

0.14

3876960

433402

47884

64021

19401

24175

-7077

-89690

-69155

-34707

-380010

-565862

-437324

-69744

28058

-2286671

-1902962

11305556

7537862

14402745

9648744

14679

10778

3082510

3848675

133715

116931

-133715

-116931

662124

1828782

25286

31140

16600000

16183000

5116533

66104

1107508

2589231

253526

848014

66104

318254

3162037

65208

134000

2140029

57152

P15Y P5Y

0.0395

0.0586

9000

11700

8400

5900

0.11

0.12

0.44

40000

400

548327

534692

1136410

994327

387239

76000

1997701

142328

57152

57000

3500

4500

459141

709141

P10Y

P5Y

P3Y

P10Y

433402

392362

45324

41040

2560

47884

.93

.0139

P5Y

325178

432003

332560

35.75

15.47

35.36

43000

98813

77000

150000

15.12

2.89

7382

21668

20.98

P7Y6M

P2Y

305265

37.10

P7Y6M

P1Y

P2Y

P1Y

P6M

0.25

0.50

3762

1876

3620

19792

26.61

193.36

15.13

16.48

127000

234000

16000

128000

20000

P180D 1100000 2000000 1920000

363700

1556300 321762

1234538

655000

2 Venaxis, Inc. 0001167419 10-Q false 2016-03-31 --12-31 Q1 2016 Smaller Reporting Company

972000

250000

3876960

1919361

133899

1748571

2064758 374000 4000000

76000

P197M

779000

757000

P1Y

19913

33336

9803

15.06 15.54 16.67

10.79

11.41

12.92

10.75

30990029

<div><div style="margin-bottom: 3pt; text-align: left; margin-top: 3pt; line-height: 1"></div> <div style="margin-bottom: 3pt; font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; margin-top: 3pt">INTERIM FINANCIAL STATEMENTS</div> <div style="margin-bottom: 3pt; text-align: justify; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">The accompanying financial statements of Venaxis, Inc. (the “Company,”  “we,” or “Venaxis”) have been prepared in accordance with the instructions to quarterly reports on Form 10-Q. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and changes in financial position at March 31, 2016 and for all periods presented have been made. Certain information and footnote data necessary for fair presentation of financial position and results of operations in conformity with accounting principles generally accepted in the United States of America have been condensed or omitted. It is therefore suggested that these financial statements be read in conjunction with the summary of significant accounting policies and notes to financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015. The results of operations for the period ended March 31, 2016 are not necessarily an indication of operating results for the full year.</div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">Management’s plans and basis of presentation:</div> <div style="margin-bottom: 12pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 12pt">The Company has experienced recurring losses and negative cash flows from operations.  At March 31, 2016, the Company had approximate balances of cash and liquid investments of $16,600,000, working capital of $16,183,000, total stockholders’ equity of $16,678,000 and an accumulated deficit of $105,023,000. To date, the Company has in large part relied on equity financing to fund its operations.  The Company expects to continue to incur losses from operations for the near-term and these losses could be significant as professional and other associated expenses in connection with possible strategic considerations, evaluations and transactions, appendicitis portfolio related expenses, public company and administrative related expenses are incurred. The Company believes that its current working capital position will be sufficient to meet its estimated cash needs into early 2017.  The Company is closely monitoring its cash balances, cash needs and expense levels.</div> <div style="margin-bottom: 12pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 12pt">As of January 26, 2016, Venaxis publically disclosed that it had entered into a series of agreements, including a Master Agreement, for a combination transaction (the “Strand transaction”) with Strand Life Sciences Private Limited and its shareholders (“Strand”).  Strand is privately-held, and operates clinical reference labs in the US and in India, providing testing and lab services in India and other world-wide markets.  Strand has commercialized a next generation sequencing (NGS) based, targeted, multi-gene, pan-cancer diagnostic panel in select international markets and has engaged in initial commercialization activities in the United States.</div> <div style="margin-bottom: 12pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 12pt">On March 11, 2016, Venaxis and Strand entered into a Mutual Termination Agreement to terminate the series of agreements.  Pursuant to the Mutual Termination Agreement, each of the parties was relieved of any obligations or responsibilities under the Master Agreement and other transaction agreements.  Each party remains responsible for its respective transaction-related costs.</div> <div style="margin-bottom: 12pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 12pt">Following the recent termination of the Strand transaction, the Company has begun evaluating potential strategic alternatives. The Company expects, in the near term, to establish the primary criteria it will consider as it evaluates its next steps and strategic path forward with the goal of maximizing value for its shareholders. As a result of the current market trends and uncertainties, and the impact on many companies, management believes that there may currently be attractive opportunities available to the Company.</div> <div style="margin-bottom: 12pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 12pt">Management’s strategic assessment includes the following potential options:</div> <div style="margin-bottom: 12pt; text-align: justify; margin-top: 12pt; line-height: 1"> <table id="a92f29f05bf134e8fa329ae452e5cdb10" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"> <tr> <td style="width: 20.25pt"></td> <td style="font: 10pt Symbol, serif; width: 27pt; vertical-align: top; color: #000000">·</td> <td style="font: 10pt Times New Roman, Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify">exploring other possible strategic options available to the Company following termination of the Strand transaction;</td> </tr> </table> </div> <div style="margin-bottom: 12pt; text-align: justify; margin-top: 12pt; line-height: 1"> <table id="a27bd492c83dd45dbbd042cabb8d7ff02" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"> <tr> <td style="width: 20.25pt"></td> <td style="font: 10pt Symbol, serif; width: 27pt; vertical-align: top; color: #000000">·</td> <td style="font: 10pt Times New Roman, Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify">evaluating options to monetize, partner or license the Company's appendicitis product portfolio;</td> </tr> </table> </div> <div style="margin-bottom: 12pt; text-align: justify; margin-top: 12pt; line-height: 1"> <table id="a06ebf9276b7c48f0b7683adcb70279ae" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"> <tr> <td style="width: 20.25pt"></td> <td style="font: 10pt Symbol, serif; width: 27pt; vertical-align: top; color: #000000">·</td> <td style="font: 10pt Times New Roman, Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify">continuing to explore prospective partnering or licensing opportunities with complementary opportunities and technologies; and</td> </tr> </table> </div> <div style="margin-bottom: 12pt; text-align: justify; margin-top: 12pt; line-height: 1"> <table id="a7f4fd3cbdce04c69a0fd61203b476fa1" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"> <tr> <td style="width: 20.25pt"></td> <td style="font: 10pt Symbol, serif; width: 27pt; vertical-align: top; color: #000000">·</td> <td style="font: 10pt Times New Roman, Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify">continuing to implement cost control initiatives to conserve cash.</td> </tr> </table> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">As part of the Company’s process to identify possible strategic partners, several targets were identified that the Company assessed as possibly having a business model that could be interested in discussions with Venaxis for possibly acquiring or licensing the appendicitis assets. Venaxis has made initial contact with several of these parties to gauge their interest level, which initially is more focused on the <font style="font: italic 10pt Times New Roman, Times, serif">APPY</font>2 development assets. Management believes that the estimated potential market for an appendicitis test continues to be significant. If Venaxis is unable to locate a new strategic target, a partner or other third-party interested in advancing development and commercial activities of the Venaxis appendicitis portfolio, the capitalized costs on the Company’s balance sheet, totaling approximately $374,000, as of March 31, 2016 for the acute appendicitis patents may be deemed impaired.</div></div>

<div><div style="margin-bottom: 3pt; font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; margin-top: 3pt">Note 2. Property and equipment:</div> <div style="margin-bottom: 3pt; text-align: left; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; margin-top: 3pt">Property and equipment consisted of the following:</div> <div style="margin-bottom: 3pt; text-align: left; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <table id="a5dbdae07fd394f9a8a29048e136e2fec" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">March 31,</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">2016</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">(Unaudited)</div> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom"> </td> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">December 31,</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">2015</div> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; vertical-align: bottom"> </td> <td style="vertical-align: bottom; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; vertical-align: bottom"></td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: left; vertical-align: bottom"> </td> <td style="vertical-align: bottom; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; vertical-align: bottom"></td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: left; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Land and improvements</div> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">-</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">1,107,508</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Building</div> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">-</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">2,589,231</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Building improvements</div> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">-</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">253,526</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Laboratory equipment</div> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">-</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">848,014</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Office and computer equipment</div> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">66,104</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">318,254</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">66,104</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">5,116,533</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Less accumulated depreciation</div> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">65,208</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">3,162,037</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">896</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">1,954,496</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> </table> <div style="margin-bottom: 3pt; text-align: center; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">Depreciation expense totaled approximately $400 and $40,000 for the three month periods ended March 31, 2016 and 2015, respectively.</div> <div style="margin-bottom: 12pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 12pt">On February 25, 2016, the Company completed the sale of its corporate headquarters, land, building and certain fixtures and equipment to a third party at a purchase price of approximately $4,000,000 . The sale resulted in a gain of approximately $1,900,000 and generated approximately $1,700,000 in net cash after expenses and mortgage payoffs. The Company is leasing back space in the building under short term lease agreements that provide office and storage space required for its current level of operations.</div></div>

<div><div style="margin-bottom: 3pt; font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; margin-top: 3pt">Note 3.  Other long-term assets:</div> <div style="margin-bottom: 3pt; text-align: left; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; margin-top: 3pt">Other long-term assets consisted of the following:<br style="line-height: 1" /> </div> <table id="a1d8871b5754a43778a3ee5b0aeca076b" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"> <tr> <td style="width: 60.94%; vertical-align: bottom"> </td> <td style="width: 1.18%; vertical-align: bottom"> </td> <td colspan="2" style="width: 17.16%; vertical-align: bottom; border-bottom: #000000 2px solid"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">March 31,</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">2016</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">(Unaudited)</div> </td> <td style="width: 1.19%; vertical-align: bottom"> </td> <td style="width: 1.19%; vertical-align: bottom"> </td> <td colspan="2" style="width: 17.16%; vertical-align: bottom; border-bottom: #000000 2px solid"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">December 31,</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">2015</div> </td> <td style="width: 1.19%; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 60.94%; vertical-align: bottom"> </td> <td style="width: 1.18%; vertical-align: bottom"> </td> <td colspan="2" style="width: 17.16%; vertical-align: bottom"> </td> <td style="width: 1.19%; vertical-align: bottom"> </td> <td style="width: 1.19%; vertical-align: bottom"> </td> <td colspan="2" style="width: 17.16%; vertical-align: bottom"> </td> <td style="width: 1.19%; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 60.94%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; margin-left: 18pt; text-indent: -18pt">Patents, trademarks and applications, net of accumulated amortization of $534,692 and $548,327, respectively</div> </td> <td style="width: 1.18%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.34%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">$</div> </td> <td style="width: 15.82%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">994,327</div> </td> <td style="width: 1.19%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.19%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.32%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">$</div> </td> <td style="width: 15.83%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">1,136,410</div> </td> <td style="width: 1.19%; vertical-align: bottom; background-color: #cceeff"> </td> </tr> <tr> <td style="width: 60.94%; vertical-align: bottom; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Goodwill</div> </td> <td style="width: 1.18%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1.34%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff"> </td> <td style="width: 15.82%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">387,239</div> </td> <td style="width: 1.19%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1.19%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1.32%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff"> </td> <td style="width: 15.83%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">387,239</div> </td> <td style="width: 1.19%; vertical-align: bottom; background-color: #ffffff"> </td> </tr> <tr> <td style="width: 60.94%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.18%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.34%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 15.82%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.19%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.19%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.32%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 15.83%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.19%; vertical-align: bottom; background-color: #cceeff"> </td> </tr> <tr> <td style="width: 60.94%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1.18%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1.34%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">$</div> </td> <td style="width: 15.82%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">1,381,566</div> </td> <td style="width: 1.19%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1.19%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1.32%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">$</div> </td> <td style="width: 15.83%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">1,523,649</div> </td> <td style="width: 1.19%; vertical-align: bottom; background-color: #ffffff"> </td> </tr> </table> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">The Company capitalizes legal costs and filing fees associated with obtaining patents on its new discoveries. Once the patents have been issued, the Company amortizes these costs over the shorter of the legal life of the patent or its estimated economic life using the straight-line method. Based upon the current status of the above intangible assets, the aggregate amortization expense is estimated to be approximately $76,000 for each of the next five fiscal years. The Company tests intangible assets with finite lives for impairment upon significant changes in the Company’s business environment. The testing resulted in net patent impairment charges of $134,000 and zero during the three months ended March 31, 2016 and 2015 respectively.  The impairment charges are related to the Company’s ongoing analysis of which specific country patents in its portfolio are determined as potentially worth pursuing.</div></div>

<div><div style="margin-bottom: 3pt; font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; margin-top: 3pt">Note 4. Notes and Other Obligations:</div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; margin-top: 3pt">Notes payable and other obligations consisted of the following:</div> <div style="margin-bottom: 3pt; text-align: left; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <table id="a6aec8bef56e143a785c077a2cb9af081" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">March 31,</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">2016</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">(Unaudited)</div> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom"> </td> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">December 31,</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">2015</div> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; vertical-align: bottom"> </td> <td style="vertical-align: bottom; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; vertical-align: bottom"></td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: left; vertical-align: bottom"> </td> <td style="vertical-align: bottom; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; vertical-align: bottom"></td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: left; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Mortgage notes</div> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">-</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">1,997,701</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Other short-term installment obligations</div> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">57,152</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">142,328</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">57,152</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">2,140,029</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Less current portion</div> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">57,152</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">301,250</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">-</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">1,838,779</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> </table> <div style="margin-bottom: 3pt; text-align: left; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; margin-top: 3pt">Mortgage notes:</div> <div style="margin-bottom: 3pt; text-align: left; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">Prior to the February 2016 sale of the corporate headquarters, the Company had a permanent mortgage on its land and building that was refinanced in May 2013. The mortgage was held by a commercial bank and included a portion guaranteed by the U. S. Small Business Administration (“SBA”). The loan was collateralized by the real property and the SBA portion was also personally guaranteed by a former officer of the Company. The commercial bank loan terms included a payment schedule based on a fifteen year amortization, with a balloon maturity at five years. The commercial bank portion had an interest rate fixed at 3.95%, and the SBA portion bore interest at the rate of 5.86%. The commercial bank portion of the loan required total monthly payments of approximately $11,700, which included approximately $4,500 per month in interest. The SBA portion of the loan required total monthly payments of approximately $9,000 through July 2023, which included approximately $3,500 per month in interest and fees in 2016.</div> <div style="margin-bottom: 12pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 12pt">On February 25, 2016, the Company completed the sale of its corporate headquarters, land and building, and also paid off its mortgage obligations.  See Note 2.</div> <div style="margin-bottom: 3pt; font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">Future maturities:</div> <div style="margin-bottom: 3pt; text-align: justify; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">The Company’s total debt obligations require minimum annual principal payments of approximately $57,000 for the remainder of 2016, with nothing due beyond that date.</div></div>

<div><div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">Note 6. Stock options and warrants:</div> <div style="margin-bottom: 3pt; text-align: justify; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; margin-top: 3pt">Stock options:</div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">The Company currently provides stock-based compensation to employees, directors and consultants, both under the Company's 2002 Stock Incentive Plan, as amended (the "Plan"), and non-qualified options and warrants issued outside of the Plan. During September 2015, the Company's shareholders approved amendments to the Plan to increase the number of shares reserved under the Plan from 459,141 to 709,141. The Company estimates the fair value of the share-based awards on the date of grant using the Black-Scholes option-pricing model (the "Black-Scholes model").  Using the Black-Scholes model, the value of the award that is ultimately expected to vest is recognized over the requisite service period in the statement of operations.  Option forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.  The Company attributes compensation to expense using the straight-line single option method for all options granted. </div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">The Company’s determination of the estimated fair value of share-based payment awards on the date of grant is affected by the following variables and assumptions:</div> <div style="margin-bottom: 3pt; text-align: left; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <table id="d711a017b34348a7b04315eaed0b801a" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"> <tr> <td style="width: 2.98%; vertical-align: top"> <div style="font: 10pt/1 Symbol, serif; color: #000000; text-align: center">·</div> </td> <td style="width: 97.02%; vertical-align: top"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify">The grant date exercise price – the closing market price of the Company’s common stock on the date of the grant;</div> </td> </tr> <tr> <td style="width: 2.98%; vertical-align: top"> <div style="font: 10pt/1 Symbol, serif; color: #000000; text-align: center">·</div> </td> <td style="width: 97.02%; vertical-align: top"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify">Estimated option term – based on historical experience with existing option holders;</div> </td> </tr> <tr> <td style="width: 2.98%; vertical-align: top"> <div style="font: 10pt/1 Symbol, serif; color: #000000; text-align: center">·</div> </td> <td style="width: 97.02%; vertical-align: top"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Estimated dividend rates – based on historical and anticipated dividends over the life of the option;</div> </td> </tr> <tr> <td style="width: 2.98%; vertical-align: top"> <div style="font: 10pt/1 Symbol, serif; color: #000000; text-align: center">·</div> </td> <td style="width: 97.02%; vertical-align: top"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify">Term of the option – based on historical experience, grants have lives of approximately 3-5 years;</div> </td> </tr> <tr> <td style="width: 2.98%; vertical-align: top"> <div style="font: 10pt/1 Symbol, serif; color: #000000; text-align: center">·</div> </td> <td style="width: 97.02%; vertical-align: top"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify">Risk-free interest rates – with maturities that approximate the expected life of the options granted;</div> </td> </tr> <tr> <td style="width: 2.98%; vertical-align: top"> <div style="font: 10pt/1 Symbol, serif; color: #000000; text-align: center">·</div> </td> <td style="width: 97.02%; vertical-align: top"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify">Calculated stock price volatility – calculated over the expected life of the options granted, which is calculated based on the daily closing price of the Company’s common stock over a period equal to the expected term of the option; and</div> </td> </tr> <tr> <td style="width: 2.98%; vertical-align: top"> <div style="font: 10pt/1 Symbol, serif; color: #000000; text-align: center">·</div> </td> <td style="width: 97.02%; vertical-align: top"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Option exercise behaviors – based on actual and projected employee stock option exercises and forfeitures.</div> </td> </tr> </table> <div style="margin-bottom: 3pt; text-align: left; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; margin-top: 3pt">The Company recognized total expenses for stock-based compensation during the three-month periods ended March 31, 2016 and 2015 of $47,884 and $433,402, respectively. These expenses are included in the accompanying statements of operations for the three-month periods ended March 31, in the following categories:</div> <div style="margin-bottom: 3pt; text-align: justify; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <table id="a2b91bc574aa6401881144dbfb80aebaf" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">2016</div> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom"> </td> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">2015</div> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; vertical-align: bottom"> </td> <td style="vertical-align: bottom; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; vertical-align: bottom"></td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: left; vertical-align: bottom"> </td> <td style="vertical-align: bottom; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; vertical-align: bottom"></td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: left; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Selling, general and administrative expenses</div> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">45,324</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">392,362</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Research and development expenses</div> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">2,560</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">41,040</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">    Total stock-based compensation</div> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">47,884</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">433,402</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> </table> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; margin-top: 3pt">During the three months ended March 31, 2016 and 2015, respectively, no options were exercised.  </div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; margin-top: 3pt">Stock incentive plan options:</div> <div style="margin-bottom: 3pt; text-align: left; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">The Company currently provides stock-based compensation to employees, directors and consultants under the Plan. The Company did not grant any stock-based compensation to employees, directors or consultants for the three months ended March 31, 2016.  Stock-based compensation to employees, directors and consultants for the three months ended March 31, 2015 utilized assumptions in the estimation of fair value of stock-based compensation as follows:  a dividend yield of 0%, an expected price volatility of 93%, a risk free interest rate of 1.39%, and an expected term of 5 years.</div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">A summary of activity under the Plan for the three months ended March 31, 2016 is presented below:</div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <table id="dead767e6f02426682184ac3c1dd608d" cellspacing="0" cellpadding="0" border="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"> <tr> <td style="width: 35.97%; vertical-align: bottom"> </td> <td style="width: 0.97%; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Shares</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Underlying</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Options</div> </td> <td style="width: 0.97%; vertical-align: bottom"> </td> <td style="width: 0.97%; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Weighted</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Average</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Exercise</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Price</div> </td> <td style="width: 0.97%; vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; border-bottom: #000000 2px solid"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Weighted</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Average</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Remaining</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Contractual</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Term (Years)</div> </td> <td style="width: 0.98%; vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; border-bottom: #000000 2px solid"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Aggregate</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Intrinsic</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Value</div> </td> <td style="width: 0.98%; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 35.97%; vertical-align: bottom"> </td> <td style="width: 0.97%; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom"> </td> <td style="width: 0.97%; vertical-align: bottom"> </td> <td style="width: 0.97%; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom"> </td> <td style="width: 0.97%; vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom"> </td> <td style="width: 0.98%; vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom"> </td> <td style="width: 0.98%; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 35.97%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Outstanding at January 1, 2016</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 11%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">332,560</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">$</div> </td> <td style="width: 11%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">35.36</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td colspan="3" style="vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #cceeff"> </td> <td colspan="3" style="vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #cceeff"> </td> </tr> <tr> <td style="width: 35.97%; vertical-align: bottom; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">     Granted</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 11%; vertical-align: bottom; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">-</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 11%; vertical-align: bottom; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">-</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td colspan="3" style="vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #ffffff"> </td> <td colspan="3" style="vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #ffffff"> </td> </tr> <tr> <td style="width: 35.97%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">     Exercised</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 11%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">-</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 11%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">-</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td colspan="3" style="vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #cceeff"> </td> <td colspan="3" style="vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #cceeff"> </td> </tr> <tr> <td style="width: 35.97%; vertical-align: bottom; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">     Forfeited</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">(7,382</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">)</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">20.98</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td colspan="3" style="vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #ffffff"> </td> <td colspan="3" style="vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #ffffff"> </td> </tr> <tr> <td style="width: 35.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 11%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 11%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td colspan="3" style="vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #cceeff"> </td> <td colspan="3" style="vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #cceeff"> </td> </tr> <tr> <td style="width: 35.97%; vertical-align: bottom; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Outstanding at March 31, 2016</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">325,178</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">35.75</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 11%; vertical-align: bottom; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">7.5</div> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1.17%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">$</div> </td> <td style="width: 12.99%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">-</div> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #ffffff"> </td> </tr> <tr> <td style="width: 35.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 11%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 11%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 11%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.17%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 12.99%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #cceeff"> </td> </tr> <tr> <td style="width: 35.97%; vertical-align: bottom; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Exercisable at March 31, 2016</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">305,265</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">37.10</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 11%; vertical-align: bottom; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">7.5</div> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1.17%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">$</div> </td> <td style="width: 12.99%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">-</div> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #ffffff"> </td> </tr> </table> <div style="margin-bottom: 3pt; text-align: left; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company’s closing stock price on March 31, 2016 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders, had all option holders been able to, and in fact had, exercised their options on March 31, 2016.</div> <div style="margin-bottom: 3pt; text-align: justify; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">During the three months ended March 31, 2015, 43<font style="font: 10pt Times New Roman, Times, serif; background-color: #ffffff">,000 options were issued to non-employee directors under the Plan, exercisable at an average of $15.12 per share. The options expire ten years from the date of grant and vested over one year, based upon 25% on the date of grant, and 25% on each of April 1, 2015, July 1, 2015, and October 1, 2015.</font></div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">During the three months ended March 31, 2015,<font style="font: 10pt Times New Roman, Times, serif; background-color: #ffffff"> 98,813 options were issued to officers and employees under the Plan, exercisable at an average of $15.12 per share. The options expire ten years from the date of grant and vest over two years with 50% vesting upon six month anniversary of grant date and the remaining balance vesting over the following six quarters in arrears.</font></div> <div style="line-height: 1; background-color: #ffffff"> <div style="line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">During the three months ended March 31, 2016, a total of 7,382 options that were granted under the Plan were forfeited, of which 3,762 were vested and 3,620 were unvested. The vested options were exercisable at an average of $26.61 per share and the unvested options were exercisable at an average of $15.13 per share. During the three months ended March 31, 2015, a total of 21,668 options that were granted under the Plan were forfeited, of which 1,876 were vested and 19,792 were unvested. The vested options were exercisable at an average of $193.36 per share and the unvested options were exercisable at an average of $16.48 per share.<br style="line-height: 1" /> </div> <div style="line-height: 1"><br style="line-height: 1" /> </div> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">The total fair value of stock options granted to employees, directors and consultants that vested and became exercisable during the three months ended March 31, 2016 and 2015, was approximately $127,000 and $234,000, respectively.   Based upon the Company’s experience, approximately 80% of the outstanding nonvested stock options, or approximately 16,000 options, are expected to vest in the future, under their terms.</div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">A summary of the activity of nonvested options under the Plan to acquire common shares granted to employees, officers, directors and consultants during the three months ended March 31, 2016 is presented below:</div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"> </div> <table id="a718fe12f39d3481a91482843dd795adf" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Nonvested Shares</div> </td> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Nonvested</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Shares</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Underlying</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Options</div> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom"> </td> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Weighted</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Average</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Exercise</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Price</div> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom"> </td> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Weighted</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Average</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Grant Date</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Fair Value</div> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; vertical-align: bottom"> </td> <td style="vertical-align: bottom; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; vertical-align: bottom"></td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: left; vertical-align: bottom"> </td> <td style="vertical-align: bottom; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; vertical-align: bottom"></td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: left; vertical-align: bottom"> </td> <td style="vertical-align: bottom; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; vertical-align: bottom"></td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: left; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 58%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Nonvested at January 1, 2016</div> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">33,336</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">15.54</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">11.41</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 58%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">     Granted</div> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">-</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">-</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">-</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 58%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">     Vested</div> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">(9,803</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">)</div> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">16.67</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">12.92</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 58%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">     Forfeited</div> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">(3,620</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">)</div> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">15.13</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">10.75</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 58%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 58%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Nonvested at March 31, 2016</div> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">19,913</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">15.06</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">10.79</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> </table> <div style="margin-bottom: 3pt; text-align: left; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">At March 31, 2016, based upon employee, officer, director and consultant options granted under the Plan to that point, there was approximately $128,000 of additional unrecognized compensation cost related to stock options that will be recorded over a weighted average future period of less than one year.</div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; margin-top: 3pt">Other common stock purchase options and warrants:</div> <div style="margin-bottom: 3pt; text-align: left; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">As of March 31, 2016, in addition to the stock incentive plan options discussed above, the Company had outstanding 432,003 non-qualified options and warrants in connection with offering warrants and an officer’s employment that were not issued under the Plan.</div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">During the three month periods ended March 31, 2016 and 2015, respectively, no stock options were granted outside of the Plan.  Operating expenses for the three months ended March 31, 2016 and 2015, did not include any value related to stock-based compensation of non-qualified options and warrants.</div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">Following is a summary of outstanding options and warrants that were issued outside of the Plan for the three months ended March 31, 2016:</div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"> <div style="line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <table id="c507b51b1d1b4fd99289628332343b42" cellspacing="0" cellpadding="0" border="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"> <tr> <td style="width: 49%; vertical-align: bottom"> </td> <td style="width: 1.46%; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Shares</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Underlying</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Options / Warrants</div> </td> <td style="width: 1.69%; vertical-align: bottom"> </td> <td style="width: 1.47%; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Weighted</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Average</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Exercise</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Price</div> </td> <td style="width: 1.47%; vertical-align: bottom"> </td> <td style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Weighted</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Average</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Remaining</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Contractual</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Term (Years)</div> </td> <td style="width: 1.27%; vertical-align: bottom"> </td> <td style="width: 1.47%; vertical-align: bottom; border-bottom: #000000 2px solid"> </td> <td style="width: 10.65%; vertical-align: bottom; border-bottom: #000000 2px solid"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Aggregate</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Intrinsic</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Value</div> </td> </tr> <tr> <td style="width: 49%; vertical-align: bottom"> </td> <td style="width: 1.46%; vertical-align: bottom"> </td> <td style="width: 1.02%; vertical-align: bottom"> </td> <td style="width: 10.16%; vertical-align: bottom"> </td> <td style="width: 1.69%; vertical-align: bottom"> </td> <td style="width: 1.47%; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom"> </td> <td style="width: 11.27%; vertical-align: bottom"> </td> <td style="width: 1.47%; vertical-align: bottom"> </td> <td style="width: 9%; vertical-align: bottom"> </td> <td style="width: 1.27%; vertical-align: bottom"> </td> <td style="width: 1.47%; vertical-align: bottom"> </td> <td style="width: 10.65%; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 49%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; background-color: #cceeff">Outstanding at January 1, 2016</div> </td> <td style="width: 1.46%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.02%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 10.16%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right; background-color: #cceeff">432,003</div> </td> <td style="width: 1.69%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.47%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; background-color: #cceeff">$</div> </td> <td style="width: 11.27%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right; background-color: #cceeff">15.47</div> </td> <td style="width: 1.47%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 9%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.27%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.47%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 10.65%; vertical-align: bottom; background-color: #cceeff"> </td> </tr> <tr> <td style="width: 49%; vertical-align: bottom; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; background-color: #ffffff">     Granted</div> </td> <td style="width: 1.46%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1.02%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 10.16%; vertical-align: bottom; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right; background-color: #ffffff">-</div> </td> <td style="width: 1.69%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1.47%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 11.27%; vertical-align: bottom; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right; background-color: #ffffff">-</div> </td> <td style="width: 1.47%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 9%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1.27%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1.47%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 10.65%; vertical-align: bottom; background-color: #ffffff"> </td> </tr> <tr> <td style="width: 49%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; background-color: #cceeff">     Exercised</div> </td> <td style="width: 1.46%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.02%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 10.16%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right; background-color: #cceeff">-</div> </td> <td style="width: 1.69%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.47%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 11.27%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right; background-color: #cceeff">-</div> </td> <td style="width: 1.47%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 9%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.27%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.47%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 10.65%; vertical-align: bottom; background-color: #cceeff"> </td> </tr> <tr> <td style="width: 49%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; background-color: #ffffff">     Forfeited</div> </td> <td style="width: 1.46%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff"> </td> <td style="width: 1.02%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff"> </td> <td style="width: 10.16%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right; background-color: #ffffff">-</div> </td> <td style="width: 1.69%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff"> </td> <td style="width: 1.47%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff"> </td> <td style="width: 11.27%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right; background-color: #ffffff">-</div> </td> <td style="width: 1.47%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff"> </td> <td style="width: 9%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff"> </td> <td style="width: 1.27%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff"> </td> <td style="width: 1.47%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff"> </td> <td style="width: 10.65%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff"> </td> </tr> <tr> <td style="width: 49%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.46%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.02%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 10.16%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.69%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.47%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 11.27%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.47%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 9%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.27%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.47%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 10.65%; vertical-align: bottom; background-color: #cceeff"> </td> </tr> <tr> <td style="width: 49%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; background-color: #ffffff">Outstanding and exercisable at March 31, 2016</div> </td> <td style="width: 1.46%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff"> </td> <td style="width: 1.02%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> </td> <td style="width: 10.16%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right; background-color: #ffffff">432,003</div> </td> <td style="width: 1.69%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff"> </td> <td style="width: 1.47%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; background-color: #ffffff">$</div> </td> <td style="width: 11.27%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right; background-color: #ffffff">15.47</div> </td> <td style="width: 1.47%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff"> </td> <td style="width: 9%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center; background-color: #ffffff">2.0</div> </td> <td style="width: 1.27%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff"> </td> <td style="width: 1.47%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; background-color: #ffffff">$</div> </td> <td style="width: 10.65%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right; background-color: #ffffff">-</div> </td> </tr> </table> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" />  </div> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">During the three months ended March 31, 2016 and 2015, no warrants were exercised.</div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company’s closing stock price on March 31, 2016 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders, had all option holders been able to, and in fact had, exercised their options on March 31, 2016.</div> <div style="margin-bottom: 3pt; text-align: justify; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">The total fair value of stock options previously granted to a former officer that vested and became exercisable during the three months ended March 31, 2016 and 2015, was zero. At March 31, 2016, there was no unrecognized cost for non-qualified options that will be recorded in the future.</div></div>

<div><div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"></div> <div style="margin-bottom: 3pt; font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; margin-top: 3pt">Note 7.  Animal Health License Agreements:</div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">Effective May 1, 2004 Washington University in St. Louis (“WU”) and Venaxis entered into an Exclusive License Agreement (“WU License Agreement”), which grants Venaxis exclusive license and right to sublicense WU’s technology (as defined under the WU License Agreement) for veterinary products worldwide, except where such products are prohibited under U.S. laws for export. The term of the WU License Agreement continues until the expiration of the last of WU’s patents (as defined in the WU License Agreement) expire.  Venaxis has agreed to pay minimum annual royalties of $20,000 annually during the term of the WU License Agreement and such amounts are creditable against future royalties.  Royalties payable to WU under the WU License Agreement for covered product sales by Venaxis carry a mid-single digit royalty rate and for sublicense fees received by Venaxis carry a low double-digit royalty rate.  The WU License Agreement contains customary terms for confidentiality, prosecution and infringement provisions for licensed patents, publication rights, indemnification and insurance coverage.  The WU License Agreement is cancelable by Venaxis with ninety days advance notice at any time and by WU with sixty days advance notice if Venaxis materially breaches the WU License Agreement and fails to cure such breach.</div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">In July 2012, the Company entered into an Exclusive License Agreement (the “License Agreement”) with Ceva Santé Animale S.A. (“Licensee”), under which the Company granted the Licensee an exclusive royalty-bearing license, until December 31, 2028, to the Company’s intellectual property and other assets, including patent rights and know-how, relating to recombinant single chain reproductive hormone technology for use in non-human mammals (the “Company’s Animal Health Assets”). The License Agreement is subject to termination by the Licensee (a) for convenience on 180 days prior written notice, (b) in the Licensee’s discretion in the event of a sale or other disposal of the Company’s animal health assets, (c) in the Licensee’s discretion upon a change in control of the Company, (d) for a material breach of the License Agreement by the Company; or (e) in the Licensee’s discretion, if the Company becomes insolvent.  The License Agreement is also terminable by the Company if there is a material breach of the License Agreement by the Licensee, or if the Licensee challenges the Company’s ownership of designated intellectual property.  The License Agreement includes a sublicense of the technology licensed to the Company by WU. Under the terms of the WU License Agreement, a portion of license fees and royalties Venaxis receives from sublicensing agreements will be paid to WU. The obligation for such license fees due to WU is included in accrued expenses at March 31, 2016.</div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">Under the License Agreement, the Licensee obtained a worldwide exclusive license to develop, seek regulatory approval for and offer to sell, market, distribute, import and export luteinizing hormone (“LH”) and/or follicle-stimulating hormone (“FSH”) products for bovine (cattle), equine and swine in the field of the assistance and facilitation of reproduction in bovine, equine and swine animals.  </div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">Under the License Agreement as of March 31, 2016, the following future milestone payments are provided, assuming future milestones are successfully achieved:</div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; text-align: justify; margin-top: 3pt; line-height: 1"> <table id="a4140b690f37043a2b0441de30bdc4f65" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"> <tr> <td style="font: 10pt Times New Roman, Times, serif; width: 27pt; vertical-align: top; color: #000000; text-align: center">•</td> <td style="font: 10pt Times New Roman, Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify">Milestone payments, totaling up to a potential of $1.1 million in the aggregate, based on the satisfactory conclusion of milestones as defined in the License Agreement;</td> </tr> </table> </div> <div style="margin-bottom: 3pt; text-align: justify; margin-top: 3pt; line-height: 1"> <table id="a703b49c5ee894e958ea8d163d2d58d3a" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"> <tr> <td style="font: 10pt Times New Roman, Times, serif; width: 27pt; vertical-align: top; color: #000000; text-align: center">•</td> <td style="font: 10pt Times New Roman, Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify">Potential for milestone payments of up to an additional $2 million for development and receipt of regulatory approval for additional licensed products; and</td> </tr> </table> </div> <div style="margin-bottom: 3pt; text-align: justify; margin-top: 3pt; line-height: 1"> <table id="a33d2afa42aa496ea0e151b10d389527" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"> <tr> <td style="font: 10pt Times New Roman, Times, serif; width: 27pt; vertical-align: top; color: #000000; text-align: center">•</td> <td style="font: 10pt Times New Roman, Times, serif; width: auto; vertical-align: top; color: #000000; text-align: justify">Royalties, at low double digit rates, based on sales of licensed products.</td> </tr> </table> </div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">Revenue recognition related to the License Agreement and WU License Agreement is based primarily on the Company’s consideration of ASC 808-10-45, “<font style="font: italic 10pt Times New Roman, Times, serif">Accounting for Collaborative Arrangements</font>”.  For financial reporting purposes, the license fees and milestone payments received from the License Agreement, net of the amounts due to third parties, including WU, have been recorded as deferred revenue and are amortized over the term of the License Agreement.  License fees and milestone revenue totaling a net of approximately $1,500,000 commenced being amortized into income upon the July 2012 date of milestone achievement. As of March 31, 2016, deferred revenue of $96,698 has been classified as a current liability and $1,137,840 has been classified as a long-term liability. The current liability represents the next twelve months’ portion of the amortizable milestone revenue. During the three months ended March 31, 2016 and 2015, $24,175 in each period was recorded as the amortized license fee revenue arising from the License Agreement.</div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">A tabular summary of the revenue categories and cumulative amounts of revenue recognition associated with the License Agreement follows:</div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <table id="a2108b99918e2466ea0bb5b2d46d4bba8" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"> <tr> <td style="width: 662px; vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify">Category</div> </td> <td style="width: 709px; vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Totals</div> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 42.03%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify">License fees and milestone amounts paid / achieved</div> </td> <td style="width: 45.02%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">1,920,000</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 42.03%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify">Third party obligations recorded, including WU</div> </td> <td style="width: 45.02%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">(363,700</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">)</div> </td> </tr> <tr> <td style="width: 42.03%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify">Deferred revenue balance</div> </td> <td style="width: 45.02%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">1,556,300</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 42.03%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify">Revenue amortization to March 31, 2016</div> </td> <td style="width: 45.02%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">(321,762</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">)</div> </td> </tr> <tr> <td style="width: 42.03%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 45.02%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 42.03%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify">Net deferred revenue balance at March 31, 2016</div> </td> <td style="width: 45.02%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">1,234,538</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 662px; vertical-align: top; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify">Commencement of license fees revenue recognition</div> </td> <td colspan="3" style="width: 897px; vertical-align: bottom; text-align: center; background-color: #cceeff"> Upon signing or receipt</td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 662px; vertical-align: top; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify">Commencement of milestone revenue recognition</div> </td> <td colspan="3" style="width: 897px; vertical-align: bottom; text-align: center; background-color: #ffffff"> Upon milestone achievement over then remaining life</td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 662px; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify">Original amortization period</div> </td> <td colspan="3" style="width: 897px; vertical-align: bottom; text-align: center; background-color: #cceeff"> 197 months</td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> </table> </div>

<div><div style="margin-bottom: 3pt; text-align: justify; margin-top: 3pt; line-height: 1"></div> <div style="margin-bottom: 3pt; font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; margin-top: 3pt">Cash, cash equivalents and investments:</div> <div style="margin-bottom: 3pt; text-align: justify; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">The Company considers all highly liquid investments with an original maturity of three months or less at the date of acquisition to be cash equivalents. From time to time, the Company’s cash account balances exceed the balances as covered by the Federal Deposit Insurance System. The Company has never suffered a loss due to such excess balances.</div> <div style="margin-bottom: 3pt; text-align: justify; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">The Company invests excess cash from time to time in highly-liquid debt and equity investments of highly-rated entities, which are classified as trading securities. Historically, the purpose of the investments has been to fund research and development, product development, FDA clearance-related activities and general corporate purposes. Such amounts are recorded at market values using Level 1 inputs in determining fair value and are generally classified as current, as the Company does not intend to hold the investments beyond twelve months. Investment securities classified as trading are those securities that are bought and held principally for the purpose of selling them in the near term, with the objective of preserving principal and generating profits. These securities are reported at fair value with unrealized gains and losses reported as an element of other (expense) income in current period earnings. The Company’s Board of Directors has approved an investment policy covering the investment parameters to be followed with the primary goals being the safety of principal amounts and maintaining liquidity. The policy provides for minimum investment rating requirements as well as limitations on investment duration and concentrations. Based upon market conditions, the investment guidelines have been tightened to increase the minimum acceptable investment ratings required for investments and shorten the maximum investment term. As of March 31, 2016, approximately 11% of the investment portfolio was in cash and cash equivalents, which is presented as such on the accompanying balance sheet, and the remaining funds were invested in marketable securities with none individually representing a material amount of the portfolio.  Investments with a scheduled maturity beyond one year are classified as long-term investments on the balance sheet.  To date, the Company’s cumulative realized market loss from the investments has not been significant. For the three months ended March 31, 2016 and 2015, there was approximately $5,900 and $8,400, respectively, in management fee expenses.</div></div>

<div><div style="margin-bottom: 3pt; font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">Recently issued and adopted accounting pronouncements:</div> <div style="margin-bottom: 12pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 12pt">The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company's financial reporting, the Company undertakes a study to determine the consequences of the change to its financial statements and assures that there are proper controls in place to ascertain that the Company's financial statements properly reflect the change.</div> <div style="margin-bottom: 12pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 12pt">In May 2014, the FASB issued Accounting Standards Update ("ASU") No. 2014-09 "Revenue from Contracts from Customers," which supersedes the revenue recognition requirements in "Revenue Recognition (Topic 605)," and requires entities to recognize revenue in a way that depicts the transfer of potential goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to the exchange for those goods or services. In July 2015, the FASB extended the effective date of ASU 2014-09 by one year, to now be effective for fiscal years, and interim periods beginning after December 15, 2017, and is to be applied retrospectively, with early adoption now permitted for fiscal years, and interim periods beginning after December 31, 2015. The Company does not believe the new standard will have a material impact on its operations and financial statements.</div></div>

<div><div style="margin-bottom: 3pt; text-align: left; margin-top: 3pt; line-height: 1"></div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; margin-top: 3pt">Property and equipment consisted of the following:</div> <div style="margin-bottom: 3pt; text-align: left; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <table id="a5dbdae07fd394f9a8a29048e136e2fec" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">March 31,</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">2016</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">(Unaudited)</div> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom"> </td> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">December 31,</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">2015</div> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; vertical-align: bottom"> </td> <td style="vertical-align: bottom; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; vertical-align: bottom"></td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: left; vertical-align: bottom"> </td> <td style="vertical-align: bottom; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; vertical-align: bottom"></td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: left; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Land and improvements</div> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">-</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">1,107,508</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Building</div> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">-</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">2,589,231</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Building improvements</div> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">-</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">253,526</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Laboratory equipment</div> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">-</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">848,014</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Office and computer equipment</div> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">66,104</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">318,254</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">66,104</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">5,116,533</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Less accumulated depreciation</div> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">65,208</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">3,162,037</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">896</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">1,954,496</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> </table> </div>

<div><div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; margin-top: 3pt">Notes payable and other obligations consisted of the following:</div> <div style="margin-bottom: 3pt; text-align: left; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <table id="a6aec8bef56e143a785c077a2cb9af081" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">March 31,</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">2016</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">(Unaudited)</div> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom"> </td> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">December 31,</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">2015</div> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; vertical-align: bottom"> </td> <td style="vertical-align: bottom; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; vertical-align: bottom"></td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: left; vertical-align: bottom"> </td> <td style="vertical-align: bottom; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; vertical-align: bottom"></td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: left; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Mortgage notes</div> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">-</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">1,997,701</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Other short-term installment obligations</div> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">57,152</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">142,328</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">57,152</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">2,140,029</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Less current portion</div> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">57,152</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">301,250</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">-</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">1,838,779</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> </table> </div>

<div><div style="margin-bottom: 3pt; text-align: left; margin-top: 3pt; line-height: 1"></div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; margin-top: 3pt">The Company recognized total expenses for stock-based compensation during the three-month periods ended March 31, 2016 and 2015 of $47,884 and $433,402, respectively. These expenses are included in the accompanying statements of operations for the three-month periods ended March 31, in the following categories:</div> <div style="margin-bottom: 3pt; text-align: justify; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <table id="a2b91bc574aa6401881144dbfb80aebaf" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">2016</div> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom"> </td> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">2015</div> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; vertical-align: bottom"> </td> <td style="vertical-align: bottom; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; vertical-align: bottom"></td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: left; vertical-align: bottom"> </td> <td style="vertical-align: bottom; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; vertical-align: bottom"></td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: left; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Selling, general and administrative expenses</div> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">45,324</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">392,362</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Research and development expenses</div> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">2,560</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">41,040</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 72%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">    Total stock-based compensation</div> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">47,884</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">433,402</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> </table> </div>

<div><div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">A summary of activity under the Plan for the three months ended March 31, 2016 is presented below:</div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <table id="dead767e6f02426682184ac3c1dd608d" cellspacing="0" cellpadding="0" border="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"> <tr> <td style="width: 35.97%; vertical-align: bottom"> </td> <td style="width: 0.97%; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Shares</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Underlying</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Options</div> </td> <td style="width: 0.97%; vertical-align: bottom"> </td> <td style="width: 0.97%; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Weighted</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Average</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Exercise</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Price</div> </td> <td style="width: 0.97%; vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; border-bottom: #000000 2px solid"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Weighted</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Average</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Remaining</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Contractual</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Term (Years)</div> </td> <td style="width: 0.98%; vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom; border-bottom: #000000 2px solid"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Aggregate</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Intrinsic</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Value</div> </td> <td style="width: 0.98%; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 35.97%; vertical-align: bottom"> </td> <td style="width: 0.97%; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom"> </td> <td style="width: 0.97%; vertical-align: bottom"> </td> <td style="width: 0.97%; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom"> </td> <td style="width: 0.97%; vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom"> </td> <td style="width: 0.98%; vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom"> </td> <td style="width: 0.98%; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 35.97%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Outstanding at January 1, 2016</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 11%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">332,560</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">$</div> </td> <td style="width: 11%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">35.36</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td colspan="3" style="vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #cceeff"> </td> <td colspan="3" style="vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #cceeff"> </td> </tr> <tr> <td style="width: 35.97%; vertical-align: bottom; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">     Granted</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 11%; vertical-align: bottom; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">-</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 11%; vertical-align: bottom; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">-</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td colspan="3" style="vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #ffffff"> </td> <td colspan="3" style="vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #ffffff"> </td> </tr> <tr> <td style="width: 35.97%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">     Exercised</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 11%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">-</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 11%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">-</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td colspan="3" style="vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #cceeff"> </td> <td colspan="3" style="vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #cceeff"> </td> </tr> <tr> <td style="width: 35.97%; vertical-align: bottom; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">     Forfeited</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">(7,382</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">)</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">20.98</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td colspan="3" style="vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #ffffff"> </td> <td colspan="3" style="vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #ffffff"> </td> </tr> <tr> <td style="width: 35.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 11%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 11%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td colspan="3" style="vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #cceeff"> </td> <td colspan="3" style="vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #cceeff"> </td> </tr> <tr> <td style="width: 35.97%; vertical-align: bottom; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Outstanding at March 31, 2016</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">325,178</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">35.75</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 11%; vertical-align: bottom; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">7.5</div> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1.17%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">$</div> </td> <td style="width: 12.99%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">-</div> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #ffffff"> </td> </tr> <tr> <td style="width: 35.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 11%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 11%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 11%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.17%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 12.99%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #cceeff"> </td> </tr> <tr> <td style="width: 35.97%; vertical-align: bottom; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Exercisable at March 31, 2016</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">305,265</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">37.10</div> </td> <td style="width: 0.97%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 11%; vertical-align: bottom; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">7.5</div> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1.17%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">$</div> </td> <td style="width: 12.99%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right">-</div> </td> <td style="width: 0.98%; vertical-align: bottom; background-color: #ffffff"> </td> </tr> </table> </div>

<div><div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">A summary of the activity of nonvested options under the Plan to acquire common shares granted to employees, officers, directors and consultants during the three months ended March 31, 2016 is presented below:</div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"> </div> <table id="a718fe12f39d3481a91482843dd795adf" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Nonvested Shares</div> </td> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Nonvested</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Shares</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Underlying</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Options</div> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom"> </td> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Weighted</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Average</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Exercise</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Price</div> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom"> </td> <td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Weighted</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Average</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Grant Date</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Fair Value</div> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; vertical-align: bottom"> </td> <td style="vertical-align: bottom; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; vertical-align: bottom"></td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: left; vertical-align: bottom"> </td> <td style="vertical-align: bottom; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; vertical-align: bottom"></td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: left; vertical-align: bottom"> </td> <td style="vertical-align: bottom; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; vertical-align: bottom"></td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: left; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 58%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Nonvested at January 1, 2016</div> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">33,336</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">15.54</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">11.41</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 58%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">     Granted</div> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">-</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">-</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">-</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 58%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">     Vested</div> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">(9,803</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">)</div> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">16.67</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">12.92</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 58%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">     Forfeited</div> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">(3,620</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">)</div> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">15.13</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">10.75</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 58%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 58%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left">Nonvested at March 31, 2016</div> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">19,913</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">15.06</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">10.79</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> </table> </div>

<div><div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">Following is a summary of outstanding options and warrants that were issued outside of the Plan for the three months ended March 31, 2016:</div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"> <div style="line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <table id="c507b51b1d1b4fd99289628332343b42" cellspacing="0" cellpadding="0" border="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"> <tr> <td style="width: 49%; vertical-align: bottom"> </td> <td style="width: 1.46%; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Shares</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Underlying</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Options / Warrants</div> </td> <td style="width: 1.69%; vertical-align: bottom"> </td> <td style="width: 1.47%; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Weighted</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Average</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Exercise</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Price</div> </td> <td style="width: 1.47%; vertical-align: bottom"> </td> <td style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Weighted</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Average</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Remaining</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Contractual</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Term (Years)</div> </td> <td style="width: 1.27%; vertical-align: bottom"> </td> <td style="width: 1.47%; vertical-align: bottom; border-bottom: #000000 2px solid"> </td> <td style="width: 10.65%; vertical-align: bottom; border-bottom: #000000 2px solid"> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Aggregate</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Intrinsic</div> <div style="font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Value</div> </td> </tr> <tr> <td style="width: 49%; vertical-align: bottom"> </td> <td style="width: 1.46%; vertical-align: bottom"> </td> <td style="width: 1.02%; vertical-align: bottom"> </td> <td style="width: 10.16%; vertical-align: bottom"> </td> <td style="width: 1.69%; vertical-align: bottom"> </td> <td style="width: 1.47%; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom"> </td> <td style="width: 11.27%; vertical-align: bottom"> </td> <td style="width: 1.47%; vertical-align: bottom"> </td> <td style="width: 9%; vertical-align: bottom"> </td> <td style="width: 1.27%; vertical-align: bottom"> </td> <td style="width: 1.47%; vertical-align: bottom"> </td> <td style="width: 10.65%; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 49%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; background-color: #cceeff">Outstanding at January 1, 2016</div> </td> <td style="width: 1.46%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.02%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 10.16%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right; background-color: #cceeff">432,003</div> </td> <td style="width: 1.69%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.47%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; background-color: #cceeff">$</div> </td> <td style="width: 11.27%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right; background-color: #cceeff">15.47</div> </td> <td style="width: 1.47%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 9%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.27%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.47%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 10.65%; vertical-align: bottom; background-color: #cceeff"> </td> </tr> <tr> <td style="width: 49%; vertical-align: bottom; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; background-color: #ffffff">     Granted</div> </td> <td style="width: 1.46%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1.02%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 10.16%; vertical-align: bottom; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right; background-color: #ffffff">-</div> </td> <td style="width: 1.69%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1.47%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 11.27%; vertical-align: bottom; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right; background-color: #ffffff">-</div> </td> <td style="width: 1.47%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 9%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1.27%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 1.47%; vertical-align: bottom; background-color: #ffffff"> </td> <td style="width: 10.65%; vertical-align: bottom; background-color: #ffffff"> </td> </tr> <tr> <td style="width: 49%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; background-color: #cceeff">     Exercised</div> </td> <td style="width: 1.46%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.02%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 10.16%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right; background-color: #cceeff">-</div> </td> <td style="width: 1.69%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.47%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 11.27%; vertical-align: bottom; background-color: #cceeff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right; background-color: #cceeff">-</div> </td> <td style="width: 1.47%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 9%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.27%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.47%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 10.65%; vertical-align: bottom; background-color: #cceeff"> </td> </tr> <tr> <td style="width: 49%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; background-color: #ffffff">     Forfeited</div> </td> <td style="width: 1.46%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff"> </td> <td style="width: 1.02%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff"> </td> <td style="width: 10.16%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right; background-color: #ffffff">-</div> </td> <td style="width: 1.69%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff"> </td> <td style="width: 1.47%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff"> </td> <td style="width: 11.27%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right; background-color: #ffffff">-</div> </td> <td style="width: 1.47%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff"> </td> <td style="width: 9%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff"> </td> <td style="width: 1.27%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff"> </td> <td style="width: 1.47%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff"> </td> <td style="width: 10.65%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff"> </td> </tr> <tr> <td style="width: 49%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.46%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.02%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 10.16%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.69%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.47%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 11.27%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.47%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 9%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.27%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 1.47%; vertical-align: bottom; background-color: #cceeff"> </td> <td style="width: 10.65%; vertical-align: bottom; background-color: #cceeff"> </td> </tr> <tr> <td style="width: 49%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; background-color: #ffffff">Outstanding and exercisable at March 31, 2016</div> </td> <td style="width: 1.46%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff"> </td> <td style="width: 1.02%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> </td> <td style="width: 10.16%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right; background-color: #ffffff">432,003</div> </td> <td style="width: 1.69%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff"> </td> <td style="width: 1.47%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; background-color: #ffffff">$</div> </td> <td style="width: 11.27%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right; background-color: #ffffff">15.47</div> </td> <td style="width: 1.47%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff"> </td> <td style="width: 9%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center; background-color: #ffffff">2.0</div> </td> <td style="width: 1.27%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff"> </td> <td style="width: 1.47%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: left; background-color: #ffffff">$</div> </td> <td style="width: 10.65%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #ffffff"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: right; background-color: #ffffff">-</div> </td> </tr> </table> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" />  </div></div></div>

<div><div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"></div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">A tabular summary of the revenue categories and cumulative amounts of revenue recognition associated with the License Agreement follows:</div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <table id="a2108b99918e2466ea0bb5b2d46d4bba8" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"> <tr> <td style="width: 662px; vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify">Category</div> </td> <td style="width: 709px; vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center">Totals</div> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 42.03%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify">License fees and milestone amounts paid / achieved</div> </td> <td style="width: 45.02%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">1,920,000</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 42.03%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify">Third party obligations recorded, including WU</div> </td> <td style="width: 45.02%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">(363,700</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">)</div> </td> </tr> <tr> <td style="width: 42.03%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify">Deferred revenue balance</div> </td> <td style="width: 45.02%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">1,556,300</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 42.03%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify">Revenue amortization to March 31, 2016</div> </td> <td style="width: 45.02%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">(321,762</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">)</div> </td> </tr> <tr> <td style="width: 42.03%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 45.02%; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> <td style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff; vertical-align: bottom"> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 42.03%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify">Net deferred revenue balance at March 31, 2016</div> </td> <td style="width: 45.02%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff; vertical-align: bottom"> </td> <td style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000">1,234,538</div> </td> <td nowrap="nowrap" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 662px; vertical-align: top; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify">Commencement of license fees revenue recognition</div> </td> <td colspan="3" style="width: 897px; vertical-align: bottom; text-align: center; background-color: #cceeff"> Upon signing or receipt</td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 662px; vertical-align: top; background-color: #ffffff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify">Commencement of milestone revenue recognition</div> </td> <td colspan="3" style="width: 897px; vertical-align: bottom; text-align: center; background-color: #ffffff"> Upon milestone achievement over then remaining life</td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"> </td> </tr> <tr> <td style="width: 662px; vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify">Original amortization period</div> </td> <td colspan="3" style="width: 897px; vertical-align: bottom; text-align: center; background-color: #cceeff"> 197 months</td> <td nowrap="nowrap" style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom"> </td> </tr> </table> </div>

<div><div style="margin-bottom: 3pt; font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">Income (loss) per share:</div> <div style="margin-bottom: 3pt; text-align: justify; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">ASC 260,<font style="font: italic 10pt Times New Roman, Times, serif"> Earnings Per Share</font>, requires dual presentation of basic and diluted earnings per share (“EPS”) with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity.</div> <div style="margin-bottom: 3pt; text-align: left; margin-top: 3pt; line-height: 1"> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">Basic net earnings (loss) per share includes no dilution and is computed by dividing net earnings (loss) available to shareholders by the weighted average number of common shares outstanding for the period. Diluted net earnings (loss) per share reflect the potential dilution of securities that could share in the Company’s earnings (loss).  The outstanding options and warrants did not have a dilutive effect on earnings per share for the three months ended March 31, 2016 pursuant to the treasury stock method. The effect of the inclusion of the dilutive shares would have resulted in a decrease in loss per share for the three months ended March 31, 2015. Accordingly, the weighted average shares outstanding have not been adjusted for dilutive shares for either period presented. Outstanding stock options and warrants are not considered in the calculation, as the impact of the potential common shares (totaling approximately 757,000 shares and 779,000 shares for the three month periods ended March 31, 2016 and 2015, respectively) would be anti-dilutive.</div> <div style="margin-bottom: 12pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 12pt">Upon the completion of a special shareholders meeting on March 24, 2016, where such action was approved by shareholders, the Board of Directors authorized a reverse stock split of the Company’s common stock at a ratio of one-for-eight, whereby each eight shares of common stock were combined into one share of common stock (the “Reverse Stock Split”).  The Reverse Stock Split was implemented and effective on March 31, 2016. All historical references to shares and share amounts in this report have been retroactively revised to reflect the Reverse Stock Split.  A reconciliation of basic and diluted weighted average number of shares outstanding adjusted for the Reverse Stock Split for the period ended March 31, 2016 was 30,990,029 shares on a pre-split basis and 3,876,960 shares on a post-split basis.</div></div>

<div><div style="margin-bottom: 3pt; font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">Note 8.  Commitments and contingencies:</div> <div style="margin-bottom: 3pt; text-align: justify; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">Commitments:</div> <div style="margin-bottom: 3pt; text-align: justify; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">As of March 31, 2016, the Company had employment agreements with two officers providing aggregate annual minimum commitments totaling $655,000.  The agreements automatically renew at the end of each year unless terminated by either party and contain customary confidentiality and benefit provisions.</div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">Venaxis determined in the first quarter of 2016 to begin winding down and ceasing its <font style="font: italic 10pt Times New Roman, Times, serif">APPY</font>1 commercial activities, due to continuing limited sales and losses from the European operations.  This decision also resulted in a reduction of the Company’s workforce, which was implemented as of January 31, 2016. In February 2016, Venaxis sent notices to its four European distributors informing them of the wind down and therefore the termination of their distribution agreements. Two of the distributors, linked by common management / ownership subsequently communicated to Venaxis that they dispute that Venaxis had the right to terminate the agreements. Under the terms of the distribution agreements, such a dispute shall first be attempted to be resolved between management of the parties and then subject to binding arbitration. Venaxis believes that the distributors’ claims are without merit and any potential settlement or resolution will not be material to the Company’s financial position.  </div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">Contingencies: </div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">In the ordinary course of business and in the general industry in which the Company is engaged, it is not atypical to periodically receive a third party communication which may be in the form of a notice, threat, or “cease and desist” letter concerning certain activities.  For example, this can occur in the context of the Company’s pursuit of intellectual property rights.  This can also occur in the context of operations such as the using, making, having made, selling, and offering to sell products and services, and in other contexts.  The Company makes rational assessments of each situation on a case-by-case basis as such may arise.  The Company periodically evaluates its options for trademark positions and considers a full spectrum of alternatives for trademark protection and product branding.</div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">We are currently not a party to any legal proceedings, the adverse outcome of which would, in our management’s opinion, have a material adverse effect on our business, financial condition and results of operations.</div></div>

<div><div style="margin-bottom: 3pt; font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: center; margin-top: 3pt"><div style="margin-bottom: 3pt; font: bold 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify; margin-top: 3pt">Note 9.  Subsequent event:</div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify">Subsequent to March 31, 2016, 77,000 options were issued to non-employee directors under the Plan, exercisable at an average of $2.89 per share. The options expire ten years from the date of grant and vest over one year, based upon 50% on the date of grant, and 25% on each of July 1, 2016, and October 1, 2016.</div> <div style="margin-bottom: 3pt; margin-top: 3pt; line-height: 1"><br style="line-height: 1" /> </div> <div style="font: 10pt/1 Times New Roman, Times, serif; color: #000000; text-align: justify">Subsequent to March 31, 2016, 150,000 options were issued to officers and employees under the Plan, exercisable at an average of $2.89 per share. The options expire ten years from the date of grant and vest 50% upon each of the six month and the one year anniversary of the grant date.</div></div></div>

EX-101.SCH 6 appy-20160331.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - INTERIM FINANCIAL STATEMENTS link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Significant accounting policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Property and equipment link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Other long-term assets link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Notes and Other Obligations link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Stockholders' equity link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Stock options and warrants link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Animal Health License Agreements link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Subsequent event link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Significant accounting policies (Policy) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Property and equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Other long-term assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Notes and Other Obligations (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Stock options and warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Animal Health License Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - INTERIM FINANCIAL STATEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Significant accounting policies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Significant accounting policies (Revenue recognition and accounts receivable) (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Property and equipment (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Property and equipment (Schedule of Property and Equipment) (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Other long-term assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Notes and Other Obligations (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Notes and Other Obligations (Schedule of Long-Term Debt) (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Stock options and warrants (Stock incentive plan options) (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Stock options and warrants (Schedule of Stock-based Compensation) (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Stock options and warrants (Schedule of Award Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Stock options and warrants (Schedule of Nonvested Awards) (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Animal Health License Agreements (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Animal Health License Agreements (Schedule of Revenue Recognition Associated with the License Agreement) (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Commitments and contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Subsequent event (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 appy-20160331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 appy-20160331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 appy-20160331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Land and improvements [Member] Property, Plant and Equipment, Type [Axis] Building [Member] Building improvements [Member] Laboratory equipment [Member] Office and computer equipment [Member] Mortgage Notes [Member] Long-term Debt, Type [Axis] U.S. Small Business Administration [Member] Debt Instrument [Axis] Commercial Banks [Member] Stock Incentive Plan [Member] Plan Name [Axis] Accounts Receivable [Member] Concentration Risk Benchmark [Axis] Customer Concentration Risk [Member] Concentration Risk Type [Axis] Net Sales [Member] Customer Concentration [Member] Customer One [Member] Customer [Axis] Customer Two [Member] Customer Three [Member] Minimum [Member] Range [Axis] Maximum [Member] Selling, General and Administrative Expenses [Member] Income Statement Location [Axis] Research and Development Expense [Member] Independent Directors [Member] Issuance Type [Axis] Directors, Employees and Consultants [Member] Nonqualified [Member] Employment Contracts [Member] Purchase Commitment, Excluding Long-term Commitment [Axis] Officers and Employees [Member] Subsequent Event [Member] Subsequent Event Type [Axis] Issuance Types [Axis] Document and Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Document Period End Date Current Fiscal Year End Date Document Fiscal Period Focus Document Fiscal Year Focus Entity Filer Category Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Common Stock, Shares Outstanding Entity Public Float Statement of Financial Position [Abstract] ASSETS Current assets: Cash and cash equivalents Short-term investments (Note 1) Prepaid expenses and other current assets (Note 1) Total current assets Property and equipment, net (Note 2) Long-term investments (Note1) Other long term assets, net (Notes 1 and 3) Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable Accrued compensation Accrued expenses Notes and other obligations, current portion (Note 4) Deferred revenue, current portion (Note 7) Total current liabilities Notes and other obligations, less current portion (Note 4) Deferred revenue, less current portion (Note 7) Total liabilities Commitments and contingencies (Notes 7 and 9) Stockholders' equity (Notes 5 and 6): Common stock, no par value, 60,000,000 shares authorized; 3,876,960 shares issued and outstanding Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Sales (Note 1) Cost of sales Gross profit Other revenue - fee (Note 7) Operating expenses: Selling, general and administrative Research and development Total operating expenses Operating loss Other (expense) income: Gain on sale of property and equipment (Note 2) Interest expense Investment income Total other income Net income (loss) Basic and diluted net loss per share (Note 1) Basic and diluted weighted average number of shares outstanding (Note 1) Statement of Cash Flows [Abstract] Cash flows from operating activities: Net income (loss) Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation for services Depreciation and amortization Amortization of license fees Other noncash charges Gain on sale of property and equipment Change in: Accounts receivable Prepaid expenses and other current assets Accounts payable Accrued compensation Accrued expenses Net cash (used in) operating activities Cash flows from investing activities: Purchases of short-term investments Sales of short-term investments Proceeds from sale of property and equipment Purchases of patent and trademark application costs Net cash provided by investing activities Cash flows from financing activities: Repayment of notes payable and other obligations Net cash (used in) financing activities Net change in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental disclosure of cash flow information: Cash paid during the period for interest Supplemental disclosure of investing information: Liability payoffs upon property sale Organization, Consolidation and Presentation of Financial Statements [Abstract] INTERIM FINANCIAL STATEMENTS Accounting Policies [Abstract] Significant accounting policies Property, Plant and Equipment [Abstract] Property and equipment Goodwill and Intangible Assets Disclosure [Abstract] Other long-term assets Debt Disclosure [Abstract] Notes and Other Obligations Equity [Abstract] Stockholders' equity Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stock options and warrants Animal Health License Agreements [Abstract] Animal Health License Agreements Commitments and Contingencies Disclosure [Abstract] Commitments and contingencies Related Party Transactions [Abstract] Related Party Transactions Subsequent Events [Abstract] Subsequent event Cash, cash equivalents and investments Fair value of financial instruments Revenue recognition and accounts receivable Recently issued and adopted accounting pronouncements Income (loss) per share Nature of operations Management's plans and basis of presentation Property and equipment Goodwill Impairment of long-lived assets Research and development Use of estimates Income taxes Stock-based compensation Schedule of Property and Equipment Schedule of Other Long-Term Assets Schedule of Long-Term Debt Schedule of the Income Statement Allocation of Stock-based Compensation Schedule of Fair Value Assumptions Used to Estimate Stock-based Compensation Summary of Stock Incentive Plan Activity Schedule of Nonvested Share Activity Schedule of Nonqualified Award Activity Schedule of Current and Long-Term Deferred Revenues Cash and liquid investments Working capital Stockholders' equity Accumulated deficit Total value of capitalized patent costs that could be impaired due to inability to locate a new strategic target, a partner or other third-party interested in advancing development and commercial activities of the Venaxis appendicitis portfolio Accounts Receivable, Net, Current [Abstract] Cash, cash equivalents and short-term investments: Cash and cash equivalent investment portfolio, percentage Management fees Accounts receivable, net Sales Income (loss) per share: Shares not included in the computation of EPS EX-101.PRE 10 appy-20160331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2016	May. 11, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	Venaxis, Inc.
Entity Central Index Key	0001167419
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2016
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		3,876,960

XML 12 R2.htm IDEA: XBRL DOCUMENT

Balance Sheets - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 3,841,065	$ 2,012,283
Short-term investments (Note 1)	12,759,109	14,147,991
Prepaid expenses and other current assets (Note 1)	241,817	251,778
Total current assets	16,841,991	16,412,052
Property and equipment, net (Note 2)	896	1,954,496
Long-term investments (Note1)	250,000	972,000
Other long term assets, net (Notes 1 and 3)	1,381,566	1,523,649
Total assets	18,474,453	20,862,197
Current liabilities:
Accounts payable	321,054	701,064
Accrued compensation	12,549	449,873
Accrued expenses	171,129	241,882
Notes and other obligations, current portion (Note 4)	57,152	301,250
Deferred revenue, current portion (Note 7)	96,698	96,698
Total current liabilities	$ 658,582	1,790,767
Notes and other obligations, less current portion (Note 4)		1,838,779
Deferred revenue, less current portion (Note 7)	$ 1,137,840	1,162,015
Total liabilities	$ 1,796,422	$ 4,791,561
Commitments and contingencies (Notes 7 and 9)
Stockholders' equity (Notes 5 and 6):
Common stock, no par value, 60,000,000 shares authorized; 3,876,960 shares issued and outstanding	$ 121,700,959	$ 121,653,075
Accumulated deficit	(105,022,928)	(105,582,439)
Total stockholders' equity	16,678,031	16,070,636
Total liabilities and stockholders' equity	$ 18,474,453	$ 20,862,197

XML 13 R3.htm IDEA: XBRL DOCUMENT

Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Common stock, par value
Common stock, shares authorized	60,000,000	60,000,000
Common stock, shares issued	3,876,960	3,876,960
Common stock, shares outstanding	3,876,960	3,876,960

XML 14 R4.htm IDEA: XBRL DOCUMENT

Statements of Operations - USD ($)	3 Months Ended
Statements of Operations - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Sales (Note 1)		$ 11,288
Cost of sales		4,007
Gross profit		7,281
Other revenue - fee (Note 7)	$ 24,175	24,175
Operating expenses:
Selling, general and administrative	1,030,126	1,535,851
Research and development	372,586	707,742
Total operating expenses	1,402,712	2,243,593
Operating loss	(1,378,537)	$ (2,212,137)
Other (expense) income:
Gain on sale of property and equipment (Note 2)	1,919,361
Interest expense	(25,598)	$ (25,064)
Investment income	44,285	50,828
Total other income	1,938,048	25,764
Net income (loss)	$ 559,511	$ (2,186,373)
Basic and diluted net loss per share (Note 1)	$ 0.14	$ (0.56)
Basic and diluted weighted average number of shares outstanding (Note 1)	3,876,960	3,876,960

XML 15 R5.htm IDEA: XBRL DOCUMENT

Statements of Cash Flows - USD ($)	3 Months Ended
Statements of Cash Flows - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net income (loss)	$ 559,511	$ (2,186,373)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation for services	47,884	433,402
Depreciation and amortization	19,401	64,021
Amortization of license fees	(24,175)	$ (24,175)
Other noncash charges	133,899
Gain on sale of property and equipment	$ (1,919,361)
Change in:
Accounts receivable		$ 7,077
Prepaid expenses and other current assets	$ 69,155	89,690
Accounts payable	(380,010)	(34,707)
Accrued compensation	(437,324)	(565,862)
Accrued expenses	28,058	(69,744)
Net cash (used in) operating activities	(1,902,962)	(2,286,671)
Cash flows from investing activities:
Purchases of short-term investments	(7,537,862)	(11,305,556)
Sales of short-term investments	9,648,744	$ 14,402,745
Proceeds from sale of property and equipment	1,748,571
Purchases of patent and trademark application costs	(10,778)	$ (14,679)
Net cash provided by investing activities	3,848,675	3,082,510
Cash flows from financing activities:
Repayment of notes payable and other obligations	(116,931)	(133,715)
Net cash (used in) financing activities	(116,931)	(133,715)
Net change in cash and cash equivalents	1,828,782	662,124
Cash and cash equivalents at beginning of period	2,012,283	3,539,911
Cash and cash equivalents at end of period	3,841,065	4,202,035
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	31,140	$ 25,286
Supplemental disclosure of investing information:
Liability payoffs upon property sale	$ 2,064,758

XML 16 R6.htm IDEA: XBRL DOCUMENT

INTERIM FINANCIAL STATEMENTS

3 Months Ended

Mar. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

INTERIM FINANCIAL STATEMENTS

Management’s plans and basis of presentation:

Management’s strategic assessment includes the following potential options:

exploring other possible strategic options available to the Company following termination of the Strand transaction;

evaluating options to monetize, partner or license the Company's appendicitis product portfolio;

continuing to explore prospective partnering or licensing opportunities with complementary opportunities and technologies; and

continuing to implement cost control initiatives to conserve cash.

XML 17 R7.htm IDEA: XBRL DOCUMENT

Significant accounting policies	3 Months Ended
Significant accounting policies	Mar. 31, 2016
Accounting Policies [Abstract]
Significant accounting policies	Note 1. Significant accounting policies: Cash, cash equivalents and investments: The Company considers all highly liquid investments with an original maturity of three months or less at the date of acquisition to be cash equivalents. From time to time, the Company’s cash account balances exceed the balances as covered by the Federal Deposit Insurance System. The Company has never suffered a loss due to such excess balances. The Company invests excess cash from time to time in highly-liquid debt and equity investments of highly-rated entities, which are classified as trading securities. Historically, the purpose of the investments has been to fund research and development, product development, FDA clearance-related activities and general corporate purposes. Such amounts are recorded at market values using Level 1 inputs in determining fair value and are generally classified as current, as the Company does not intend to hold the investments beyond twelve months. Investment securities classified as trading are those securities that are bought and held principally for the purpose of selling them in the near term, with the objective of preserving principal and generating profits. These securities are reported at fair value with unrealized gains and losses reported as an element of other (expense) income in current period earnings. The Company’s Board of Directors has approved an investment policy covering the investment parameters to be followed with the primary goals being the safety of principal amounts and maintaining liquidity. The policy provides for minimum investment rating requirements as well as limitations on investment duration and concentrations. Based upon market conditions, the investment guidelines have been tightened to increase the minimum acceptable investment ratings required for investments and shorten the maximum investment term. As of March 31, 2016, approximately 11% of the investment portfolio was in cash and cash equivalents, which is presented as such on the accompanying balance sheet, and the remaining funds were invested in marketable securities with none individually representing a material amount of the portfolio. Investments with a scheduled maturity beyond one year are classified as long-term investments on the balance sheet. To date, the Company’s cumulative realized market loss from the investments has not been significant. For the three months ended March 31, 2016 and 2015, there was approximately $5,900 and $8,400, respectively, in management fee expenses. Fair value of financial instruments: The Company accounts for financial instruments under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification Topic (“ASC”) 820, Fair Value Measurements. This statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements, ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels as follows: Level 1— quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 — observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and Level 3 — assets and liabilities whose significant value drivers are unobservable. Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment. There were no financial assets or liabilities measured at fair value, with the exception of cash, cash equivalents and short-term investments as of March 31, 2016 and December 31, 2015. The carrying amounts of the Company’s financial instruments (other than cash, cash equivalents and short-term investments as discussed above) approximate fair value because of their variable interest rates and / or short maturities combined with the recent historical interest rate levels. Revenue recognition and accounts receivable: We recognize sales of goods under the provisions of ASC 605 and the U.S. Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin (“SAB”) 104, Revenue Recognition. Future revenue is expected to be generated primarily from the sale of products. Product revenue primarily consists of sales of instrumentation and consumables. Revenue is recognized when the following four basic criteria have been met: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred and risk of loss has passed; (iii) the seller’s price to the buyer is fixed or determinable; and (iv) collectability is reasonably assured. In international markets, the Company sells its products to distributors or re-sellers, who subsequently resell the products to hospitals. The Company has an agreement with the distributor which provides that title and risk of loss pass to the distributor upon shipment of the products, FOB to the distributor. Revenue is recognized upon shipment of products to the distributor as the products are shipped based on FOB shipping point terms. Revenues are recorded less a reserve for estimated product returns and allowances which to date has not been significant. Determination of the reserve for estimated product returns and allowances is based on management’s analyses and judgments regarding certain conditions. Should future changes in conditions prove management’s conclusions and judgments on previous analyses to be incorrect, revenue recognized for any reporting period could be adversely affected. The Company extends credit to customers generally without requiring collateral. As of March 31, 2016, there were no accounts receivable and no sales. At December 31, 2015, the Company did not have any accounts receivable. During the three months ended March 31, 2015, three European-based customers accounted for the total net sales, each representing 12%, 44% and 44%, respectively. The Company monitors its exposure for credit losses and maintains allowances for anticipated losses. The Company records an allowance for doubtful accounts when it is probable that the accounts receivable balance will not be collected. When estimating the allowance, the Company takes into consideration such factors as its day-to-day knowledge of the financial position of specific clients, the industry and size of its clients. A financial decline of any one of the Company’s large clients could have an adverse and material effect on the collectability of receivables and thus the adequacy of the allowance for doubtful accounts receivable. Increases in the allowance are recorded as charges to bad debt expense and are reflected in other operating expenses in the Company’s statements of operations. Write-offs of uncollectible accounts are charged against the allowance. Recently issued and adopted accounting pronouncements: The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company's financial reporting, the Company undertakes a study to determine the consequences of the change to its financial statements and assures that there are proper controls in place to ascertain that the Company's financial statements properly reflect the change. In May 2014, the FASB issued Accounting Standards Update ("ASU") No. 2014-09 "Revenue from Contracts from Customers," which supersedes the revenue recognition requirements in "Revenue Recognition (Topic 605)," and requires entities to recognize revenue in a way that depicts the transfer of potential goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to the exchange for those goods or services. In July 2015, the FASB extended the effective date of ASU 2014-09 by one year, to now be effective for fiscal years, and interim periods beginning after December 15, 2017, and is to be applied retrospectively, with early adoption now permitted for fiscal years, and interim periods beginning after December 31, 2015. The Company does not believe the new standard will have a material impact on its operations and financial statements. Income (loss) per share: ASC 260, Earnings Per Share, requires dual presentation of basic and diluted earnings per share (“EPS”) with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity. Basic net earnings (loss) per share includes no dilution and is computed by dividing net earnings (loss) available to shareholders by the weighted average number of common shares outstanding for the period. Diluted net earnings (loss) per share reflect the potential dilution of securities that could share in the Company’s earnings (loss). The outstanding options and warrants did not have a dilutive effect on earnings per share for the three months ended March 31, 2016 pursuant to the treasury stock method. The effect of the inclusion of the dilutive shares would have resulted in a decrease in loss per share for the three months ended March 31, 2015. Accordingly, the weighted average shares outstanding have not been adjusted for dilutive shares for either period presented. Outstanding stock options and warrants are not considered in the calculation, as the impact of the potential common shares (totaling approximately 757,000 shares and 779,000 shares for the three month periods ended March 31, 2016 and 2015, respectively) would be anti-dilutive. Upon the completion of a special shareholders meeting on March 24, 2016, where such action was approved by shareholders, the Board of Directors authorized a reverse stock split of the Company’s common stock at a ratio of one-for-eight, whereby each eight shares of common stock were combined into one share of common stock (the “Reverse Stock Split”). The Reverse Stock Split was implemented and effective on March 31, 2016. All historical references to shares and share amounts in this report have been retroactively revised to reflect the Reverse Stock Split. A reconciliation of basic and diluted weighted average number of shares outstanding adjusted for the Reverse Stock Split for the period ended March 31, 2016 was 30,990,029 shares on a pre-split basis and 3,876,960 shares on a post-split basis.

XML 18 R8.htm IDEA: XBRL DOCUMENT

Property and equipment

3 Months Ended

Mar. 31, 2016

Property, Plant and Equipment [Abstract]

Property and equipment

Note 2. Property and equipment:

Property and equipment consisted of the following:

	March 31, 2016 (Unaudited)		December 31, 2015

Land and improvements	$	-	$	1,107,508
Building		-		2,589,231
Building improvements		-		253,526
Laboratory equipment		-		848,014
Office and computer equipment		66,104		318,254

		66,104		5,116,533
Less accumulated depreciation		65,208		3,162,037

	$	896	$	1,954,496

Depreciation expense totaled approximately $400 and $40,000 for the three month periods ended March 31, 2016 and 2015, respectively.

XML 19 R9.htm IDEA: XBRL DOCUMENT

Other long-term assets

3 Months Ended

Mar. 31, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Other long-term assets

Note 3. Other long-term assets:

Other long-term assets consisted of the following:

	March 31, 2016 (Unaudited)		December 31, 2015

Patents, trademarks and applications, net of accumulated amortization of $534,692 and $548,327, respectively	$	994,327	$	1,136,410
Goodwill		387,239		387,239

	$	1,381,566	$	1,523,649

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

XML 20 R10.htm IDEA: XBRL DOCUMENT

Notes and Other Obligations

3 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

Notes and Other Obligations

Note 4. Notes and Other Obligations:

Notes payable and other obligations consisted of the following:

	March 31, 2016 (Unaudited)		December 31, 2015

Mortgage notes	$	-	$	1,997,701
Other short-term installment obligations		57,152		142,328

		57,152		2,140,029
Less current portion		57,152		301,250

	$	-	$	1,838,779

Mortgage notes:

On February 25, 2016, the Company completed the sale of its corporate headquarters, land and building, and also paid off its mortgage obligations. See Note 2.

Future maturities:

The Company’s total debt obligations require minimum annual principal payments of approximately $57,000 for the remainder of 2016, with nothing due beyond that date.

XML 21 R11.htm IDEA: XBRL DOCUMENT

Stockholders' equity	3 Months Ended
Stockholders' equity	Mar. 31, 2016
Equity [Abstract]
Stockholders' equity	Note 5. Stockholders’ equity: Upon the completion of a special shareholders meeting on March 24, 2016, where such action was approved by shareholders, the Board of Directors authorized the Reverse Stock Split at a ratio of one-for-eight, whereby each eight shares of common stock were combined into one share of common stock . The Reverse Stock Split was implemented and effective on March 31, 2016. All historical references to shares and share amounts in this report have been retroactively revised to reflect the Reverse Stock Split. Following the Reverse Stock Split, the Company regained its compliance with the Nasdaq minimum bid price, allowing its common stock to continue to be listed on the Nasdaq Capital Market. For the three months periods ended March 31, 2016 and 2015, the Company did not issue any common shares and no options or warrants were exercised during those same periods.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 22 R12.htm IDEA: XBRL DOCUMENT

Stock options and warrants

3 Months Ended

Mar. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock options and warrants

Note 6. Stock options and warrants:

Stock options:

The Company’s determination of the estimated fair value of share-based payment awards on the date of grant is affected by the following variables and assumptions:

·	The grant date exercise price – the closing market price of the Company’s common stock on the date of the grant;
·	Estimated option term – based on historical experience with existing option holders;
·	Estimated dividend rates – based on historical and anticipated dividends over the life of the option;
·	Term of the option – based on historical experience, grants have lives of approximately 3-5 years;
·	Risk-free interest rates – with maturities that approximate the expected life of the options granted;
·	Calculated stock price volatility – calculated over the expected life of the options granted, which is calculated based on the daily closing price of the Company’s common stock over a period equal to the expected term of the option; and
·	Option exercise behaviors – based on actual and projected employee stock option exercises and forfeitures.

	2016		2015

Selling, general and administrative expenses	$	45,324	$	392,362
Research and development expenses		2,560		41,040

Total stock-based compensation	$	47,884	$	433,402

During the three months ended March 31, 2016 and 2015, respectively, no options were exercised.

Stock incentive plan options:

A summary of activity under the Plan for the three months ended March 31, 2016 is presented below:

	Shares Underlying Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value

Outstanding at January 1, 2016		332,560		$	35.36
Granted		-			-
Exercised		-			-
Forfeited		(7,382	)		20.98

Outstanding at March 31, 2016		325,178		$	35.75		7.5		$	-

Exercisable at March 31, 2016		305,265		$	37.10		7.5		$	-

Nonvested Shares	Nonvested Shares Underlying Options			Weighted Average Exercise Price		Weighted Average Grant Date Fair Value

Nonvested at January 1, 2016		33,336		$	15.54	$	11.41
Granted		-			-		-
Vested		(9,803	)		16.67		12.92
Forfeited		(3,620	)		15.13		10.75

Nonvested at March 31, 2016		19,913		$	15.06	$	10.79

Other common stock purchase options and warrants:

Following is a summary of outstanding options and warrants that were issued outside of the Plan for the three months ended March 31, 2016:

	Shares Underlying Options / Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value

Outstanding at January 1, 2016		432,003	$	15.47
Granted		-		-
Exercised		-		-
Forfeited		-		-

Outstanding and exercisable at March 31, 2016		432,003	$	15.47	2.0	$	-

During the three months ended March 31, 2016 and 2015, no warrants were exercised.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 23 R13.htm IDEA: XBRL DOCUMENT

Animal Health License Agreements

3 Months Ended

Mar. 31, 2016

Animal Health License Agreements [Abstract]

Animal Health License Agreements

Note 7. Animal Health License Agreements:

Under the License Agreement as of March 31, 2016, the following future milestone payments are provided, assuming future milestones are successfully achieved:

•	Milestone payments, totaling up to a potential of $1.1 million in the aggregate, based on the satisfactory conclusion of milestones as defined in the License Agreement;

•	Potential for milestone payments of up to an additional $2 million for development and receipt of regulatory approval for additional licensed products; and

•	Royalties, at low double digit rates, based on sales of licensed products.

A tabular summary of the revenue categories and cumulative amounts of revenue recognition associated with the License Agreement follows:

Category		Totals
License fees and milestone amounts paid / achieved		$	1,920,000
Third party obligations recorded, including WU			(363,700	)
Deferred revenue balance			1,556,300
Revenue amortization to March 31, 2016			(321,762	)

Net deferred revenue balance at March 31, 2016		$	1,234,538
Commencement of license fees revenue recognition	Upon signing or receipt
Commencement of milestone revenue recognition	Upon milestone achievement over then remaining life
Original amortization period	197 months

XML 24 R14.htm IDEA: XBRL DOCUMENT

Commitments and contingencies	3 Months Ended
Commitments and contingencies	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Note 8. Commitments and contingencies: Commitments: As of March 31, 2016, the Company had employment agreements with two officers providing aggregate annual minimum commitments totaling $655,000. The agreements automatically renew at the end of each year unless terminated by either party and contain customary confidentiality and benefit provisions. Venaxis determined in the first quarter of 2016 to begin winding down and ceasing its APPY1 commercial activities, due to continuing limited sales and losses from the European operations. This decision also resulted in a reduction of the Company’s workforce, which was implemented as of January 31, 2016. In February 2016, Venaxis sent notices to its four European distributors informing them of the wind down and therefore the termination of their distribution agreements. Two of the distributors, linked by common management / ownership subsequently communicated to Venaxis that they dispute that Venaxis had the right to terminate the agreements. Under the terms of the distribution agreements, such a dispute shall first be attempted to be resolved between management of the parties and then subject to binding arbitration. Venaxis believes that the distributors’ claims are without merit and any potential settlement or resolution will not be material to the Company’s financial position. Contingencies: In the ordinary course of business and in the general industry in which the Company is engaged, it is not atypical to periodically receive a third party communication which may be in the form of a notice, threat, or “cease and desist” letter concerning certain activities. For example, this can occur in the context of the Company’s pursuit of intellectual property rights. This can also occur in the context of operations such as the using, making, having made, selling, and offering to sell products and services, and in other contexts. The Company makes rational assessments of each situation on a case-by-case basis as such may arise. The Company periodically evaluates its options for trademark positions and considers a full spectrum of alternatives for trademark protection and product branding. We are currently not a party to any legal proceedings, the adverse outcome of which would, in our management’s opinion, have a material adverse effect on our business, financial condition and results of operations.

XML 25 R15.htm IDEA: XBRL DOCUMENT

Subsequent event	3 Months Ended
Subsequent event	Mar. 31, 2016
Subsequent Events [Abstract]
Subsequent event	Note 9. Subsequent event: Subsequent to March 31, 2016, 77,000 options were issued to non-employee directors under the Plan, exercisable at an average of $2.89 per share. The options expire ten years from the date of grant and vest over one year, based upon 50% on the date of grant, and 25% on each of July 1, 2016, and October 1, 2016. Subsequent to March 31, 2016, 150,000 options were issued to officers and employees under the Plan, exercisable at an average of $2.89 per share. The options expire ten years from the date of grant and vest 50% upon each of the six month and the one year anniversary of the grant date.

XML 26 R16.htm IDEA: XBRL DOCUMENT

Significant accounting policies (Policy)	3 Months Ended
Significant accounting policies (Policy)	Mar. 31, 2016
Accounting Policies [Abstract]
Cash, cash equivalents and investments	Cash, cash equivalents and investments: The Company considers all highly liquid investments with an original maturity of three months or less at the date of acquisition to be cash equivalents. From time to time, the Company’s cash account balances exceed the balances as covered by the Federal Deposit Insurance System. The Company has never suffered a loss due to such excess balances. The Company invests excess cash from time to time in highly-liquid debt and equity investments of highly-rated entities, which are classified as trading securities. Historically, the purpose of the investments has been to fund research and development, product development, FDA clearance-related activities and general corporate purposes. Such amounts are recorded at market values using Level 1 inputs in determining fair value and are generally classified as current, as the Company does not intend to hold the investments beyond twelve months. Investment securities classified as trading are those securities that are bought and held principally for the purpose of selling them in the near term, with the objective of preserving principal and generating profits. These securities are reported at fair value with unrealized gains and losses reported as an element of other (expense) income in current period earnings. The Company’s Board of Directors has approved an investment policy covering the investment parameters to be followed with the primary goals being the safety of principal amounts and maintaining liquidity. The policy provides for minimum investment rating requirements as well as limitations on investment duration and concentrations. Based upon market conditions, the investment guidelines have been tightened to increase the minimum acceptable investment ratings required for investments and shorten the maximum investment term. As of March 31, 2016, approximately 11% of the investment portfolio was in cash and cash equivalents, which is presented as such on the accompanying balance sheet, and the remaining funds were invested in marketable securities with none individually representing a material amount of the portfolio. Investments with a scheduled maturity beyond one year are classified as long-term investments on the balance sheet. To date, the Company’s cumulative realized market loss from the investments has not been significant. For the three months ended March 31, 2016 and 2015, there was approximately $5,900 and $8,400, respectively, in management fee expenses.
Fair value of financial instruments	Fair value of financial instruments: The Company accounts for financial instruments under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification Topic (“ASC”) 820, Fair Value Measurements. This statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements, ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels as follows: Level 1— quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 — observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and Level 3 — assets and liabilities whose significant value drivers are unobservable. Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment. There were no financial assets or liabilities measured at fair value, with the exception of cash, cash equivalents and short-term investments as of March 31, 2016 and December 31, 2015. The carrying amounts of the Company’s financial instruments (other than cash, cash equivalents and short-term investments as discussed above) approximate fair value because of their variable interest rates and / or short maturities combined with the recent historical interest rate levels.
Revenue recognition and accounts receivable	Revenue recognition and accounts receivable: We recognize sales of goods under the provisions of ASC 605 and the U.S. Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin (“SAB”) 104, Revenue Recognition. Future revenue is expected to be generated primarily from the sale of products. Product revenue primarily consists of sales of instrumentation and consumables. Revenue is recognized when the following four basic criteria have been met: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred and risk of loss has passed; (iii) the seller’s price to the buyer is fixed or determinable; and (iv) collectability is reasonably assured. In international markets, the Company sells its products to distributors or re-sellers, who subsequently resell the products to hospitals. The Company has an agreement with the distributor which provides that title and risk of loss pass to the distributor upon shipment of the products, FOB to the distributor. Revenue is recognized upon shipment of products to the distributor as the products are shipped based on FOB shipping point terms. Revenues are recorded less a reserve for estimated product returns and allowances which to date has not been significant. Determination of the reserve for estimated product returns and allowances is based on management’s analyses and judgments regarding certain conditions. Should future changes in conditions prove management’s conclusions and judgments on previous analyses to be incorrect, revenue recognized for any reporting period could be adversely affected. The Company extends credit to customers generally without requiring collateral. As of March 31, 2016, there were no accounts receivable and no sales. At December 31, 2015, the Company did not have any accounts receivable. During the three months ended March 31, 2015, three European-based customers accounted for the total net sales, each representing 12%, 44% and 44%, respectively. The Company monitors its exposure for credit losses and maintains allowances for anticipated losses. The Company records an allowance for doubtful accounts when it is probable that the accounts receivable balance will not be collected. When estimating the allowance, the Company takes into consideration such factors as its day-to-day knowledge of the financial position of specific clients, the industry and size of its clients. A financial decline of any one of the Company’s large clients could have an adverse and material effect on the collectability of receivables and thus the adequacy of the allowance for doubtful accounts receivable. Increases in the allowance are recorded as charges to bad debt expense and are reflected in other operating expenses in the Company’s statements of operations. Write-offs of uncollectible accounts are charged against the allowance.
Recently issued and adopted accounting pronouncements	Recently issued and adopted accounting pronouncements: The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company's financial reporting, the Company undertakes a study to determine the consequences of the change to its financial statements and assures that there are proper controls in place to ascertain that the Company's financial statements properly reflect the change. In May 2014, the FASB issued Accounting Standards Update ("ASU") No. 2014-09 "Revenue from Contracts from Customers," which supersedes the revenue recognition requirements in "Revenue Recognition (Topic 605)," and requires entities to recognize revenue in a way that depicts the transfer of potential goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to the exchange for those goods or services. In July 2015, the FASB extended the effective date of ASU 2014-09 by one year, to now be effective for fiscal years, and interim periods beginning after December 15, 2017, and is to be applied retrospectively, with early adoption now permitted for fiscal years, and interim periods beginning after December 31, 2015. The Company does not believe the new standard will have a material impact on its operations and financial statements.
Income (loss) per share	Income (loss) per share: ASC 260, Earnings Per Share, requires dual presentation of basic and diluted earnings per share (“EPS”) with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity. Basic net earnings (loss) per share includes no dilution and is computed by dividing net earnings (loss) available to shareholders by the weighted average number of common shares outstanding for the period. Diluted net earnings (loss) per share reflect the potential dilution of securities that could share in the Company’s earnings (loss). The outstanding options and warrants did not have a dilutive effect on earnings per share for the three months ended March 31, 2016 pursuant to the treasury stock method. The effect of the inclusion of the dilutive shares would have resulted in a decrease in loss per share for the three months ended March 31, 2015. Accordingly, the weighted average shares outstanding have not been adjusted for dilutive shares for either period presented. Outstanding stock options and warrants are not considered in the calculation, as the impact of the potential common shares (totaling approximately 757,000 shares and 779,000 shares for the three month periods ended March 31, 2016 and 2015, respectively) would be anti-dilutive. Upon the completion of a special shareholders meeting on March 24, 2016, where such action was approved by shareholders, the Board of Directors authorized a reverse stock split of the Company’s common stock at a ratio of one-for-eight, whereby each eight shares of common stock were combined into one share of common stock (the “Reverse Stock Split”). The Reverse Stock Split was implemented and effective on March 31, 2016. All historical references to shares and share amounts in this report have been retroactively revised to reflect the Reverse Stock Split. A reconciliation of basic and diluted weighted average number of shares outstanding adjusted for the Reverse Stock Split for the period ended March 31, 2016 was 30,990,029 shares on a pre-split basis and 3,876,960 shares on a post-split basis.

XML 27 R17.htm IDEA: XBRL DOCUMENT

Property and equipment (Tables)

3 Months Ended

Mar. 31, 2016

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

Property and equipment consisted of the following:

	March 31, 2016 (Unaudited)		December 31, 2015

Land and improvements	$	-	$	1,107,508
Building		-		2,589,231
Building improvements		-		253,526
Laboratory equipment		-		848,014
Office and computer equipment		66,104		318,254

		66,104		5,116,533
Less accumulated depreciation		65,208		3,162,037

	$	896	$	1,954,496

XML 28 R18.htm IDEA: XBRL DOCUMENT

Other long-term assets (Tables)

3 Months Ended

Mar. 31, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Other Long-Term Assets

Other long-term assets consisted of the following:

	March 31, 2016 (Unaudited)		December 31, 2015

Patents, trademarks and applications, net of accumulated amortization of $534,692 and $548,327, respectively	$	994,327	$	1,136,410
Goodwill		387,239		387,239

	$	1,381,566	$	1,523,649

XML 29 R19.htm IDEA: XBRL DOCUMENT

Notes and Other Obligations (Tables)

3 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

Schedule of Long-Term Debt

Notes payable and other obligations consisted of the following:

	March 31, 2016 (Unaudited)		December 31, 2015

Mortgage notes	$	-	$	1,997,701
Other short-term installment obligations		57,152		142,328

		57,152		2,140,029
Less current portion		57,152		301,250

	$	-	$	1,838,779

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

XML 30 R20.htm IDEA: XBRL DOCUMENT

Stock options and warrants (Tables)

3 Months Ended

Mar. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of the Income Statement Allocation of Stock-based Compensation

	2016		2015

Selling, general and administrative expenses	$	45,324	$	392,362
Research and development expenses		2,560		41,040

Total stock-based compensation	$	47,884	$	433,402

Summary of Stock Incentive Plan Activity

A summary of activity under the Plan for the three months ended March 31, 2016 is presented below:

	Shares Underlying Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value

Outstanding at January 1, 2016		332,560		$	35.36
Granted		-			-
Exercised		-			-
Forfeited		(7,382	)		20.98

Outstanding at March 31, 2016		325,178		$	35.75		7.5		$	-

Exercisable at March 31, 2016		305,265		$	37.10		7.5		$	-

Schedule of Nonvested Share Activity

Nonvested Shares	Nonvested Shares Underlying Options			Weighted Average Exercise Price		Weighted Average Grant Date Fair Value

Nonvested at January 1, 2016		33,336		$	15.54	$	11.41
Granted		-			-		-
Vested		(9,803	)		16.67		12.92
Forfeited		(3,620	)		15.13		10.75

Nonvested at March 31, 2016		19,913		$	15.06	$	10.79

Schedule of Nonqualified Award Activity

Following is a summary of outstanding options and warrants that were issued outside of the Plan for the three months ended March 31, 2016:

	Shares Underlying Options / Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value

Outstanding at January 1, 2016		432,003	$	15.47
Granted		-		-
Exercised		-		-
Forfeited		-		-

Outstanding and exercisable at March 31, 2016		432,003	$	15.47	2.0	$	-

XML 31 R21.htm IDEA: XBRL DOCUMENT

Animal Health License Agreements (Tables)

3 Months Ended

Mar. 31, 2016

Animal Health License Agreements [Abstract]

Schedule of Current and Long-Term Deferred Revenues

A tabular summary of the revenue categories and cumulative amounts of revenue recognition associated with the License Agreement follows:

Category		Totals
License fees and milestone amounts paid / achieved		$	1,920,000
Third party obligations recorded, including WU			(363,700	)
Deferred revenue balance			1,556,300
Revenue amortization to March 31, 2016			(321,762	)

Net deferred revenue balance at March 31, 2016		$	1,234,538
Commencement of license fees revenue recognition	Upon signing or receipt
Commencement of milestone revenue recognition	Upon milestone achievement over then remaining life
Original amortization period	197 months

XML 32 R22.htm IDEA: XBRL DOCUMENT

INTERIM FINANCIAL STATEMENTS (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and liquid investments	$ 16,600,000
Working capital	16,183,000
Stockholders' equity	16,678,031	$ 16,070,636
Accumulated deficit	105,022,928	$ 105,582,439
Total value of capitalized patent costs that could be impaired due to inability to locate a new strategic target, a partner or other third-party interested in advancing development and commercial activities of the Venaxis appendicitis portfolio	$ 374,000

XML 33 R23.htm IDEA: XBRL DOCUMENT

Significant accounting policies (Narrative) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash, cash equivalents and short-term investments:
Cash and cash equivalent investment portfolio, percentage	11.00%
Management fees	$ 5,900	$ 8,400
Accounts receivable, net
Sales		$ 11,288
Income (loss) per share:
Shares not included in the computation of EPS	757,000	779,000
Basic and diluted weighted average number of shares outstanding pre-stock split basis	30,990,029
Basic and diluted weighted average number of shares outstanding	3,876,960	3,876,960

XML 34 R24.htm IDEA: XBRL DOCUMENT

Significant accounting policies (Revenue recognition and accounts receivable) (Details) - Customer Concentration [Member] - Net Sales [Member]	3 Months Ended
	Mar. 31, 2015 item
Concentration Risk [Line Items]
Number of customers	3
Customer One [Member]
Concentration Risk [Line Items]
Risk percentage	12.00%
Customer Two [Member]
Concentration Risk [Line Items]
Risk percentage	44.00%
Customer Three [Member]
Concentration Risk [Line Items]
Risk percentage	44.00%

XML 35 R25.htm IDEA: XBRL DOCUMENT

Property and equipment (Narrative) (Details) - USD ($)	3 Months Ended
Property and equipment (Narrative) (Details) - USD ($)	Mar. 31, 2016	Mar. 31, 2015	Feb. 29, 2016
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 400	$ 40,000
Sales price of corporate headquarters, land and building to a third party			$ 4,000,000
Proceeds from sale of property and equipment	1,748,571
Gain on sale of property and equipment (Note 2)	$ 1,919,361

XML 36 R26.htm IDEA: XBRL DOCUMENT

Property and equipment (Schedule of Property and Equipment) (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property and equipment	$ 66,104	$ 5,116,533
Less accumulated depreciation	65,208	3,162,037
Total property and equipment, net	$ 896	1,954,496
Land and improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment		1,107,508
Building [Member]
Property, Plant and Equipment [Line Items]
Property and equipment		2,589,231
Building improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment		253,526
Laboratory equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment		848,014
Office and computer equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 66,104	$ 318,254

XML 37 R27.htm IDEA: XBRL DOCUMENT

Other long-term assets (Details) - USD ($)	3 Months Ended
Other long-term assets (Details) - USD ($)	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Patents, trademarks and applications, net of accumulated amortization	$ 994,327		$ 1,136,410
Goodwill	387,239		387,239
Total other long-term assets	1,381,566		1,523,649
Finite-lived assets, accumulated amortization	534,692		$ 548,327
Future amortization
2016	76,000
2017	76,000
2018	76,000
2019	76,000
2020	76,000
Impairment charges	$ 134,000

XML 38 R28.htm IDEA: XBRL DOCUMENT

Notes and Other Obligations (Narrative) (Details)	3 Months Ended
Notes and Other Obligations (Narrative) (Details)	Mar. 31, 2016 USD ($)
Future Maturities:
Remainder of 2016	$ 57,000
Mortgage Notes [Member]
Debt Instrument [Line Items]
Amortization period	15 years
Balloon maturity period	5 years
Commercial Banks [Member] \| Mortgage Notes [Member]
Debt Instrument [Line Items]
Fixed interest rate	3.95%
Periodic payments, principal and interest	$ 11,700
Periodic payments, interest	$ 4,500
U.S. Small Business Administration [Member] \| Mortgage Notes [Member]
Debt Instrument [Line Items]
Fixed interest rate	5.86%
Periodic payments, principal and interest	$ 9,000
Periodic payments, interest	$ 3,500

XML 39 R29.htm IDEA: XBRL DOCUMENT

Notes and Other Obligations (Schedule of Long-Term Debt) (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
Mortgage notes		$ 1,997,701
Other short-term installment obligations	$ 57,152	142,328
Notes and other obligations	57,152	2,140,029
Less current portion	$ 57,152	301,250
Notes and other obligations, noncurrent		$ 1,838,779

XML 40 R30.htm IDEA: XBRL DOCUMENT

Stock options and warrants (Stock incentive plan options) (Narrative) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Sep. 01, 2015	Aug. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares reserved under the Plan			709,141	459,141
Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive stock options exercised to purchase common shares
Options granted
Options granted, exercise price
Options forfeited	7,382	21,668
Options expired	3,762	1,876
Options forfeited, unvested	3,620	19,792
Options forfeited, exercise price	$ 20.98
Options expired, exercise price	26.61	$ 193.36
Options forfeited, unvested, exercise price	$ 15.13	$ 16.48
Fair value of options vested	$ 127,000	$ 234,000
Expected to vest	16,000
Unrecognized compensation cost	$ 128,000
Stock Incentive Plan [Member] \| Directors, Employees and Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield		0.00%
Expected price volatility		93.00%
Risk free interest rate		1.39%
Expected term		5 years
Stock Incentive Plan [Member] \| Independent Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		1 year
Options granted		43,000
Options granted, exercise price		$ 15.12
Expiration period		10 years
Vesting rate		25.00%
Stock Incentive Plan [Member] \| Officers and Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		2 years
Options granted		98,813
Options granted, exercise price		$ 15.12
Expiration period		10 years
Vesting rate		50.00%
Stock Incentive Plan [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	3 years
Stock Incentive Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	5 years
Unrecognized compensation cost, period for recognition	1 year

XML 41 R31.htm IDEA: XBRL DOCUMENT

Stock options and warrants (Schedule of Stock-based Compensation) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation	$ 47,884	$ 433,402
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation	45,324	392,362
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation	$ 2,560	$ 41,040

XML 42 R32.htm IDEA: XBRL DOCUMENT

Stock options and warrants (Schedule of Award Activity) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Stock Incentive Plan [Member]
Shares Underlying Options
Outstanding, beginning	332,560
Granted
Exercised
Forfeited	(7,382)	(21,668)
Outstanding, ending	325,178
Exercisable	305,265
Weighted Average Exercise Price
Outstanding, beginning	$ 35.36
Granted
Exercised
Forfeited	$ 20.98
Outstanding, ending	35.75
Exercisable	$ 37.10
Weighted Average Remaining Contractual Term
Outstanding	7 years 6 months
Outstanding and exercisable	7 years 6 months
Aggregate Intrinsic Value
Outstanding
Exercisable
Nonqualified [Member]
Shares Underlying Options
Outstanding, beginning	432,003
Granted
Exercised
Forfeited
Outstanding, ending	432,003
Weighted Average Exercise Price
Outstanding, beginning	$ 15.47
Granted
Exercised
Forfeited
Outstanding, ending	$ 15.47
Weighted Average Remaining Contractual Term
Outstanding	2 years
Aggregate Intrinsic Value
Outstanding
Exercisable

XML 43 R33.htm IDEA: XBRL DOCUMENT

Stock options and warrants (Schedule of Nonvested Awards) (Details) - Stock Incentive Plan [Member] - $ / shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Nonvested Shares Underlying Options
Beginning balance	33,336
Granted
Vested	(9,803)
Forfeited	(3,620)	(19,792)
Ending balance	19,913
Weighted Average Exercise Price
Beginning balance	$ 15.54
Granted
Vested	$ 16.67
Forfeited	15.13	$ 16.48
Ending balance	15.06
Weighted Average Grant Date Fair Value
Beginning balance	$ 11.41
Granted
Vested	$ 12.92
Forfeited	10.75
Ending balance	$ 10.79

XML 44 R34.htm IDEA: XBRL DOCUMENT

Animal Health License Agreements (Narrative) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Animal Health License Agreements [Abstract]
Annual royalty commitment	$ 20,000
Prior written notice period for termination of license agreement by the licensee	180 days
Aggregate milestone payments, maximum	$ 1,100,000
Additional milestone payments, maximum	2,000,000
Original amount of deferred revenue	1,556,300
Deferred revenue	96,698		$ 96,698
Deferred revenue, noncurrent	1,137,840		$ 1,162,015
Recognition of license fee revenue	$ 24,175	$ 24,175

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References + Details

- Definition

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References + Details

XML 45 R35.htm IDEA: XBRL DOCUMENT

Animal Health License Agreements (Schedule of Revenue Recognition Associated with the License Agreement) (Details)	3 Months Ended
	Mar. 31, 2016 USD ($)
Animal Health License Agreements [Abstract]
License fees and milestone amounts paid / achieved	$ 1,920,000
Third party obligations recorded, including WU	(363,700)
Deferred revenue balance	1,556,300
Revenue recognized	(321,762)
Deferred revenue balance	$ 1,234,538
Original amortization period	197 months

XML 46 R36.htm IDEA: XBRL DOCUMENT

Commitments and contingencies (Details)	3 Months Ended
Commitments and contingencies (Details)	Mar. 31, 2016 USD ($) Officers
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Number of officers \| Officers	2
Employment Contracts [Member]
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Annual commitment amount \| $	$ 655,000

XML 47 R37.htm IDEA: XBRL DOCUMENT

Subsequent event (Details) - Stock Incentive Plan [Member] - $ / shares	1 Months Ended	3 Months Ended
	May. 11, 2016	Mar. 31, 2016	Mar. 31, 2015
Subsequent Event [Line Items]
Options granted
Options granted, exercise price
Subsequent Event [Member] \| Independent Directors [Member]
Subsequent Event [Line Items]
Options granted	77,000
Options granted, exercise price	$ 2.89
Expiration period	10 years
Vesting period	1 year
Subsequent Event [Member] \| Officers and Employees [Member]
Subsequent Event [Line Items]
Options granted	150,000
Options granted, exercise price	$ 2.89
Expiration period	10 years
Vesting period	6 months

EXCEL 48 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( %!%JTB)6B0\O $ "88 3 6T-O;G1E;G1?5'EP97-= M+GAM;,V9S4[#,!"$7Z7*%36N;?Y%>P&N@ 0O8))M8S6.+=N4\O;8*2"H"FJ! M2G/)3V>],\DZWZ47#R^.PF!IVBZ,BR9&=\Y8J!HR*I3649>4J?5&Q73K9\RI M:JYFQ,1H=,PJVT7JXC#F'L7DXG9!WNN:!I%\JY5EO=1W: MZ5175-OJR:0E94S6=)#T8G"G?+Q1)K5@RY;UPNK(RZRS_S$,SI.J0T,435N& M^-)2V.2_4MZ=KVBJGMJXD_';NRL]M7U-:+1[L[I>IBXA_38NDAJV]89>DXKND!I9:_\G[?:=4UM-6AKEPCQ]%HSS5]]&G^6[^-CX7 M["]'GFM__=W0>S&P_K1'2.R40X#DD" Y#D%R'('D. ;)<0*2XQ0DQQE(#CY" M"8)"5(Z"5(["5(X"58Y"58Z"58["58X"5HY"5H%"5H%"5H%"5H%"5H%"5H%" M5H%"5H%"5H%"5H%"5HE"5HE"5HE"5HE"5HE"5HE"5HE"5OE!5M;_/3!Y!5!+ M P04 " !01:M(2'4%[L4 K @ "P %]R96QS+RYR96QSK9++;L) M#$5_)9I]<4HE%A%AQ88=0OR .^,\E,QXY#$B_?N.V(#"0ZW$TJ][CZZ\#JFL M#C2B]AQ2U\=43'X,JQW8OG*\M"_V/Z'D4X$G1H>)%]2-F Q+M*;V"^GH A3&^.R6: ME((C-Z."N[_8_ )02P,$% @ 4$6K2,3+)$.4 0 /!< !H !X;"]? M&?/ODKC;671NJN@^S]^;: MANWP?Y]5,?9;8T)1N<:&AZYW[;!Z[GQCX_#I2]/;XF)+9SC/E\9/YV2'W<_9 ML^-IG_GCB;+9B_6EB_OLK?.74#D7@QE?]#!L,"S?>O>?[;OSN2[<8U>\-JZ- M?U28KPTRDP[B=!!#@B0=))"@>3IH#@E:I(,6D*!E.F@)"5JE@U:0H'4Z: T) MVJ2#-I @RA49C-&;%;T9HSC-&;U;T M9HS>K.C-&+U9T9LQ>K.B-V/T%D5OP>@MBMZ"T5L4O05T5Z)=EF#T%D5OP>@M MBMZ"T5L4O06CMRAZ"T9OF>@=*NO=Z3GZNBW#O6N^#5>+)GB'>+NZ^Z>,4]7[ MR(G6<=C)F?%Y=Q3'J9\AYM=%^>$#4$L#!!0 ( %!%JTACQE2(PP( (,* M 0 9&]C4')O<',O87!P+GAM;+U646_:,!#^*U9>QA[:4.A:"=%(#*B& MU$*U9-VS<2Z)5ARC+.8*+8J@1IPUZW>Q7" MBP690GI6[9P&T=!%&565X(Q:KF1TSYE61F663%\8B&'X%N 9Z#D&MM+<;J)N MC=DW>4S,J( QQHHR*@S4J+]&CQFKLJ)R$]:[.RZ?S(\J41-J89]U>%![+ZB& M%(,>>-\9/>;;!O,4CCLNJ,PAW<>^/]QJ\0C:N$PO>N==_.TDV-IKWT!3+O,' MRK6)AFL[6 .S2K^6:6T_6J54,5=T\YC@_4Q EM2 6]X$:ZHYE38@AO_&;2^H MP]96OQ:5L3KZJ?23*0"L&88[HU_N8_?7_#+J7WL$K@Z1X2ZSZ%6V@[R=)>%6 M@%ED#U3;_R2%SVDK1/\ZV,M^ZX)0F9*IM-B.9";K4%B\?4EVJZ]44,F Q.]4 M.P(A'4P6@Q1@\5F(SXV4V&*SNJL8HC*RP&[S-VCV?P@>4U.06Z&>F\&S>3+] M/KLGM[/Y:#Z>C>Y(G(R2Z?UTGL3-WGDN.0I,G2Z,J17J(G-2*7S5. 8:.:^C M9^.%A%\K7KGK-4(7*(0F0LG\S((N"37FF(YS97&6.9[(X%U:<*)%?SN@/4$L#!!0 ( %!%JT@!M=N=/@$ &D# 1 9&]C4')O M<',O8V]R92YX;6S-D\%.PS ,AE\%]=ZE[6!"4=<#($Y,0F((Q"TDWA;6)E'B MJ>O;DWFE9/2>GCTUH%'#>%BW]0F<.GFR0;1<<:"W$ C MPB16F)A<6=\(C*%?,R?D5JR!%5DV8PV@4 (%.P!3-Q"3JE222P\"K>_Q2@YX MM_,UP91D4$,#!@/+)SE+JF>S-;8U)1OU51D=UR+@PBJ]TJ!NNK'L=RIV1O!- M.,I!#>WI[Y\>*,.2OG(?]%#5MNVDG5)='#AGKXN')SJ;5)N PDB(JJ Y=@[F MR5?GE^GMW?(^J8HLGZ7959KGR^R:7Q:\F+X=)COQ-QIN^B'^K>,O@[1=U%C# MF;LEC:+ETB>!% 3IM4-MS5DXPGP3$RSLWC] XOF@7DB7;0M=:[T*%=VO,3J\ MG+BRM?7=,?4C.GE5U2=02P,$% @ 4$6K2)E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNT MF83M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB& MB)3R> +]O6N[!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2- M9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG M/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@X MMLO2BW A(5M>5 MTR 6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. M #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K M;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5 MP/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M" M/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^ M8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_ MZ3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K M^(+ .7\N?<^E[[GT/:'2MSAD6R4)RU33 M93>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W MF)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&& MF,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& M RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/ M55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7 M&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP M# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[ M&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D M*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F- M"F]!U4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M " !01:M(*QSBQ#D" """0 #0 'AL+W-T>6QEAJ&T8A,-C*H/FP;T6V95N@%T^6,[N_?GIQ_!((S=IN2[[H M].CNN>?.RMEAK3J*'TJ,%6@9Y74$2Z6J3YY7IR5FJ%Z*"G-]D@O)D-);67AU M)3'*:A/$J+?R_;7'$.$P#GG#-DS5(!4-5Q%<#1!P\7XA?VX!("Q_$EBV"POH;>Z:1+_SBO/CN@7AMJKZ\A#G/!YZ48 M( [K)[!#5/L'QCT55$B@=*^T!HMPQ+#SN$.4))(8,$>,T,[!*P/8]O9^C' A M;6Z7X3#/TA\SR2*)H-__3D^7C.QV,>412N?E:2 .*Z04EGRC-Z"WMUVEB^." M8R?2^CWC74C4!:OK28!==-Y$R S+(7, ]U <4IPK'2!)49I5BXI MK?\B7M#F0P(=C:J*=I\I*3C#3JR#-J+?/4VU^3.%+2_Z;FMZ^:Z,:?07_=7O^:_+IL[%_0WB@ MYX1'<=^P!,N-GLY6V/E=I5S>O5.;UTW[YLS:<:[;4X42_4$TRZ+),IRCAJKO9">4/8S@:'\U M\H/UX+4=*"(XVM]P1AIV8Q6,7UWQ;U!+ P04 " !01:M(>Q_#G+X# #> M# #P 'AL+W=O6@;1,Z0Q- MR)69A&0*TSX+6V!-9,DGR:'M7]^5G+1K$&[S!/ZQGU;:3_*^L].#-H];K1_) MUTHJ.S6SI'2NG@X&-B]YQ>R_NN8*GNVTJ9B#2[,?Z-U.Y/Q:YTW%E1O0X7 R M,%PR)[2RI:AM\DRS?T*SM>&LL"7GKI(MK&)")>_?V>E.2/Z9&PM@PNIZQ2H^ M2[[*A$AFW:(0CA>S9 27^L [-TQ3?VB$]!?CX3@9>-C+5!\,R77!6]BF%/;+ M\X.$%'S'&NDVD.S+N+,DI2-*)RW#O_99\(/%0'^#L-R))[YAVUDR3 AKG+X1 MTG%SS1S_S^BF%FH/K(3LA+%N[:<;WJR$$I7X[O.&*UOJPT=MQ'>M')/KW&@I M0Y1_$()@!/OS#N3H1-YYT;'M)U^)63(9 O!)6+$54KAOLR3\E]S/9' TE;#\ MO_X1%1;GI<2$J8(LE ,*6:JV>+ T/@=X>5F$@9CTWXB3(4YVRED[J(*?B25Z1^YK;EI9$6&$"*/? M$:Z8+U%J*7'"B]K-#\6]0 M_)O3^'LH@X&-I_;_@.458=9V2_L6Q;\]C5]IQVT8O"7=;Z78GU0E'6*QAK&Z MZ/RQU+* W?I7F(?[AN,[8D;,#/%$UV'@D,Z!&0.KV\D":YI&/)W#'F:2?.1, MNI+'\:%53;&H:4?5*5Y5PK6D^G5R'"G-U5-X4"YO&C&VV%M;# M;U_^=)0$5C6-N-IK63K!*.QK&A$V[AFY@'-, M'OL\#Z.PQVE$Y/,&AS6B*49AKVG$Z[[3AEQ<8U3G#([(W2L# MS3 *RTUCYW O:H116&\:T?N<5RN_^$Y@%+:=1FP_AUI#TU(T$J.P[31B^SE% MK[EC0G:^?-AV&K&]5]$55I1BV^EK;5_G&(5MIZ^T'9[A3S*V/3MW=)]#Y25& M8=NS5YWB@,HH1F';LYCMO2AL>]9I.B*V]V[G#-N>8=NSB.W]J#%&8=NSB.V] M'QAR@5'8]BS6C!Q]8GYZWFG-L.C9Y7/W^:OAA)Y;*%[X=MR&$:"URWV/#C_M MQWPO[Z#OGV6^.8:^NA&RBNX=Z]N-0LM:$M^Z\7=1$2+!9T-;L0TJ*;M-&(IC11HLGEA'6O7ES'B#I1KR2R@Z M3O#)F!H:HBC*P@;7;5 69NZ5EP6[2EJWY)4#<6T:S/_L"&7]-H#!?>*MOE12 M3X1E$8Z^4]V05M2L!9RP)I3J2(G\,0;^8VNCV[]&_F735\@]8D#VCO^N3K-1JHP"PQ(9X#4L>=30&L!5I'9'899GL#U8TPVPV0.9N7-PU4L .0S0.[8H;]4 M)I(%M;*:(5:NWULLNXED0;6L9XBUZT^\B(DD?8R T?Q,16Z$S'^JK":UFGP! MY9^3"UW*REM9@\:6%HK@@O*%:,Y!+F?MS\;5H&@!97Z*8>Q&@+YL]H/&9A.O M\FR=S5&A<_LUA%_,JR# D5U;::^Y<79\>9Z1N3V_Y&71X0OYB?FE;@4X,*GN M8'/]GAF31*TD>E)'ME)OXSB@Y"QU-U=];E\+.Y"LNS]^XPM<_@502P,$% M @ 4$6K2(R' B/) P ,Q !@ !X;"]W;W)KRQ?6P?^0_Y#AQV'6EZ;]WAW*LD]^U-6I>UP=^O[\D*;=\Z&LB^Y3WX>J.S2EIR_WCZG=XR-$,DE'Q M][&\=.0^&'/W>-*#![*JGSNAR8*?WDK\[*JAI9\S__.C?[LOM/15?F3?7/<=D.Q?#;,.#E[=#([[EQ"?3C8_C<$UOWS:(Z_1M:">0;"<)3A).D0<*^2Y) M??^L"8Q,X!@OIWAU/UY&\7*,5U.\#BV>IB0FB1TETBD0AM7E5(<"$-V"?%3D M1U$_AO4S2J(G8BM)1VYC)W5G&H@TTH1 MW4TO+O+BB! H$(;)!FL7<*S&+! ":MN\"PC(P0@K8M]7ST%C 7C2QA]WQ/& MC$7*6,62=-?9^+1(H;]0B*3G>G8N7\J^B?3F>NN2IZ?U)<3PD[INF+WU[XI//\N!/ M\.\/5;GOAUOK[]OI3#L]],WY>D1__S_!YG]02P,$% @ 4$6K2'P;7<#2 M 0 7 4 !@ !X;"]W;W)K1 ^=V6F$Y$2;4!ZQZB60VIDXPW$8YI@3 MV@5EX=9>95F(DV:T@U>)U(ES(O_L@(EA&T3!9>&-'EMM%W!9X,E74PZ=HJ)# M$IIM\#7:5+E5.,%/"H.:S9%EWPOQ;H.7>AN$%@$8'+3-0,QPA@H8LXE,X=]C MSK\EK7$^OV3_[KHU]'NBH!+L%ZUU:V## -70D!/3;V)XAK&%S"8\"*;<&QU. M2@M^L02(DP\_TLZ-@]])T]&V;HA'0SP9HON&9#0D"P/V9*ZO;T23LI!B0*HG M]F='&R.7-HG)C$PSRH7N<_G52G9?$3A*O*:HK13))L*F_"A$O M(&+G3SQ$]&]_LO GSI]Z_RKB;BY)H]4N;DAN4J0+BG1.D5R7Z#R%E^1.DH?^ M61-6=X4WB;(%438G2E>)LEFAY.DQ_Y*O ]W3W>3)%SSYG"=;Y>SO/@ MV4'HR1%^$'FDG4)[HI$4*#R18^F/9:<]5- 8-&V^FCF4M_^GV@17^Y MRZ8+M?P$4$L#!!0 ( %!%JTABU@8]0@, +(, 8 >&PO=V]R:W-H M965T&ULC5?!=;-:WM0J@O>J[)N'\)#UQWOHZC= M'%25MW?ZJ&KSRTXW5=Z9RV8?M<=&Y=N!5)41)22)JKRHP]5R6'MJ5DM]ZLJB M5D]-T)ZJ*F_^9*K4YX<0PH^%YV)_Z/J%:+6,+KQM4:FZ+70=-&KW$#["_9J2 M'C(@?A;JW*+SH!?_HO5K?_%]^Q"27H,JU:;K0^3F\*;6JBS[2";S[S'H9\Z> MB,\_HG\=RC7R7_)6K77YJ]AV!Z.6A,%6[?)3V3WK\S_V6-3#\6Q_$6RD^0ET)- +X9+'3V C@7T2XJ%2JVRHZTO>Y:ME MH\]!>\S[W89[ V_Z("9R8(IIA\NA77;U;<639?36QYE ,@NA P0NB,@$]V:@ MTPP9173J2[#&""YN9V!.#6S@,\N7M_FQPX\'?FSYJ;<'&!+#%%+;*BQ$V#8! ME3.$<$<(1UD2XA7";PNQD,1"")G1T,31D6 =X-61W-:1(!V"RAFWCG!T"*R# M^I)D G6=QB"X5XI 4J:HJUJDHT6BFRQAM_FIPT]Q+;&WEA2I!,((T,1;S03' M&9=\1F^!N$\^P8J\?SM@UH*XFBC4)OR:*4BV "D?9V75 *%-B,YQ-#C6U!.4^EO\E\ MTF1.T.-V79'K@8 =3G@=+@-L<7%,I=]])C!.))VS8:X7 C9#X3=#$),-8Y+$ M5UHT,40N9G7(=4206!'S*Y)H+\R.VV'Z,\QJ>[(NZ#5YT9P;5 M84;=:=TIH]"T+ P.Y@7B?"G/>V)':7G3Z^/&&<'E-6?T%4$L#!!0 M ( %!%JTCU'27^400 .,2 8 >&PO=V]R:W-H965T&ULG9A-;^,V$(;_BN![UISAA\C ,;!V4;2' HL]M&$[$N^^[[&=5'MN'Q;[K3O?+9?NT]U71?JE/ M_MC_Y[ENJJ+K+YN797MJ?+$;@ZIRB4*8954N/!S]MR9K M7ZNJ:/[;^+(^/RQ@<;GQ_?"R[X8;R_5J>8W;'2I_; _U,6O\\\/B*]QOI1PD MH^+O@S^WY'LVF'^LZQ_#Q9^[AX48//C2/W5#BJ+_>/-;7Y9#IG[D?^>D[V,. M@?3[)?OO8[F]_<>B]=NZ_.>PZ_:]6['(=OZY>"V[[_7Y#S_7H(>$3W79CG^S MI]>VJZM+R"*KBI_3Y^$X?IZG_^1F#N,#< [ :\!U'#Y S@'R/4"-E4[.QKI^ M*[IBO6KJ<]:>BN%MPWTO;X8D?>:L+Z8=+\?'-=U]6^=FM7P;\@22S23!40)7 MQ;)/SHZ X0@;).'(#;"E"IU_/H*,:I!CO)QJ2(A74;P:X]44+T.+QZF(29)/ M%K73 )QL2V5W"-9(DN^F'QWYT;0>^WF\B>(-K<>Q]4P2,TI4;JUBRPE44BJ! MGYO)(S,Y,6,%:R8GPX!3@G^V5&5Z*PE3T49>+/7"CK*Q9)0[5)!KUHP-7G0@ MN^G&16X<=8.L&T>?C)36.;:!:":5\%Q Q!00U O? K-FKAD<.&F M1-D2_+S M@4I 6H!,SML9,,Z M"+-@PUYG_1%SYJIZERDX 5B/H&D7@S_="49QSC0_+R; M9=.,L,XXD> GYAU0X$FV]3>S9FX$:84 MGFWD5#USRC!4HP\T-026_MFULPC MJ1ZMR&,K%&JCK4D %\08!>.U442B%=KRCJCLSKAYEKF]55>@!)!" M:VT^MX4Q%)%BS/%+UZR9!G-&6?IFJ2ND] 35KU^Y2E@S,"8C C7%KV&S9EXV M8D0B1:3C$8G!?M.BS?G=US80&H. *:\NYB/27:=C MI_X&Z;83!?0T9F?N-A!*+9V#E+:-B8N4N/&F\N+)A4T"PMQH$BI4*%#(A%)04T)NQ#Y MX<>M#&KB@2;I[A&%47F\$9F)'V3[0/PE.3NH?/,RGJFTV5/]>NRF'^C7N]=S MFZ\XG#U$]S=POYU.7][3K%>GXL7_530OAV.;/=9=5U?CH<9S77>^-R>^]%S: M^V)WO2C]ERI'0]UUK_#U!+ P04 " !01:M("KV# MWIT! "Q P & 'AL+W=O;0_@R)N2VNYH[]RP9*THRMZ*KR(KG>AP*J2+;Q&*-!6H"8& MVAV]7VWW14!$P!\!DSV+2?!^0'P-R:]F1[-@ 234+BAPOQSA :0,0K[QOUGS MHV4@GL4/X5C>N]V8R2!EH^2O>"TQ/,(VR"8(W2QB^I1^M0 MG2B4*/Z65J'C.J4_=]E,^YR0SX3\BL!2HVCS)W>\*@U.Q X\G-UJZ^$FB'AE MXKW9F,;I4_58K;*B9,<@=('9)TR>, N">?5/6^27+?;Y&3W_GKZ^!/9S8:2WK^?)9'0NA#^\+%)5RHE#H?3 UE>:?4. M4$L#!!0 ( %!%JTAN0?S@H $ +$# 8 >&PO=V]R:W-H965T&ULA5/+;MLP$/P5@A\0RK+=)(8L('91M(< 00[-F996$A&2JY*4 ME?Q]^9 5VPB2B[B[FIF=Y:,8T;S:#L"1-R6UW=+.N7[#F*TZ4-S>8 _:_VG0 M*.Y\:EIF>P.\CB0E69YE/YCB0M.RB+4G4Q8X."DT/!EB!Z6X>=^!Q'%+%_14 M>!9MYT*!E06;>;50H*U 30PT6_JPV.Q6 1$!?P6,]BPFP?L!\34D?^HMS8(% MD%"YH,#]&H4 M;?[DCI>%P9'8GH>S6VP\W 01KTR\-QO3.'VJ'LM%=ENP8Q"ZP.P2)D^8&<&\ M^J/5 ML:3"0;NT>7-UOIT/\1#9![PL>M["(S>MT)8 0 L0, M !@ !X;"]W;W)KQ-W5S.PL']6,YLT. (Z\ M*ZGMC@[.C5O&;#. XO8&1]#^3X=&<>=3TS,[&N!M)"G)BBR[8XH+3>LJUEY, M7>'DI-#P8HB=E.+F]QXDSCN:TU/A5?2#"P565VSEM4*!M@(U,=#MZ'V^W9_8%;>$#Y4[1N\&8S2EKH^"3=*\Z/L(QP&P0;E#9^23-9A^I$H43Q][0* M'=F7AO-J9Q M^E0]UGF>5>P8A"XP^X0I$F9%,*_^:8OBLL6^.*,7_Z9OKAQN(GVS./R/_N65 M0!D%RK^.>(FY=LG.]E2!Z>/5L:3!2;NT>6MUO9WW13R3#WA=C;R'9VYZH2TY MH/,G&P^U0W3@360WMY0,_OVLB83.A?"+CTVZ4BEQ.)X>R/I*ZS]02P,$% M @ 4$6K2$M,>&V? 0 L0, !@ !X;"]W;W)K,JJ:M0>]%UA9,57,&+)F:2DNF_>Q X[Y(L.15>>3]87Z!U M15=>RR4HPU$1#=TNN2IW26IMP "&NL5F%N. M< ]">"'7^'W1_&SIB>?Q2?TA3.O<'YB!>Q1_>&L'9S9-2 L=FX1]Q?D1EA$V M7K!!8<*7-).Q*$^4A$CV$5>NPCK'/YMBH7U-R!="OA)^IL%X;!1L_F*6U97& MF9B1^;/+M@ZNO8A3)LZ;"6F8/E:/=985%3UZH0O,/F+RB%D1U*E_V2*_;+'/ MS^CY]_3BRF$1Z,7BL/Q>H+P2*(- ^=\1+S&;JR;T;$\EZ#Y<'4,:G)2-F[=6 MU]MYEX&:ZY\J0 UIWLN%0.T0+SD1ZLTG(X-[/F@CHK ]_N%C' M*Q43B^/I@:ROM/X'4$L#!!0 ( %!%JTC,44;[H $ +$# 9 >&PO M=V]R:W-H965T[# M2E4?=I\=&,"J[:&V"=V_7U\(3:*J?<$SPSEGSOA23FA>;0_@R+N2VNYH[]RP M9*THSD]%5Y$U[M08%7)%EXC%&@K4!,#[8X^Y-O].B BX(^ R9[% M)'@_(+Z&Y%>SHUFP !)J%Q2X7X[P"%(&(=_X;=;\:!F(Y_%)_4>;$9) RT?I7O!Z2?,(]P&P1JEC5]2C]:A.E$H4?P]K4+'=4I_BLU, M^YQ0S(1B(6RR:#PUBC:?N.-5:7 B=N#A[/*MAYL@XI6)]V9C&J=/U6.5YW6( MEYC-51-VMJ<*3!>OCB4UCMJES5NJR^U\*.*9?,"K&PO=V]R:W-H965TZ:EE42$Y"HD9:5_7SYLQ3:"Y"+N MKF9F9_FH9K3/;@#PY%4KX[9T\'[<,.:: ;1P-SB""7\ZM%KXD-J>N=&":!-) M*\:+X@O30AI:5ZGV:.L*)Z^D@4=+W*2UL/]VH'#>TI*>"D^R'WPLL+IB"Z^5 M&HR3:(B%;DOORLUN'1$)\$?"[,YB$KWO$9]C\JO=TB): 6-CPHB+ >X!Z6B M4&C\:-KC?"P?WJ/[*U@_!;$%)"YV8E'_"^2<<1[B-@@TJ ME[ZDF9Q'?:)0HL5K7J5)ZYS_\/)(>Y_ CP2^$+X5R7ANE&P^""_JRN),W"CB MV96; +=1)"B3X,VE-$V?JX>Z++]7[!"%+C"[C.$9LR!84'^W!;]LL>-G=/XY M?77E<)7HJ]R=%Y\+K*\$UDE@_>&(%QA^/20[VU,-MD]7QY$&)^/SYBW5Y7;> M\70F;_"Z&D4/OX7MI7%DCSZ<;#K4#M%#,%'S) HZ'\.O(;;Y2N7$ MXWAZ(,LKK?\#4$L#!!0 ( %!%JT@^^7$HGP$ +$# 9 >&PO=V]R M:W-H965T-9]HMI(7M:%K'V9,H"1Z=D#T^&V%%K M8?[O0.&TI2MZ+#S+MG.AP,J"+;Q::NBMQ)X8:+;T;K79Y0$1 2\2)GL2D^!] MC_@6DC_UEF;! BBH7% 0?CG /2@5A'SC?[/F9\M /(V/Z@]Q6N]^+RSN\V8R2&AHQ*O>,TR/,(UP'P0J5C5]2C=:A/E(HT>(]K;*/ZY3^W.0S[6L" MGPE\(=QFT7AJ%&W^%DZ4A<&)V$&$LUMM/-P$$:],O#<;TSA]JA[*%><%.P2A M,\PN87C"+ CFU;]LP<];[/@)G?],7U\X7$?Z>G:X_ED@OQ#(HT#^[8CGF/RB M"3O94PVFC5?'D@K'WJ7-6ZK+[;SC\4P^X64QB!;^"M/*WI(].G^R\5 ;1 ?> M1'9U34GGW\^2*&A<"&]\;-*52HG#X?A EE=:?@!02P,$% @ 4$6K2!-\ MT(:@ 0 L0, !D !X;"]W;W)K&ULA5/;;J,P M$/T5RQ]0$T+:*B)(35>KW8>5JCZTSPX,8-7VL+8)W;^O+X0F4;5]P3/#.6?. M^%).:-YL#^#(NY+:[FCOW+!ES-8]*&YO< #M_[1H%'<^-1VS@P'>1)*2+,^R M6Z:XT+0J8^W)5"6.3@H-3X;842EN_NU!XK2C*WHJ/(NN=Z' JI(MO$8HT%:@ M)@;:'7U8;?=%0$3 BX#)GL4D>#\@OH7D=[.C6; $FH7%+A?CO (4@8AW_CO MK/G9,A#/XY/ZSSBM=W_@%AY1OHK&]=YL1DD#+1^E>\;I%\PC;()@C=+&+ZE' MZU"=*)0H_IY6H>,ZI3]%,=.^)N0S(5\(]UDTGAI%FS^XXU5I<")VX.'L5EL/ M-T'$*Q/OS<8T3I^JQVJ5;TIV#$(7F'W"Y FS()A7_[)%?MEBGY_1\^_IZRN' MZTA?SPYOOQ1':SH:3W[V=))+0NA'<^-NE*I<3A<'H@ MRRNM/@!02P,$% @ 4$6K2.-\FJ&A 0 L0, !D !X;"]W;W)K&ULA5/+;MLP$/P5@A\0RK3=IH8L($Y1M(<"00[MF996 M$A&2JY*4E?Y]^9 5VPB:B[B[FIF=Y:.^V''F*M[T,+= MX0 F_&G1:N%#:COF!@NB222M&"^*3TP+:6A5IMJ3K4H)9=[V.!525;>(W48)Q$0RRT>_JPVATV$9$ OR1,[B(FT?L1\24F M/YH]+:(%4%#[J"#"&Z4;'X57E2EQ8FX0<2S6^T"W$:1H$R"-Y?2-'VNGJH5OR_9*0I=80X9 MPS-F0;"@_FX+?MWBP"_H_&/Z^L;A.M'7L\,O'PML;@0V26#SWQ&O,.OBI@F[ MV%,-MDM7QY$:1^/SYBW5Y78^I$-D;_"J'$0'/X7MI''DB#Z<;#K4%M%#,%'< M;2GIP_M9$@6MC^'G$-M\I7+B<3@_D.655O\ 4$L#!!0 ( %!%JTB4"0[Z MH $ +$# 9 >&PO=V]R:W-H965TZ:EE42$Y"HD9:5_7Y*2%=L(TE[$W=7,["P? MY83VV?4 GKQJ9=R.]MX/6\9!Z?U+^E:8/[@W!PC^JW;'P?S&:4--"*4?DGG+[#,L)M%*Q1N?0E]>@\ MZA.%$BU>YU6:M$[S'_YUH;U/X N!KX0O63(^-THV'X0756EQ(FX0\>SR;8#; M*!*42?#F4IJFGZO'*B_RDAVCT 5F/V/XC%D1+*B_VX)?MMCS,SK_-[VXK$X_ ^!S97 )@EL/ASQ$E-<-6%G>ZK!=NGJ.%+C:/R\>6MUO9UW/)W)&[PJ M!]'!3V$[:1PYH \GFPZU1?003&0WMY3TX?VLB8+6Q_!SB.U\I>;$XW!Z(.LK MK?X"4$L#!!0 ( %!%JT@>RC\4V $ $4% 9 >&PO=V]R:W-H965T M ^= M/JFX8$3I4-18]@)(:4F,XM#W=YB1MO/RS.9>19[Q0=&V@U>!Y, 8$?].0/EX M] +OFGAKZT:9!,XSO/#*ED$G6]XA =71>PP.I]0@+.!/"Z.\V2-3^YGS=Q/\ M*H^>;TH "H4R"D0O%W@"2HV0-OZ8-;\L#?%V?U5_L=WJZL]$PA.G?]M2-;I8 MWT,E5&2@ZHV//V%N(3&"!:?2?E$Q2,79E>(A1CZGM>WL.DXG23S3M@GA3 @7 M0NK;PB1'&&+T;(P9PF M3#AA%@36ZIL6H6MQ"F_HX7UZM*HPLO1HLLN+\1C:.?F"YUE/:OA-1-UV$IVYTM-F M!ZWB7($NPG_0E];H-VT)*%3*;/=Z+Z8QGP+%^^NCM;R<^7]02P,$% @ M4$6K2 MC]-2B 0 L0, !D !X;"]W;W)K&UL MC5/;;J,P$/T5BP^H@9!V%1&DIE75/JQ4]6'WV8$!K-H>:IO0_?OUA= DBM2^ MX)GAG#-G?"DGU.^F![#D4PIEMDEO[;"AU-0]2&9N< #E_K2H);,NU1TU@P;6 M!)(4-$_36RH95TE5AMJKKDH *7C4QHY1,_]N!P&F;9,FQ\,:[WOH"K4JZ M\!HN01F.BFAHM\E]MMD5'A$ ?SA,YB0FWOL>\=TG+\TV2;T%$%!;K\#<C45YI"1$LL^XH84N.H;-R\ MI;K:75?U!+ P04 " !01:M(T8@7#J,! "Q P &0 'AL M+W=O!I"3+DN26*2YZ6A:A]J++ D1=M97V!EP19>+13T1F!/-#1;>I]N=KE'!,";@,F< MQ,1[WR.^^^1/O:6)MP 2*NL5N%L.\ !2>B'7^&/6_&[IB:?Q4?TI3.O<[[F! M!Y3_1&T[9S:AI(:&C]*^XO0,\PAK+UBA-.%+JM%85$<*)8I_QE7T89WBG_5J MIETG9#,A6PAW23 >&P6;C]SRLM X$3-P?W;IQL&U%W'*Q'DS(0W3Q^JA3/.[ M@AV\T!EF%S%9Q"P(YM2OMLC.6^RR$WKV,WUUX7 5Z*O8/H84N'8V[AY2W6YG?=9.)-O>%D,O(6_7+>B-V2/ MUIUL.-0&T8(SD=RL*>G<^UD2"8WUX2\7ZWBE8F)Q.#Z0Y9667U!+ P04 M" !01:M((8HIOZ(! "Q P &0 'AL+W=O&P.]\X-6T)LW8-D]DX/H/R?5AO)G$]-1^Q@ M@#61) 6A679/).,*5V6LO9FJU*,37,&;07:4DIG_>Q!ZVN$Q2AX/VC]$9+79H>S8 $$U"XH,+\< MX0F$"$*^\;]9\[ME()[')_7G.*UW?V 6GK3XRQO7>[,91@VT;!3N74\O,(^P M#H*U%C9^43U:I^6)@I%DGVGE*JY3^E-L9MIM IT)="$\9-%X:A1M_F*.5:71 M$[(#"V>7;SWJWR=E^08A"XP^X2A";,@B%>_V8)>MMC3 M,SK]F5Y<.2PBO4C=\\W/ JLK@5446,TCTILC7F**JR;D;$\EF"Y>'8MJ/2J7 M-F^I+K?SD<8S^897Y< Z^,U,QY5%!^W\R<9#;;5VX$UD=VN,>O]^ED1 ZT*X M\;%)5RHE3@^G![*\TNH+4$L#!!0 ( %!%JTBJ8]-2RP$ . $ 9 M>&PO=V]R:W-H965T*%)@Y"X8%?QEBIP.1NY^) -@$)?C';RY#5* M]4>,9=$ (_*!]]#I-Q47C"@=BAK+7@ I+8E1'/I^@AEI.R_/;.Y-Y!D?%&T[ M>!-(#HP1\>\,E(\G+_!NB?>V;I1)X#S#,Z]L&72RY1T24)V\I^!X3@W" OZT M,,J[/3*U7SC_,,&O\N3YI@2@4"BC0/1RA6>@U AIX\])\]O2$._W-_57VZVN M_D(D/'/ZMRU5HXOU/51"10:JWOGX$Z868B-8<"KM$Q6#5)S=*!YBY,NM;6?7 MT;U)HXFV30@G0C@3'GU;N#.R9;X01?),\!')GIA_%QPU7!@1K8QT;=*&MGN7 MO>9!'&7X:H06F+/#A XS([!6W[0(EQ;G\(X>[M,/JPH/EGYP[N%A7R!:"416 M()I:C#=;7&*2?9-X91(O!-)-DR7F<=\D69DD"X$?FR8+3.+OFZ0KDW0A$&R: M+#'KGXKOCB #4=M)DZC@0Z?<69NS\S _A?8(?\/SK"CK9@XH5,IL4[T7;@)=H'A_NT_F2RW_#U!+ P04 " !0 M1:M(B?3H7*,! "Q P &0 'AL+W=OP)$/);7=T]ZY8<>8K7M0W#[@ -K_:=$H[GQJ.F8' [R) M)"59GF5;IKC0M"IC[=54)8Y."@VOAMA1*6[^'4#BM*BZ\B:YWH<"JDBV\ M1BC05J F!MH]?5SM#D5 1,!O 9.]B$GP?D1\#\G/9D^S8 $DU"XH<+^8S4T3=K&G"DP7KXXE-8[:I]A0TOOWLR026A?";SXV MZ4JEQ.%P?B#+*ZW^ U!+ P04 " !01:M(=L<_J_0! ")!0 &0 'AL M+W=O\5X>PT7K8 M Z!.#>NH>A(#Z\V76LB.:E/*,U"#9+1RI(X#!"$!'6W[L,C=VHLLNH_/W,N!@/813>%E[;E17>CA$%'W_W8 M]FX<_9<,3K1M IH(Z$Z(XG\2\$3 *P+PR5Q?GZFF12[%&*B!VL..]@8NK8A1 M#DPSRI5NN_SJM8@(R<'5"BTPSQZ#' 9M(I)/-(,$DR M%./=XTSI*E.Z.)#M;4IG5CB-/QX'F-V:@9[9=RK/;:^"H]#F KJ[5PNAF1&# M3V8O&_,NW@O.:FVGJ9E+_U3X0HOA]O#=7]_B#U!+ P04 " !01:M(/DGY M_4@" !I!P &0 'AL+W=O3JEYLUT[B!%2,F>V$[NWG Z' W"4W8)OO]&/X70R, MOXF:$ G>:=N)K5=+V6]\7QQJ0K%X8CWIU),3XQ1+->5G7_2L )Z>M]QQL=H&!&,3/A@QB-@8Z_)ZQ-SWY?MQZ4&<@+3E(+8'5[4IVI&VU MDG+^/8I^>&KB?'Q3_VK*5?'W6) =:W\U1UFKM- #1W+"EU:^LN$;&6M(M."! MM<)

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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 50 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 48 177 1 false 26 0 false 6 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://venaxis.com/role/appy-daei Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Balance Sheets Sheet http://venaxis.com/role/appy-bs Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Balance Sheets (Parenthetical) Sheet http://venaxis.com/role/appy-bsp Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Statements of Operations Sheet http://venaxis.com/role/appy-soo Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Statements of Cash Flows Sheet http://venaxis.com/role/appy-socf Statements of Cash Flows Statements 5 false false R6.htm 00000006 - Disclosure - INTERIM FINANCIAL STATEMENTS Sheet http://venaxis.com/role/appy-ifs INTERIM FINANCIAL STATEMENTS Notes 6 false false R7.htm 00000007 - Disclosure - Significant accounting policies Sheet http://venaxis.com/role/appy-sap Significant accounting policies Notes 7 false false R8.htm 00000008 - Disclosure - Property and equipment Sheet http://venaxis.com/role/appy-pae Property and equipment Notes 8 false false R9.htm 00000009 - Disclosure - Other long-term assets Sheet http://venaxis.com/role/appy-ola Other long-term assets Notes 9 false false R10.htm 00000010 - Disclosure - Notes and Other Obligations Notes http://venaxis.com/role/appy-naoo Notes and Other Obligations Notes 10 false false R11.htm 00000011 - Disclosure - Stockholders' equity Sheet http://venaxis.com/role/appy-se Stockholders' equity Notes 11 false false R12.htm 00000012 - Disclosure - Stock options and warrants Sheet http://venaxis.com/role/appy-soaw Stock options and warrants Notes 12 false false R13.htm 00000013 - Disclosure - Animal Health License Agreements Sheet http://venaxis.com/role/appy-ahla Animal Health License Agreements Notes 13 false false R14.htm 00000014 - Disclosure - Commitments and contingencies Sheet http://venaxis.com/role/appy-cac Commitments and contingencies Notes 14 false false R15.htm 00000016 - Disclosure - Subsequent event Sheet http://venaxis.com/role/SubsequentEvent Subsequent event Notes 15 false false R16.htm 00000017 - Disclosure - Significant accounting policies (Policy) Sheet http://venaxis.com/role/appy-sapp Significant accounting policies (Policy) Policies 16 false false R17.htm 00000018 - Disclosure - Property and equipment (Tables) Sheet http://venaxis.com/role/appy-paet Property and equipment (Tables) Tables http://venaxis.com/role/appy-pae 17 false false R18.htm 00000019 - Disclosure - Other long-term assets (Tables) Sheet http://venaxis.com/role/appy-olat Other long-term assets (Tables) Tables http://venaxis.com/role/appy-ola 18 false false R19.htm 00000020 - Disclosure - Notes and Other Obligations (Tables) Notes http://venaxis.com/role/appy-naoot Notes and Other Obligations (Tables) Tables http://venaxis.com/role/appy-naoo 19 false false R20.htm 00000021 - Disclosure - Stock options and warrants (Tables) Sheet http://venaxis.com/role/appy-soawt Stock options and warrants (Tables) Tables http://venaxis.com/role/appy-soaw 20 false false R21.htm 00000022 - Disclosure - Animal Health License Agreements (Tables) Sheet http://venaxis.com/role/appy-ahlat Animal Health License Agreements (Tables) Tables http://venaxis.com/role/appy-ahla 21 false false R22.htm 00000023 - Disclosure - INTERIM FINANCIAL STATEMENTS (Details) Sheet http://venaxis.com/role/appy-ifsd INTERIM FINANCIAL STATEMENTS (Details) Details http://venaxis.com/role/appy-ifs 22 false false R23.htm 00000024 - Disclosure - Significant accounting policies (Narrative) (Details) Sheet http://venaxis.com/role/SignificantAccountingPoliciesNarrativeDetails Significant accounting policies (Narrative) (Details) Details http://venaxis.com/role/appy-sapp 23 false false R24.htm 00000025 - Disclosure - Significant accounting policies (Revenue recognition and accounts receivable) (Details) Sheet http://venaxis.com/role/SignificantAccountingPoliciesRevenueRecognitionAndAccountsReceivableDetails Significant accounting policies (Revenue recognition and accounts receivable) (Details) Details http://venaxis.com/role/appy-sapp 24 false false R25.htm 00000026 - Disclosure - Property and equipment (Narrative) (Details) Sheet http://venaxis.com/role/PropertyAndEquipmentNarrativeDetails Property and equipment (Narrative) (Details) Details http://venaxis.com/role/appy-paet 25 false false R26.htm 00000027 - Disclosure - Property and equipment (Schedule of Property and Equipment) (Details) Sheet http://venaxis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails Property and equipment (Schedule of Property and Equipment) (Details) Details http://venaxis.com/role/appy-paet 26 false false R27.htm 00000028 - Disclosure - Other long-term assets (Details) Sheet http://venaxis.com/role/appy-olad Other long-term assets (Details) Details http://venaxis.com/role/appy-olat 27 false false R28.htm 00000029 - Disclosure - Notes and Other Obligations (Narrative) (Details) Notes http://venaxis.com/role/appy-naoond Notes and Other Obligations (Narrative) (Details) Details http://venaxis.com/role/appy-naoot 28 false false R29.htm 00000030 - Disclosure - Notes and Other Obligations (Schedule of Long-Term Debt) (Details) Notes http://venaxis.com/role/appy-naoosoldd Notes and Other Obligations (Schedule of Long-Term Debt) (Details) Details http://venaxis.com/role/appy-naoot 29 false false R30.htm 00000031 - Disclosure - Stock options and warrants (Stock incentive plan options) (Narrative) (Details) Sheet http://venaxis.com/role/appy-soawsipond12 Stock options and warrants (Stock incentive plan options) (Narrative) (Details) Details http://venaxis.com/role/appy-soawt 30 false false R31.htm 00000032 - Disclosure - Stock options and warrants (Schedule of Stock-based Compensation) (Details) Sheet http://venaxis.com/role/appy-soawsoscd1 Stock options and warrants (Schedule of Stock-based Compensation) (Details) Details http://venaxis.com/role/appy-soawt 31 false false R32.htm 00000033 - Disclosure - Stock options and warrants (Schedule of Award Activity) (Details) Sheet http://venaxis.com/role/appy-soawsoaad Stock options and warrants (Schedule of Award Activity) (Details) Details http://venaxis.com/role/appy-soawt 32 false false R33.htm 00000034 - Disclosure - Stock options and warrants (Schedule of Nonvested Awards) (Details) Sheet http://venaxis.com/role/appy-soawsonad Stock options and warrants (Schedule of Nonvested Awards) (Details) Details http://venaxis.com/role/appy-soawt 33 false false R34.htm 00000035 - Disclosure - Animal Health License Agreements (Narrative) (Details) Sheet http://venaxis.com/role/appy-ahland Animal Health License Agreements (Narrative) (Details) Details http://venaxis.com/role/appy-ahlat 34 false false R35.htm 00000036 - Disclosure - Animal Health License Agreements (Schedule of Revenue Recognition Associated with the License Agreement) (Details) Sheet http://venaxis.com/role/appy-ahlasorrawlad Animal Health License Agreements (Schedule of Revenue Recognition Associated with the License Agreement) (Details) Details http://venaxis.com/role/appy-ahlat 35 false false R36.htm 00000037 - Disclosure - Commitments and contingencies (Details) Sheet http://venaxis.com/role/CommitmentsAndContingenciesDetails Commitments and contingencies (Details) Details http://venaxis.com/role/appy-cac 36 false false R37.htm 00000038 - Disclosure - Subsequent event (Details) Sheet http://venaxis.com/role/SubsequentEventDetails Subsequent event (Details) Details http://venaxis.com/role/SubsequentEvent 37 false false All Reports Book All Reports appy-20160331.xml appy-20160331.xsd appy-20160331_cal.xml appy-20160331_def.xml appy-20160331_lab.xml appy-20160331_pre.xml true true ZIP 54 0001079973-16-000953-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001079973-16-000953-xbrl.zip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�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end